BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Fonseca R, Bergsagel PL, Drach J, Shaughnessy J, Gutierrez N, Stewart AK, Morgan G, Van Ness B, Chesi M, Minvielle S, Neri A, Barlogie B, Kuehl WM, Liebisch P, Davies F, Chen-Kiang S, Durie BG, Carrasco R, Sezer O, Reiman T, Pilarski L, Avet-Loiseau H;  International Myeloma Working Group. International Myeloma Working Group molecular classification of multiple myeloma: spotlight review. Leukemia. 2009;23:2210-2221. [PMID: 19798094 DOI: 10.1038/leu.2009.174] [Cited by in Crossref: 564] [Cited by in F6Publishing: 520] [Article Influence: 47.0] [Reference Citation Analysis]
Number Citing Articles
1 Demir I, Pehlivan S, Okan V, Sahin HH, Durusoy SS, Serin I, Oyaci Y, Pehlivan M. Effect of the uncoupling protein-2 (UCP-2) and nuclear receptor subfamily 3 group C member 1 (NR3C1) genes on treatment efficacy and survival in patients with multiple myeloma: a single-center study. BMC Res Notes 2021;14:346. [PMID: 34481515 DOI: 10.1186/s13104-021-05758-7] [Reference Citation Analysis]
2 Canella A, Cordero Nieves H, Sborov DW, Cascione L, Radomska HS, Smith E, Stiff A, Consiglio J, Caserta E, Rizzotto L, Zanesi N, Stefano V, Kaur B, Mo X, Byrd JC, Efebera YA, Hofmeister CC, Pichiorri F. HDAC inhibitor AR-42 decreases CD44 expression and sensitizes myeloma cells to lenalidomide. Oncotarget 2015;6:31134-50. [PMID: 26429859 DOI: 10.18632/oncotarget.5290] [Cited by in Crossref: 26] [Cited by in F6Publishing: 26] [Article Influence: 5.2] [Reference Citation Analysis]
3 Morgan G. Myeloma: diagnosis complications and supportive care. Hematology 2012;17 Suppl 1:S109-11. [PMID: 22507795 DOI: 10.1179/102453312X13336169156177] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
4 Tandon N, Rajkumar SV, LaPlant B, Pettinger A, Lacy MQ, Dispenzieri A, Buadi FK, Gertz MA, Hayman SR, Leung N, Go RS, Dingli D, Kapoor P, Lin Y, Hwa YL, Fonder AL, Hobbs MA, Zeldenrust SR, Lust JA, Gonsalves WI, Russell SJ, Kumar SK. Clinical utility of the Revised International Staging System in unselected patients with newly diagnosed and relapsed multiple myeloma. Blood Cancer J 2017;7:e528. [PMID: 28211889 DOI: 10.1038/bcj.2017.13] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 4.3] [Reference Citation Analysis]
5 Roh J, Jeon Y, Lee AN, Lee SM, Kim Y, Sung CO, Park CJ, Hong JY, Yoon DH, Suh C, Huh J, Choi I, Park CS. The immune checkpoint molecule V-set Ig domain-containing 4 is an independent prognostic factor for multiple myeloma. Oncotarget 2017;8:58122-32. [PMID: 28938542 DOI: 10.18632/oncotarget.19468] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.5] [Reference Citation Analysis]
6 Maschio M, Zarabla A, Maialetti A, Marchesi F, Giannarelli D, Gumenyuk S, Pisani F, Renzi D, Galiè E, Mengarelli A. Prevention of Bortezomib-Related Peripheral Neuropathy With Docosahexaenoic Acid and α-Lipoic Acid in Patients With Multiple Myeloma: Preliminary Data. Integr Cancer Ther 2018;17:1115-24. [PMID: 30295079 DOI: 10.1177/1534735418803758] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 5.3] [Reference Citation Analysis]
7 San Miguel J. Multiple myeloma: a model for scientific and clinical progress. Hematology 2014;2014:1-7. [DOI: 10.1182/asheducation-2014.1.1] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 1.9] [Reference Citation Analysis]
8 Gaballa S, Saliba RM, Srour S, Lu G, Brammer JE, Shah N, Bashir Q, Patel K, Bock F, Parmar S, Hosing C, Popat U, Delgado R, Rondon G, Shah JJ, Manasanch EE, Orlowski RZ, Champlin R, Qazilbash MH. Outcomes in patients with multiple myeloma with TP53 deletion after autologous hematopoietic stem cell transplant. Am J Hematol 2016;91:E442-7. [PMID: 27420405 DOI: 10.1002/ajh.24487] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 2.2] [Reference Citation Analysis]
9 Chhabra S, Jain S, Wallace C, Hong F, Liu B. High expression of endoplasmic reticulum chaperone grp94 is a novel molecular hallmark of malignant plasma cells in multiple myeloma. J Hematol Oncol 2015;8:77. [PMID: 26108343 DOI: 10.1186/s13045-015-0177-6] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 3.0] [Reference Citation Analysis]
10 Todinova S, Krumova S, Gartcheva L, Robeerst C, Taneva SG. Microcalorimetry of blood serum proteome: a modified interaction network in the multiple myeloma case. Anal Chem 2011;83:7992-8. [PMID: 21928840 DOI: 10.1021/ac202055m] [Cited by in Crossref: 54] [Cited by in F6Publishing: 32] [Article Influence: 5.4] [Reference Citation Analysis]
11 Kassambara A, Gourzones-Dmitriev C, Sahota S, Rème T, Moreaux J, Goldschmidt H, Constantinou A, Pasero P, Hose D, Klein B. A DNA repair pathway score predicts survival in human multiple myeloma: the potential for therapeutic strategy. Oncotarget 2014;5:2487-98. [PMID: 24809299 DOI: 10.18632/oncotarget.1740] [Cited by in Crossref: 29] [Cited by in F6Publishing: 27] [Article Influence: 4.8] [Reference Citation Analysis]
12 Perrot A, Lauwers-Cances V, Tournay E, Hulin C, Chretien ML, Royer B, Dib M, Decaux O, Jaccard A, Belhadj K, Brechignac S, Fontan J, Voillat L, Demarquette H, Collet P, Rodon P, Sohn C, Lifermann F, Orsini-Piocelle F, Richez V, Mohty M, Macro M, Minvielle S, Moreau P, Leleu X, Facon T, Attal M, Avet-Loiseau H, Corre J. Development and Validation of a Cytogenetic Prognostic Index Predicting Survival in Multiple Myeloma. J Clin Oncol 2019;37:1657-65. [PMID: 31091136 DOI: 10.1200/JCO.18.00776] [Cited by in Crossref: 37] [Cited by in F6Publishing: 20] [Article Influence: 18.5] [Reference Citation Analysis]
13 Muchtar E, Ram R, Raanani P, Yeshurun M, Oniashvili N, Shpilberg O, Magen H. First line and salvage therapy with total therapy 3-based treatment for multiple myeloma- an extended single center experience. Leuk Res 2014;38:1401-6. [PMID: 25060304 DOI: 10.1016/j.leukres.2014.06.024] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 0.9] [Reference Citation Analysis]
14 Kim MK, Suh C, Lee DH, Min CK, Kim SJ, Kim K, Moon JH, Yoon SS, Lee GW, Kang HJ, Kim SH, Choi CW, Eom HS, Kwak JY, Kim HJ, Mun YC, Bang SM, Lee K, Shin HJ, Lee JH;  Korean Multiple Myeloma Working Party. Immunoglobulin D multiple myeloma: response to therapy, survival, and prognostic factors in 75 patients. Ann Oncol. 2011;22:411-416. [PMID: 20682550 DOI: 10.1093/annonc/mdq393] [Cited by in Crossref: 27] [Cited by in F6Publishing: 20] [Article Influence: 2.5] [Reference Citation Analysis]
15 Hasipek M, Grabowski D, Guan Y, Alugubelli RR, Tiwari AD, Gu X, DeAvila GA, Silva AS, Meads MB, Parker Y, Lindner DJ, Saunthararajah Y, Shain KH, Maciejewski JP, Reu FJ, Phillips JG, Jha BK. Therapeutic Targeting of Protein Disulfide Isomerase PDIA1 in Multiple Myeloma. Cancers (Basel) 2021;13:2649. [PMID: 34071205 DOI: 10.3390/cancers13112649] [Reference Citation Analysis]
16 Rajkumar SV. Multiple myeloma: 2012 update on diagnosis, risk-stratification, and management. Am J Hematol 2012;87:78-88. [PMID: 22180161 DOI: 10.1002/ajh.22237] [Cited by in Crossref: 104] [Cited by in F6Publishing: 82] [Article Influence: 11.6] [Reference Citation Analysis]
17 Yabe M, Ozkaya N, de Jong D, Aypar U, Ritorto MS, Barbé E, Miedema IHC, Sen F, Chapman JR, Landau HJ, Dogan A. Localized Peritumoral AL Amyloidosis Associated With Mantle Cell Lymphoma With Plasmacytic Differentiation. Am J Surg Pathol 2021;45:939-44. [PMID: 33739787 DOI: 10.1097/PAS.0000000000001684] [Reference Citation Analysis]
18 Wang X, Yan Z, Fulciniti M, Li Y, Gkotzamanidou M, Amin SB, Shah PK, Zhang Y, Munshi NC, Li C. Transcription factor-pathway coexpression analysis reveals cooperation between SP1 and ESR1 on dysregulating cell cycle arrest in non-hyperdiploid multiple myeloma. Leukemia 2014;28:894-903. [PMID: 23925045 DOI: 10.1038/leu.2013.233] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 2.1] [Reference Citation Analysis]
19 Taiana E, Gallo Cantafio ME, Favasuli VK, Bandini C, Viglietto G, Piva R, Neri A, Amodio N. Genomic Instability in Multiple Myeloma: A "Non-Coding RNA" Perspective. Cancers (Basel) 2021;13:2127. [PMID: 33924959 DOI: 10.3390/cancers13092127] [Reference Citation Analysis]
20 Talley PJ, Chantry AD, Buckle CH. Genetics in myeloma: genetic technologies and their application to screening approaches in myeloma. Br Med Bull 2015;113:15-30. [PMID: 25662536 DOI: 10.1093/bmb/ldu041] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
21 Prideaux SM, Conway O'Brien E, Chevassut TJ. The RAG Model: A New Paradigm for Genetic Risk Stratification in Multiple Myeloma. Bone Marrow Res 2014;2014:526568. [PMID: 25295194 DOI: 10.1155/2014/526568] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
22 Cumova J, Kovarova L, Potacova A, Buresova I, Kryukov F, Penka M, Michalek J, Hajek R. Optimization of immunomagnetic selection of myeloma cells from bone marrow using magnetic activated cell sorting. Int J Hematol 2010;92:314-9. [DOI: 10.1007/s12185-010-0651-4] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 1.8] [Reference Citation Analysis]
23 Rajkumar SV. Treatment of multiple myeloma. Nat Rev Clin Oncol 2011;8:479-91. [PMID: 21522124 DOI: 10.1038/nrclinonc.2011.63] [Cited by in Crossref: 189] [Cited by in F6Publishing: 172] [Article Influence: 18.9] [Reference Citation Analysis]
24 Moreaux J, Klein B, Bataille R, Descamps G, Maïga S, Hose D, Goldschmidt H, Jauch A, Rème T, Jourdan M, Amiot M, Pellat-Deceunynck C. A high-risk signature for patients with multiple myeloma established from the molecular classification of human myeloma cell lines. Haematologica 2011;96:574-82. [PMID: 21173094 DOI: 10.3324/haematol.2010.033456] [Cited by in Crossref: 107] [Cited by in F6Publishing: 100] [Article Influence: 9.7] [Reference Citation Analysis]
25 Landgren O. Monoclonal gammopathy of undetermined significance and smoldering multiple myeloma: biological insights and early treatment strategies. Hematology Am Soc Hematol Educ Program 2013;2013:478-87. [PMID: 24319222 DOI: 10.1182/asheducation-2013.1.478] [Cited by in Crossref: 39] [Cited by in F6Publishing: 42] [Article Influence: 5.6] [Reference Citation Analysis]
26 Qiang YW, Ye S, Chen Y, Buros AF, Edmonson R, van Rhee F, Barlogie B, Epstein J, Morgan GJ, Davies FE. MAF protein mediates innate resistance to proteasome inhibition therapy in multiple myeloma. Blood 2016;128:2919-30. [PMID: 27793878 DOI: 10.1182/blood-2016-03-706077] [Cited by in Crossref: 30] [Cited by in F6Publishing: 29] [Article Influence: 6.0] [Reference Citation Analysis]
27 Lorsbach RB, Hsi ED, Dogan A, Fend F. Plasma cell myeloma and related neoplasms. Am J Clin Pathol. 2011;136:168-182. [PMID: 21757591 DOI: 10.1309/ajcpenj68ffbriyb] [Cited by in Crossref: 74] [Cited by in F6Publishing: 27] [Article Influence: 7.4] [Reference Citation Analysis]
28 Sekiguchi N, Ootsubo K, Wagatsuma M, Midorikawa K, Nagata A, Noto S, Yamada K, Takezako N. Impact of C-Myc gene-related aberrations in newly diagnosed myeloma with bortezomib/dexamethasone therapy. Int J Hematol 2014;99:288-95. [PMID: 24496825 DOI: 10.1007/s12185-014-1514-1] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 2.0] [Reference Citation Analysis]
29 Lê GN, Bones J, Coyne M, Bazou D, Dowling P, O'Gorman P, Larkin AM. Current and future biomarkers for risk-stratification and treatment personalisation in multiple myeloma. Mol Omics 2019;15:7-20. [PMID: 30652172 DOI: 10.1039/c8mo00193f] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
30 Amodio N, Leotta M, Bellizzi D, Di Martino MT, D'Aquila P, Lionetti M, Fabiani F, Leone E, Gullà AM, Passarino G, Caraglia M, Negrini M, Neri A, Giordano A, Tagliaferri P, Tassone P. DNA-demethylating and anti-tumor activity of synthetic miR-29b mimics in multiple myeloma. Oncotarget 2012;3:1246-58. [PMID: 23100393 DOI: 10.18632/oncotarget.675] [Cited by in Crossref: 108] [Cited by in F6Publishing: 104] [Article Influence: 13.5] [Reference Citation Analysis]
31 Loscocco GG, Antonioli E, Romano I, Vergoni F, Rotunno G, Mannelli F, Guglielmelli P, Vannucchi AM. Lenalidomide: A double-edged sword for concomitant multiple myeloma and post-essential thrombocythemia myelofibrosis. Am J Hematol 2021;96:749-54. [PMID: 33719069 DOI: 10.1002/ajh.26153] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
32 Lee LX, Li SC. Hunting down the dominating subclone of cancer stem cells as a potential new therapeutic target in multiple myeloma: An artificial intelligence perspective. World J Stem Cells 2020; 12(8): 706-720 [PMID: 32952853 DOI: 10.4252/wjsc.v12.i8.706] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 7.0] [Reference Citation Analysis]
33 Oliveira V, Mahajan N, Bates ML, Tripathi C, Kim KQ, Zaher HS, Maggi LB Jr, Tomasson MH. The snoRNA target of t(4;14) in multiple myeloma regulates ribosome biogenesis. FASEB Bioadv 2019;1:404-14. [PMID: 32095781 DOI: 10.1096/fba.2018-00075] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
34 Dechow T, Steidle S, Götze KS, Rudelius M, Behnke K, Pechloff K, Kratzat S, Bullinger L, Fend F, Soberon V, Mitova N, Li Z, Thaler M, Bauer J, Pietschmann E, Albers C, Grundler R, Schmidt-Supprian M, Ruland J, Peschel C, Duyster J, Rose-John S, Bassermann F, Keller U. GP130 activation induces myeloma and collaborates with MYC. J Clin Invest 2014;124:5263-74. [PMID: 25384216 DOI: 10.1172/JCI69094] [Cited by in Crossref: 25] [Cited by in F6Publishing: 17] [Article Influence: 3.6] [Reference Citation Analysis]
35 Tuchman SA, Lonial S. High-Risk Multiple Myeloma: Does it Still Exist? Clinical Lymphoma Myeloma and Leukemia 2011;11:S70-6. [DOI: 10.1016/j.clml.2011.02.008] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
36 Kapoor R, Kumar R, Dubey AP. Risk Stratification in Multiple Myeloma in Indian Settings. Indian J Hematol Blood Transfus 2020;36:464-72. [PMID: 32647419 DOI: 10.1007/s12288-019-01240-4] [Reference Citation Analysis]
37 Hájek R, Delforge M, Raab MS, Schoen P, DeCosta L, Spicka I, Radocha J, Pour L, Gonzalez-McQuire S, Bouwmeester W. Development and validation of a novel risk stratification algorithm for relapsed multiple myeloma. Br J Haematol 2019;187:447-58. [PMID: 31388996 DOI: 10.1111/bjh.16105] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
38 Colombo M, Galletti S, Garavelli S, Platonova N, Paoli A, Basile A, Taiana E, Neri A, Chiaramonte R. Notch signaling deregulation in multiple myeloma: A rational molecular target. Oncotarget 2015;6:26826-40. [PMID: 26308486 DOI: 10.18632/oncotarget.5025] [Cited by in Crossref: 27] [Cited by in F6Publishing: 27] [Article Influence: 5.4] [Reference Citation Analysis]
39 Nishihori T, Shain K. Insights on Genomic and Molecular Alterations in Multiple Myeloma and Their Incorporation towards Risk-Adapted Treatment Strategy: Concise Clinical Review. Int J Genomics 2017;2017:6934183. [PMID: 29250532 DOI: 10.1155/2017/6934183] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
40 Biran N, Malhotra J, Bagiella E, Cho HJ, Jagannath S, Chari A. Patients with newly diagnosed multiple myeloma and chromosome 1 amplification have poor outcomes despite the use of novel triplet regimens. Am J Hematol 2014;89:616-20. [PMID: 24616227 DOI: 10.1002/ajh.23705] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 2.4] [Reference Citation Analysis]
41 Cleynen A, Szalat R, Kemal Samur M, Robiou du Pont S, Buisson L, Boyle E, Chretien ML, Anderson K, Minvielle S, Moreau P, Attal M, Parmigiani G, Corre J, Munshi N, Avet-Loiseau H. Expressed fusion gene landscape and its impact in multiple myeloma. Nat Commun. 2017;8:1893. [PMID: 29196615 DOI: 10.1038/s41467-017-00638-w] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 4.8] [Reference Citation Analysis]
42 Sonneveld P, Schmidt-Wolf IG, van der Holt B, El Jarari L, Bertsch U, Salwender H, Zweegman S, Vellenga E, Broyl A, Blau IW, Weisel KC, Wittebol S, Bos GM, Stevens-Kroef M, Scheid C, Pfreundschuh M, Hose D, Jauch A, van der Velde H, Raymakers R, Schaafsma MR, Kersten MJ, van Marwijk-Kooy M, Duehrsen U, Lindemann W, Wijermans PW, Lokhorst HM, Goldschmidt HM. Bortezomib induction and maintenance treatment in patients with newly diagnosed multiple myeloma: results of the randomized phase III HOVON-65/ GMMG-HD4 trial. J Clin Oncol 2012;30:2946-55. [PMID: 22802322 DOI: 10.1200/JCO.2011.39.6820] [Cited by in Crossref: 555] [Cited by in F6Publishing: 216] [Article Influence: 61.7] [Reference Citation Analysis]
43 Chang H, Jiang N, Jiang H, Saha MN, Qi C, Xu W, Reece D. CKS1B nuclear expression is inversely correlated with p27Kip1 expression and is predictive of an adverse survival in patients with multiple myeloma. Haematologica 2010;95:1542-7. [PMID: 20421271 DOI: 10.3324/haematol.2010.022210] [Cited by in Crossref: 23] [Cited by in F6Publishing: 18] [Article Influence: 2.1] [Reference Citation Analysis]
44 Cypris O, Božić T, Wagner W. Chicken or Egg: Is Clonal Hematopoiesis Primarily Caused by Genetic or Epigenetic Aberrations? Front Genet 2019;10:785. [PMID: 31552094 DOI: 10.3389/fgene.2019.00785] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
45 Larocca A, Cavallo F, Mina R, Boccadoro M, Palumbo A. Current treatment strategies with lenalidomide in multiple myeloma and future perspectives. Future Oncol 2012;8:1223-38. [PMID: 23130924 DOI: 10.2217/fon.12.124] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.1] [Reference Citation Analysis]
46 Byun JM, Shin DY, Hong J, Kim I, Kim HK, Lee DS, Koh Y, Yoon SS. Distinct predictive impact of FISH abnormality in proteasome inhibitors and immunomodulatory agents response: redefining high-risk multiple myeloma in Asian patients. Cancer Med 2018;7:831-41. [PMID: 29380550 DOI: 10.1002/cam4.1340] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
47 de Mel S, Lim SH, Tung ML, Chng WJ. Implications of heterogeneity in multiple myeloma. Biomed Res Int 2014;2014:232546. [PMID: 25101266 DOI: 10.1155/2014/232546] [Cited by in Crossref: 24] [Cited by in F6Publishing: 26] [Article Influence: 3.4] [Reference Citation Analysis]
48 Boyd KD, Ross FM, Walker BA, Wardell CP, Tapper WJ, Chiecchio L, Dagrada G, Konn ZJ, Gregory WM, Jackson GH, Child JA, Davies FE, Morgan GJ; NCRI Haematology Oncology Studies Group. Mapping of chromosome 1p deletions in myeloma identifies FAM46C at 1p12 and CDKN2C at 1p32.3 as being genes in regions associated with adverse survival. Clin Cancer Res 2011;17:7776-84. [PMID: 21994415 DOI: 10.1158/1078-0432.CCR-11-1791] [Cited by in Crossref: 108] [Cited by in F6Publishing: 56] [Article Influence: 10.8] [Reference Citation Analysis]
49 Faiman B. Myeloma Genetics and Genomics: Practice Implications and Future Directions. Clinical Lymphoma Myeloma and Leukemia 2014;14:436-40. [DOI: 10.1016/j.clml.2014.07.008] [Cited by in Crossref: 8] [Cited by in F6Publishing: 11] [Article Influence: 1.1] [Reference Citation Analysis]
50 Abdallah N, Rajkumar SV, Greipp P, Kapoor P, Gertz MA, Dispenzieri A, Baughn LB, Lacy MQ, Hayman SR, Buadi FK, Dingli D, Go RS, Hwa YL, Fonder A, Hobbs M, Lin Y, Leung N, Kourelis T, Warsame R, Siddiqui M, Lust J, Kyle RA, Bergsagel L, Ketterling R, Kumar SK. Cytogenetic abnormalities in multiple myeloma: association with disease characteristics and treatment response. Blood Cancer J 2020;10:82. [PMID: 32782240 DOI: 10.1038/s41408-020-00348-5] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 9.0] [Reference Citation Analysis]
51 An G, Xu Y, Shi L, Shizhen Z, Deng S, Xie Z, Sui W, Zhan F, Qiu L. Chromosome 1q21 gains confer inferior outcomes in multiple myeloma treated with bortezomib but copy number variation and percentage of plasma cells involved have no additional prognostic value. Haematologica 2014;99:353-9. [PMID: 24213147 DOI: 10.3324/haematol.2013.088211] [Cited by in Crossref: 57] [Cited by in F6Publishing: 60] [Article Influence: 7.1] [Reference Citation Analysis]
52 Dunavin NC, Wei L, Elder P, Phillips GS, Benson DM Jr, Hofmeister CC, Penza S, Greenfield C, Rose KS, Rieser G, Merritt L, Ketcham J, Heerema N, Byrd JC, Devine SM, Efebera YA. Early versus delayed autologous stem cell transplant in patients receiving novel therapies for multiple myeloma. Leuk Lymphoma 2013;54:1658-64. [PMID: 23194056 DOI: 10.3109/10428194.2012.751528] [Cited by in Crossref: 49] [Cited by in F6Publishing: 48] [Article Influence: 5.4] [Reference Citation Analysis]
53 Govindasamy P, Pandurangan P, Tarigopula A, Mani R, R Samuel C. Cytogenetic Abnormalities in Multiple Myeloma Patients at a Tertiary Healthcare Center in India. Asian Pac J Cancer Prev 2019;20:235-41. [PMID: 30678438 DOI: 10.31557/APJCP.2019.20.1.235] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
54 Venner CP, Connors JM, Sutherland HJ, Shepherd JD, Hamata L, Mourad YA, Barnett MJ, Broady R, Forrest DL, Hogge DE, Nantel SH, Narayanan S, Nevill TJ, Nitta J, Power MM, Toze CL, Smith CA, Song KW. Novel agents improve survival of transplant patients with multiple myeloma including those with high-risk disease defined by early relapse (<12 months). Leukemia & Lymphoma 2010;52:34-41. [DOI: 10.3109/10428194.2010.531409] [Cited by in Crossref: 29] [Cited by in F6Publishing: 26] [Article Influence: 2.6] [Reference Citation Analysis]
55 Dhakal B, D'Souza A, Callander N, Chhabra S, Fraser R, Davila O, Anderson K, Assal A, Badawy SM, Berdeja J, Cerny J, Comenzo R, Chakraborty R, Peter Gale R, Kamble R, Kharfan-Dabaja MA, Krem M, Ganguly S, Janakiram M, Kansagra A, Munker R, Murthy H, Patel S, Kumar S, Shah N, Qazilbash M, Hari P. Novel prognostic scoring system for autologous hematopoietic cell transplantation in multiple myeloma. Br J Haematol 2020;191:442-52. [PMID: 33094839 DOI: 10.1111/bjh.16987] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
56 Gagelmann N, Eikema DJ, de Wreede LC, Rambaldi A, Iacobelli S, Koster L, Caillot D, Blaise D, Remémyi P, Bulabois CE, Passweg J, Leleu X, Zver S, Kobbe G, Ljungman P, Chevallier P, Ringhoffer M, Martin M, Salmenniemi U, Poiré X, Lenhoff S, Pioltelli P, Mordini N, Delforge M, Garderet L, Schönland S, Yakoub-Agha I, Kröger N. Upfront stem cell transplantation for newly diagnosed multiple myeloma with del(17p) and t(4;14): a study from the CMWP-EBMT. Bone Marrow Transplant 2021;56:210-7. [PMID: 32710010 DOI: 10.1038/s41409-020-01007-w] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
57 Liu H, Wang G, Huang Y, Zhao C, Chen J, Wang X. Identification specific miRNA in t(4;14) multiple myeloma based on miRNA-mRNA expressing profile correlation analysis. J Cell Biochem 2018. [PMID: 30230597 DOI: 10.1002/jcb.27537] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
58 Laubach JP, Voorhees PM, Hassoun H, Jakubowiak A, Lonial S, Richardson PG. Current strategies for treatment of relapsed/refractory multiple myeloma. Expert Rev Hematol 2014;7:97-111. [PMID: 24471924 DOI: 10.1586/17474086.2014.882764] [Cited by in Crossref: 53] [Cited by in F6Publishing: 49] [Article Influence: 7.6] [Reference Citation Analysis]
59 Huang SY, Yu YB, Yeh SP, Chen TY, Kao WY, Chen CC, Wang MC, Lin HY, Lin SF, Lin TH, Hua Y, Puccio-Pick M, DeMarco D, Jacques C, Dunn P. A noninterventional observational registry of patients with multiple myeloma treated with lenalidomide in Taiwan. J Formos Med Assoc 2017;116:705-10. [PMID: 28012677 DOI: 10.1016/j.jfma.2016.11.005] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
60 Pagano L, Valentini CG, De Stefano V, Venditti A, Visani G, Petrucci MT, Candoni A, Specchia G, Visco C, Pogliani EM, Ferrara F, Galieni P, Gozzetti A, Fianchi L, De Muro M, Leone G, Musto P, Pulsoni A; for GIMEMA-ALWP (Gruppo Italiano Malattie EMatologiche dell'Adulto, Acute Leukemia Working Party: coordinator Sergio Amadori). Primary plasma cell leukemia: a retrospective multicenter study of 73 patients. Ann Oncol 2011;22:1628-35. [PMID: 21252060 DOI: 10.1093/annonc/mdq646] [Cited by in Crossref: 50] [Cited by in F6Publishing: 46] [Article Influence: 5.0] [Reference Citation Analysis]
61 Forsberg PA, Hammes A, Abbott D, Sherbenou DW, Rossi A, Jayabalan D, Niesvizky R, Mark TM, Ely S. Cellular proliferation by multiplex immunohistochemistry identifies aggressive disease behavior in relapsed multiple myeloma. Leuk Lymphoma 2019;60:2085-7. [PMID: 30632821 DOI: 10.1080/10428194.2018.1551537] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
62 Kancharla P, Patel E, Hennrick K, Ibrahim S, Goldfinger M. A Rare Presentation of Biclonal Gammopathy in Multiple Myeloma with Simultaneous Extramedullary Involvement: A Case Report. Case Rep Oncol 2019;12:537-42. [PMID: 31427948 DOI: 10.1159/000499902] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
63 Ortega M, Mallo M, Solé F, Sánchez-Morata C, López-Andreoni L, Martínez-Morgado N, Gironella M, Valcárcel D, Vallespí T. 5q- syndrome and multiple myeloma diagnosed simultaneously and successful treated with lenalidomide. Leuk Res 2013;37:1248-50. [PMID: 23891188 DOI: 10.1016/j.leukres.2013.06.021] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
64 Bolli N, Avet-Loiseau H, Wedge DC, Van Loo P, Alexandrov LB, Martincorena I, Dawson KJ, Iorio F, Nik-Zainal S, Bignell GR, Hinton JW, Li Y, Tubio JM, McLaren S, O' Meara S, Butler AP, Teague JW, Mudie L, Anderson E, Rashid N, Tai YT, Shammas MA, Sperling AS, Fulciniti M, Richardson PG, Parmigiani G, Magrangeas F, Minvielle S, Moreau P, Attal M, Facon T, Futreal PA, Anderson KC, Campbell PJ, Munshi NC. Heterogeneity of genomic evolution and mutational profiles in multiple myeloma. Nat Commun 2014;5:2997. [PMID: 24429703 DOI: 10.1038/ncomms3997] [Cited by in Crossref: 524] [Cited by in F6Publishing: 492] [Article Influence: 87.3] [Reference Citation Analysis]
65 Painuly U, Ramakrishnan V, Kimlinger T, Wellik L, Haug J, Gonsalves W, Bi L, Huang Z, Rajkumar SV, Kumar S. Aurora kinase and FGFR3 inhibition results in significant apoptosis in molecular subgroups of multiple myeloma. Oncotarget 2018;9:34582-94. [PMID: 30349651 DOI: 10.18632/oncotarget.26180] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
66 Liu H, Tamashiro S, Baritaki S, Penichet M, Yu Y, Chen H, Berenson J, Bonavida B. TRAF6 activation in multiple myeloma: a potential therapeutic target. Clin Lymphoma Myeloma Leuk 2012;12:155-63. [PMID: 22440007 DOI: 10.1016/j.clml.2012.01.006] [Cited by in Crossref: 47] [Cited by in F6Publishing: 35] [Article Influence: 5.2] [Reference Citation Analysis]
67 Yang N, Mun YC, Seong CM, Huh HJ, Huh J. Clinicopathological Characteristics of Hyperdiploidy with High-Risk Cytogenetics in Multiple Myeloma. Ann Lab Med 2018;38:160-4. [PMID: 29214761 DOI: 10.3343/alm.2018.38.2.160] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
68 Siegel D, Martin T, Nooka A, Harvey RD, Vij R, Niesvizky R, Badros AZ, Jagannath S, McCulloch L, Rajangam K. Integrated safety profile of single-agent carfilzomib: experience from 526 patients enrolled in 4 phase II clinical studies. Haematologica. 2013;98:1753-1761. [PMID: 23935022 DOI: 10.3324/haematol.2013.089334] [Cited by in Crossref: 223] [Cited by in F6Publishing: 206] [Article Influence: 27.9] [Reference Citation Analysis]
69 Fonseca R, Monge J. Myeloma: Classification and Risk Assessment. Seminars in Oncology 2013;40:554-66. [DOI: 10.1053/j.seminoncol.2013.07.002] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 2.4] [Reference Citation Analysis]
70 Kumar SK, Uno H, Jacobus SJ, Van Wier SA, Ahmann GJ, Henderson KJ, Callander NS, Haug JL, Siegel DS, Greipp PR, Fonseca R, Rajkumar SV. Impact of gene expression profiling-based risk stratification in patients with myeloma receiving initial therapy with lenalidomide and dexamethasone. Blood 2011;118:4359-62. [PMID: 21860025 DOI: 10.1182/blood-2011-03-342089] [Cited by in Crossref: 33] [Cited by in F6Publishing: 29] [Article Influence: 3.3] [Reference Citation Analysis]
71 Caltagirone S, Ruggeri M, Aschero S, Gilestro M, Oddolo D, Gay F, Bringhen S, Musolino C, Baldini L, Musto P, Petrucci MT, Gaidano G, Passera R, Bruno B, Palumbo A, Boccadoro M, Omedè P. Chromosome 1 abnormalities in elderly patients with newly diagnosed multiple myeloma treated with novel therapies. Haematologica 2014;99:1611-7. [PMID: 25015938 DOI: 10.3324/haematol.2014.103853] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 2.1] [Reference Citation Analysis]
72 Glavey SV, Manier S, Sacco A, Salem K, Kawano Y, Bouyssou J, Ghobrial IM, Roccaro AM. Epigenetics in Multiple Myeloma. Cancer Treat Res 2016;169:35-49. [PMID: 27696257 DOI: 10.1007/978-3-319-40320-5_4] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
73 Terragna C, Remondini D, Martello M, Zamagni E, Pantani L, Patriarca F, Pezzi A, Levi G, Offidani M, Proserpio I, De Sabbata G, Tacchetti P, Cangialosi C, Ciambelli F, Viganò CV, Dico FA, Santacroce B, Borsi E, Brioli A, Marzocchi G, Castellani G, Martinelli G, Palumbo A, Cavo M. The genetic and genomic background of multiple myeloma patients achieving complete response after induction therapy with bortezomib, thalidomide and dexamethasone (VTD). Oncotarget 2016;7:9666-79. [PMID: 26575327 DOI: 10.18632/oncotarget.5718] [Cited by in Crossref: 22] [Cited by in F6Publishing: 18] [Article Influence: 4.4] [Reference Citation Analysis]
74 Kim M, Ju YS, Lee EJ, Kang HJ, Kim HS, Cho HC, Kim HJ, Kim JA, Lee DS, Lee YK. Abnormalities in Chromosomes 1q and 13 Independently Correlate With Factors of Poor Prognosis in Multiple Myeloma. Ann Lab Med 2016;36:573-82. [PMID: 27578511 DOI: 10.3343/alm.2016.36.6.573] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
75 Kim Y, Park SS, Min CK, Lee GD, Son J, Jo SJ, Han E, Han K, Kim M. KRAS, NRAS, and BRAF mutations in plasma cell myeloma at a single Korean institute. Blood Res 2020;55:159-68. [PMID: 32989177 DOI: 10.5045/br.2020.2020137] [Reference Citation Analysis]
76 Alzrigat M, Jernberg-Wiklund H, Licht JD. Targeting EZH2 in Multiple Myeloma-Multifaceted Anti-Tumor Activity. Epigenomes 2018;2:16. [PMID: 30761216 DOI: 10.3390/epigenomes2030016] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 3.3] [Reference Citation Analysis]
77 Abdallah N, Baughn LB, Rajkumar SV, Kapoor P, Gertz MA, Dispenzieri A, Lacy MQ, Hayman SR, Buadi FK, Dingli D, Go RS, Hwa YL, Fonder A, Hobbs M, Lin Y, Leung N, Kourelis T, Warsame R, Siddiqui M, Lust J, Kyle RA, Ketterling R, Bergsagel L, Greipp P, Kumar SK. Implications of MYC Rearrangements in Newly Diagnosed Multiple Myeloma. Clin Cancer Res 2020;26:6581-8. [PMID: 33008815 DOI: 10.1158/1078-0432.CCR-20-2283] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 5.0] [Reference Citation Analysis]
78 Jimenez-Zepeda VH, Braggio E, Fonseca R. Dissecting karyotypic patterns in non-hyperdiploid multiple myeloma: an overview on the karyotypic evolution. Clin Lymphoma Myeloma Leuk 2013;13:552-8. [PMID: 23856591 DOI: 10.1016/j.clml.2013.05.005] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
79 Pellegrino S, Ronda L, Annoni C, Contini A, Erba E, Gelmi ML, Piano R, Paredi G, Mozzarelli A, Bettati S. Molecular insights into dimerization inhibition of c-Maf transcription factor. Biochim Biophys Acta 2014;1844:2108-15. [PMID: 25220806 DOI: 10.1016/j.bbapap.2014.09.003] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 1.7] [Reference Citation Analysis]
80 Stella F, Pedrazzini E, Baialardo E, Fantl DB, Schutz N, Slavutsky I. Quantitative analysis of CKS1B mRNA expression and copy number gain in patients with plasma cell disorders. Blood Cells Mol Dis 2014;53:110-7. [PMID: 24973170 DOI: 10.1016/j.bcmd.2014.05.006] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 1.1] [Reference Citation Analysis]
81 Steinbrunn T, Siegmund D, Andrulis M, Grella E, Kortüm M, Einsele H, Wajant H, Bargou RC, Stühmer T. Integrin-linked kinase is dispensable for multiple myeloma cell survival. Leuk Res 2012;36:1165-71. [PMID: 22658851 DOI: 10.1016/j.leukres.2012.05.005] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
82 Rajkumar SV. Multiple myeloma: 2013 update on diagnosis, risk-stratification, and management. Am J Hematol 2013;88:226-35. [PMID: 23440663 DOI: 10.1002/ajh.23390] [Cited by in Crossref: 81] [Cited by in F6Publishing: 70] [Article Influence: 10.1] [Reference Citation Analysis]
83 Bringhen S, Gay F, Pautasso C, Cerrato C, Boccadoro M, Palumbo A. Evaluation of the pharmacokinetics, preclinical, and clinical efficacy of lenalidomide for the treatment of multiple myeloma. Expert Opinion on Drug Metabolism & Toxicology 2012;8:1209-22. [DOI: 10.1517/17425255.2012.712685] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.8] [Reference Citation Analysis]
84 Linardi CC, Martinez G, Velloso ED, Leal AM, Kumeda CA, Buccheri V, Azevedo RS, Peliçario LM, Dorlhiac-Llacer P. Evaluation of chromosomal abnormalities by cIg-FISH and association with proliferative and apoptotic indexes in multiple myeloma. Braz J Med Biol Res 2012;45:1074-9. [PMID: 22911347 DOI: 10.1590/s0100-879x2012007500135] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
85 van de Donk NW, Sonneveld P. Diagnosis and risk stratification in multiple myeloma. Hematol Oncol Clin North Am 2014;28:791-813. [PMID: 25212883 DOI: 10.1016/j.hoc.2014.06.007] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 2.3] [Reference Citation Analysis]
86 Krishnan A. How to Think About Risk in Myeloma. Clin Lymphoma Myeloma Leuk 2016;16 Suppl:S135-8. [PMID: 27521310 DOI: 10.1016/j.clml.2016.02.015] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
87 Bergsagel PL, Mateos MV, Gutierrez NC, Rajkumar SV, San Miguel JF. Improving overall survival and overcoming adverse prognosis in the treatment of cytogenetically high-risk multiple myeloma. Blood 2013;121:884-92. [PMID: 23165477 DOI: 10.1182/blood-2012-05-432203] [Cited by in Crossref: 124] [Cited by in F6Publishing: 120] [Article Influence: 13.8] [Reference Citation Analysis]
88 Alpar D, de Jong D, Holczer-Nagy Z, Kajtar B, Savola S, Jakso P, David M, Kosztolanyi S, Kereskai L, Pajor L, Szuhai K. Multiplex ligation-dependent probe amplification and fluorescence in situ hybridization are complementary techniques to detect cytogenetic abnormalities in multiple myeloma. Genes Chromosomes Cancer 2013;52:785-93. [PMID: 23720363 DOI: 10.1002/gcc.22074] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 1.4] [Reference Citation Analysis]
89 Kassambara A, Schoenhals M, Moreaux J, Veyrune JL, Rème T, Goldschmidt H, Hose D, Klein B. Inhibition of DEPDC1A, a bad prognostic marker in multiple myeloma, delays growth and induces mature plasma cell markers in malignant plasma cells. PLoS One 2013;8:e62752. [PMID: 23646139 DOI: 10.1371/journal.pone.0062752] [Cited by in Crossref: 18] [Cited by in F6Publishing: 20] [Article Influence: 2.3] [Reference Citation Analysis]
90 Wong KY, Li Z, Zhang X, Leung GK, Chan GC, Chim CS. Epigenetic silencing of a long non-coding RNA KIAA0495 in multiple myeloma. Mol Cancer 2015;14:175. [PMID: 26410378 DOI: 10.1186/s12943-015-0444-8] [Cited by in Crossref: 35] [Cited by in F6Publishing: 35] [Article Influence: 5.8] [Reference Citation Analysis]
91 Wang H, Meng H, Wang J, Lou Y, Zhou Y, Lin P, Li F, Liu L, Xu H, Yang M, Jin J. Clinical characteristics and prognostic values of 1p32.3 deletion detected through fluorescence in situ hybridization in patients with newly diagnosed multiple myeloma: a single-center study in China. Front Med 2020;14:327-34. [DOI: 10.1007/s11684-019-0712-x] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
92 Palumbo A, Rajkumar SV, San Miguel JF, Larocca A, Niesvizky R, Morgan G, Landgren O, Hajek R, Einsele H, Anderson KC, Dimopoulos MA, Richardson PG, Cavo M, Spencer A, Stewart AK, Shimizu K, Lonial S, Sonneveld P, Durie BG, Moreau P, Orlowski RZ. International Myeloma Working Group consensus statement for the management, treatment, and supportive care of patients with myeloma not eligible for standard autologous stem-cell transplantation. J Clin Oncol 2014;32:587-600. [PMID: 24419113 DOI: 10.1200/JCO.2013.48.7934] [Cited by in Crossref: 221] [Cited by in F6Publishing: 96] [Article Influence: 31.6] [Reference Citation Analysis]
93 Boyd KD, Ross FM, Chiecchio L, Dagrada GP, Konn ZJ, Tapper WJ, Walker BA, Wardell CP, Gregory WM, Szubert AJ, Bell SE, Child JA, Jackson GH, Davies FE, Morgan GJ; NCRI Haematology Oncology Studies Group. A novel prognostic model in myeloma based on co-segregating adverse FISH lesions and the ISS: analysis of patients treated in the MRC Myeloma IX trial. Leukemia 2012;26:349-55. [PMID: 21836613 DOI: 10.1038/leu.2011.204] [Cited by in Crossref: 200] [Cited by in F6Publishing: 189] [Article Influence: 20.0] [Reference Citation Analysis]
94 Rajan AM, Rajkumar SV. Treatment of newly diagnosed myeloma: Bortezomib-based triplet. Semin Oncol 2016;43:700-2. [PMID: 28061990 DOI: 10.1053/j.seminoncol.2016.11.003] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
95 Korde N, Maric I. Myelomagenesis: capturing early microenvironment changes. Semin Hematol 2011;48:13-21. [PMID: 21232654 DOI: 10.1053/j.seminhematol.2010.11.004] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
96 Stein CK, Qu P, Epstein J, Buros A, Rosenthal A, Crowley J, Morgan G, Barlogie B. Removing batch effects from purified plasma cell gene expression microarrays with modified ComBat. BMC Bioinformatics 2015;16:63. [PMID: 25887219 DOI: 10.1186/s12859-015-0478-3] [Cited by in Crossref: 44] [Cited by in F6Publishing: 35] [Article Influence: 7.3] [Reference Citation Analysis]
97 Ho M, Bianchi G, Anderson KC. Proteomics-inspired precision medicine for treating and understanding multiple myeloma. Expert Rev Precis Med Drug Dev 2020;5:67-85. [PMID: 34414281 DOI: 10.1080/23808993.2020.1732205] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
98 Weiss BM, Kuehl WM. Advances in understanding monoclonal gammopathy of undetermined significance as a precursor of multiple myeloma. Expert Rev Hematol 2010;3:165-74. [PMID: 20473362 DOI: 10.1586/ehm.10.13] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
99 Ajise OE, Roshal M, Wang L, Sukhram GN, Smith KM, Maslak P, Dogan A. Clinical utility of morphology, immunohistochemistry, flow cytometry, and FISH analysis in monitoring of plasma cell neoplasms in the bone marrow. J Hematopathol 2016;9:9-18. [DOI: 10.1007/s12308-015-0264-1] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
100 Tagliafico AS. Imaging in multiple myeloma: Computed tomography or magnetic resonance imaging? World J Radiol 2021; 13(7): 223-226 [PMID: 34367508 DOI: 10.4329/wjr.v13.i7.223] [Reference Citation Analysis]
101 Usmani SZ, Rodriguez-Otero P, Bhutani M, Mateos MV, Miguel JS. Defining and treating high-risk multiple myeloma. Leukemia 2015;29:2119-25. [PMID: 26265183 DOI: 10.1038/leu.2015.209] [Cited by in Crossref: 37] [Cited by in F6Publishing: 37] [Article Influence: 6.2] [Reference Citation Analysis]
102 Anderson KC, Alsina M, Atanackovic D, Biermann JS, Chandler JC, Costello C, Djulbegovic B, Fung HC, Gasparetto C, Godby K, Hofmeister C, Holmberg L, Holstein S, Huff CA, Kassim A, Krishnan AY, Kumar SK, Liedtke M, Lunning M, Raje N, Singhal S, Smith C, Somlo G, Stockerl-Goldstein K, Treon SP, Weber D, Yahalom J, Shead DA, Kumar R; National Comprehensive Cancer Network. Multiple Myeloma, Version 2.2016: Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw 2015;13:1398-435. [PMID: 26553768 DOI: 10.6004/jnccn.2015.0167] [Cited by in Crossref: 43] [Cited by in F6Publishing: 38] [Article Influence: 8.6] [Reference Citation Analysis]
103 Berry NK, Bain NL, Enjeti AK, Rowlings P. Genomic profiling of plasma cell disorders in a clinical setting: integration of microarray and FISH, after CD138 selection of bone marrow. J Clin Pathol 2014;67:66-9. [PMID: 23969274 DOI: 10.1136/jclinpath-2013-201691] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 1.4] [Reference Citation Analysis]
104 Ting KR, Henry M, Meiller J, Larkin A, Clynes M, Meleady P, Bazou D, Dowling P, O'Gorman P. Novel panel of protein biomarkers to predict response to bortezomib-containing induction regimens in multiple myeloma patients. BBA Clin 2017;8:28-34. [PMID: 28725572 DOI: 10.1016/j.bbacli.2017.05.003] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 3.3] [Reference Citation Analysis]
105 Ong SY, de Mel S, Chen YX, Ooi MG, Surendran S, Lin A, Koh LP, Linn YC, Ho AYL, Hwang WYK, Phipps C, Loh SMY, Goh YT, Tan D, Chng WJ, Gopalakrishnan SK. Early relapse post autologous transplant is a stronger predictor of survival compared with pretreatment patient factors in the novel agent era: analysis of the Singapore Multiple Myeloma Working Group. Bone Marrow Transplant 2016;51:933-7. [DOI: 10.1038/bmt.2016.43] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 2.4] [Reference Citation Analysis]
106 Lionetti M, Barbieri M, Manzoni M, Fabris S, Bandini C, Todoerti K, Nozza F, Rossi D, Musto P, Baldini L, Neri A. Molecular spectrum of TP53 mutations in plasma cell dyscrasias by next generation sequencing: an Italian cohort study and overview of the literature. Oncotarget 2016;7:21353-61. [PMID: 26870891 DOI: 10.18632/oncotarget.7241] [Cited by in Crossref: 30] [Cited by in F6Publishing: 30] [Article Influence: 7.5] [Reference Citation Analysis]
107 Rajkumar SV, Gupta V, Fonseca R, Dispenzieri A, Gonsalves WI, Larson D, Ketterling RP, Lust JA, Kyle RA, Kumar SK. Impact of primary molecular cytogenetic abnormalities and risk of progression in smoldering multiple myeloma. Leukemia 2013;27:1738-44. [PMID: 23515097 DOI: 10.1038/leu.2013.86] [Cited by in Crossref: 129] [Cited by in F6Publishing: 112] [Article Influence: 16.1] [Reference Citation Analysis]
108 Brioli A, Melchor L, Walker BA, Davies FE, Morgan GJ. Biology and treatment of myeloma. Clin Lymphoma Myeloma Leuk 2014;14 Suppl:S65-70. [PMID: 25486959 DOI: 10.1016/j.clml.2014.06.011] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 2.2] [Reference Citation Analysis]
109 Mina R, Bonello F, Petrucci MT, Liberati AM, Conticello C, Ballanti S, Musto P, Olivieri A, Benevolo G, Capra A, Gilestro M, Galieni P, Cavo M, Siniscalchi A, Palumbo A, Montefusco V, Gaidano G, Omedé P, Boccadoro M, Bringhen S. Carfilzomib, cyclophosphamide and dexamethasone for newly diagnosed, high-risk myeloma patients not eligible for transplant: a pooled analysis of two studies. Haematologica 2021;106:1079-85. [PMID: 32107329 DOI: 10.3324/haematol.2019.243428] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
110 Deng C, Si C, Ye X, Zhou Q, Zeng T, Huang Z, Huang W, Zhu P, Zhong Q, Wu Z, Zhu H, Lin Q, Zhang W, Fu L, Zheng Y, Qian T. Prognostic significance of FSCN family in multiple myeloma. J Cancer 2021;12:1936-44. [PMID: 33753991 DOI: 10.7150/jca.53675] [Reference Citation Analysis]
111 Vincent Rajkumar S. Multiple myeloma: 2014 Update on diagnosis, risk-stratification, and management. Am J Hematol 2014;89:999-1009. [PMID: 25223428 DOI: 10.1002/ajh.23810] [Cited by in Crossref: 64] [Cited by in F6Publishing: 84] [Article Influence: 9.1] [Reference Citation Analysis]
112 Mao XH, Zhuang JL, Zhao DD, Li XQ, Du X, Hao M, Xu Y, Yan YT, Liu JH, Fan HS, Sui WW, Deng SH, Li CW, Zhao JW, Yi SH, Du CX, Zou DH, Li ZJ, Zhao YZ, Zhan FH, Tai YT, Fang BJ, Song YP, Wang JX, Anderson KC, Qiu LG, An G. IgH translocation with undefined partners is associated with superior outcome in multiple myeloma patients. Eur J Haematol 2020;105:326-34. [PMID: 32421883 DOI: 10.1111/ejh.13440] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
113 Pichiorri F, De Luca L, Aqeilan RI. MicroRNAs: New Players in Multiple Myeloma. Front Genet 2011;2:22. [PMID: 22303318 DOI: 10.3389/fgene.2011.00022] [Cited by in Crossref: 23] [Cited by in F6Publishing: 28] [Article Influence: 2.3] [Reference Citation Analysis]
114 Yu W, Guo R, Qu X, Qiu H, Li J, Zhang R, Chen L. The amplification of 1q21 is an adverse prognostic factor in patients with multiple myeloma in a Chinese population. Onco Targets Ther 2016;9:295-302. [PMID: 26834489 DOI: 10.2147/OTT.S95381] [Cited by in Crossref: 1] [Cited by in F6Publishing: 6] [Article Influence: 0.2] [Reference Citation Analysis]
115 Palumbo A, Cerrato C. Diagnosis and therapy of multiple myeloma. Korean J Intern Med 2013;28:263-73. [PMID: 23682217 DOI: 10.3904/kjim.2013.28.3.263] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 1.4] [Reference Citation Analysis]
116 Ríos-Tamayo R, Lupiañez CB, Campa D, Hielscher T, Weinhold N, Martínez-López J, Jerez A, Landi S, Jamroziak K, Dumontet C, Wątek M, Lesueur F, Reis RM, Marques H, Jurczyszyn A, Vogel U, Buda G, García-Sanz R, Orciuolo E, Petrini M, Vangsted AJ, Gemignani F, Försti A, Goldschmidt H, Hemminki K, Canzian F, Jurado M, Sainz J. A common variant within the HNF1B gene is associated with overall survival of multiple myeloma patients: results from the IMMEnSE consortium and meta-analysis. Oncotarget 2016;7:59029-48. [PMID: 27437873 DOI: 10.18632/oncotarget.10665] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 3.3] [Reference Citation Analysis]
117 San-miguel JF, Paiva B, Gutiérrez NC. New Tools for Diagnosis and Monitoring of Multiple Myeloma. American Society of Clinical Oncology Educational Book 2013. [DOI: 10.14694/edbook_am.2013.33.e313] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
118 Dutta AK, Hewett DR, Fink JL, Grady JP, Zannettino ACW. Cutting edge genomics reveal new insights into tumour development, disease progression and therapeutic impacts in multiple myeloma. Br J Haematol 2017;178:196-208. [PMID: 28466550 DOI: 10.1111/bjh.14649] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
119 Borrelli EP, McGladrigan CG. Differences in safety profiles of newly approved medications for multiple myeloma in real-world settings versus randomized controlled trials. J Oncol Pharm Pract 2021;27:887-96. [PMID: 32686617 DOI: 10.1177/1078155220941937] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
120 Wong AH, Shin EM, Tergaonkar V, Chng WJ. Targeting NF-κB Signaling for Multiple Myeloma. Cancers (Basel) 2020;12:E2203. [PMID: 32781681 DOI: 10.3390/cancers12082203] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 7.0] [Reference Citation Analysis]
121 Barwick BG, Gupta VA, Matulis SM, Patton JC, Powell DR, Gu Y, Jaye DL, Conneely KN, Lin YC, Hofmeister CC, Nooka AK, Keats JJ, Lonial S, Vertino PM, Boise LH. Chromatin Accessibility Identifies Regulatory Elements Predictive of Gene Expression and Disease Outcome in Multiple Myeloma. Clin Cancer Res 2021;27:3178-89. [PMID: 33731366 DOI: 10.1158/1078-0432.CCR-20-2931] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
122 Richard S, Chari A, Delimpasi S, Simonova M, Spicka I, Pour L, Kriachok I, Dimopoulos MA, Pylypenko H, Auner HW, Leleu X, Usenko G, Hajek R, Benjamin R, Dolai TK, Sinha DK, Venner CP, Garg M, Stevens DA, Quach H, Jagannath S, Moreau P, Levy M, Badros A, Anderson LD Jr, Bahlis NJ, Facon T, Mateos MV, Cavo M, Chang H, Landesman Y, Chai Y, Arazy M, Shah J, Shacham S, Kauffman MG, Grosicki S, Richardson PG. Selinexor, bortezomib, and dexamethasone versus bortezomib and dexamethasone in previously treated multiple myeloma: Outcomes by cytogenetic risk. Am J Hematol 2021;96:1120-30. [PMID: 34062004 DOI: 10.1002/ajh.26261] [Reference Citation Analysis]
123 Kiyota M, Kobayashi T, Fuchida S, Yamamoto-Sugitani M, Ohshiro M, Shimura Y, Mizutani S, Nagoshi H, Sasaki N, Nakayama R, Chinen Y, Sakamoto N, Uchiyama H, Matsumoto Y, Horiike S, Shimazaki C, Kuroda J, Taniwaki M. Monosomy 13 in metaphase spreads is a predictor of poor long-term outcome after bortezomib plus dexamethasone treatment for relapsed/refractory multiple myeloma. Int J Hematol 2012;95:516-26. [PMID: 22426624 DOI: 10.1007/s12185-012-1035-8] [Cited by in Crossref: 13] [Cited by in F6Publishing: 8] [Article Influence: 1.4] [Reference Citation Analysis]
124 Magrangeas F, Avet-Loiseau H, Gouraud W, Lodé L, Decaux O, Godmer P, Garderet L, Voillat L, Facon T, Stoppa AM, Marit G, Hulin C, Casassus P, Tiab M, Voog E, Randriamalala E, Anderson KC, Moreau P, Munshi NC, Minvielle S. Minor clone provides a reservoir for relapse in multiple myeloma. Leukemia 2013;27:473-81. [PMID: 22874878 DOI: 10.1038/leu.2012.226] [Cited by in Crossref: 81] [Cited by in F6Publishing: 74] [Article Influence: 9.0] [Reference Citation Analysis]
125 Fend F. [Molecular pathology of plasma cell neoplasms]. Pathologe 2010;31 Suppl 2:188-92. [PMID: 20852863 DOI: 10.1007/s00292-010-1375-1] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
126 Giannakoulas N, Ntanasis-Stathopoulos I, Terpos E. The Role of Marrow Microenvironment in the Growth and Development of Malignant Plasma Cells in Multiple Myeloma. Int J Mol Sci 2021;22:4462. [PMID: 33923357 DOI: 10.3390/ijms22094462] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
127 Noll JE, Hewett DR, Williams SA, Vandyke K, Kok C, To LB, Zannettino AC. SAMSN1 is a tumor suppressor gene in multiple myeloma. Neoplasia 2014;16:572-85. [PMID: 25117979 DOI: 10.1016/j.neo.2014.07.002] [Cited by in Crossref: 30] [Cited by in F6Publishing: 32] [Article Influence: 5.0] [Reference Citation Analysis]
128 Zito Marino F, Brunelli M, Rossi G, Calabrese G, Caliò A, Nardiello P, Martignoni G, Squire JA, Cheng L, Massi D, Franco R. Multitarget fluorescence in situ hybridization diagnostic applications in solid and hematological tumors. Expert Rev Mol Diagn 2021;21:161-73. [PMID: 33593207 DOI: 10.1080/14737159.2021.1887733] [Reference Citation Analysis]
129 Kishimoto RK, de Freitas SL, Ratis CA, Borri D, Sitnik R, Velloso ED. Validation of interphase fluorescence in situ hybridization (iFISH) for multiple myeloma using CD138 positive cells. Rev Bras Hematol Hemoter 2016;38:113-20. [PMID: 27208569 DOI: 10.1016/j.bjhh.2016.01.005] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
130 Dimopoulos M, Terpos E. Multiple myeloma. Annals of Oncology 2010;21:vii143-50. [DOI: 10.1093/annonc/mdq370] [Cited by in Crossref: 54] [Cited by in F6Publishing: 46] [Article Influence: 4.9] [Reference Citation Analysis]
131 Oyekunle A, Shumilov E, Kostrewa P, Burchert A, Trümper L, Wuchter P, Wulf G, Bacher U, Kröger N. Chemotherapy-Based Stem Cell Mobilization Does Not Result in Significant Paraprotein Reduction in Myeloma Patients in the Era of Novel Induction Regimens. Biology of Blood and Marrow Transplantation 2018;24:276-81. [DOI: 10.1016/j.bbmt.2017.10.008] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 3.7] [Reference Citation Analysis]
132 Sherbenou DW, Aftab BT, Su Y, Behrens CR, Wiita A, Logan AC, Acosta-Alvear D, Hann BC, Walter P, Shuman MA, Wu X, Atkinson JP, Wolf JL, Martin TG, Liu B. Antibody-drug conjugate targeting CD46 eliminates multiple myeloma cells. J Clin Invest 2016;126:4640-53. [PMID: 27841764 DOI: 10.1172/JCI85856] [Cited by in Crossref: 54] [Cited by in F6Publishing: 41] [Article Influence: 10.8] [Reference Citation Analysis]
133 Stengel C, Cheung CW, Quinn J, Yong K, Khwaja A. Optimal induction of myeloma cell death requires dual blockade of phosphoinositide 3-kinase and mTOR signalling and is determined by translocation subtype. Leukemia 2012;26:1761-70. [PMID: 22415553 DOI: 10.1038/leu.2012.69] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 1.6] [Reference Citation Analysis]
134 Grzasko N, Hus M, Pluta A, Jurczyszyn A, Walter-Croneck A, Morawska M, Chocholska S, Hajek R, Dmoszynska A. Additional genetic abnormalities significantly worsen poor prognosis associated with 1q21 amplification in multiple myeloma patients. Hematol Oncol 2013;31:41-8. [PMID: 22674819 DOI: 10.1002/hon.2018] [Cited by in Crossref: 22] [Cited by in F6Publishing: 22] [Article Influence: 2.4] [Reference Citation Analysis]
135 Abe M. Guest editorial: understanding the pathogenesis and the evolving treatment paradigm for multiple myeloma in the era of novel agents. Int J Hematol 2011;94:307-9. [PMID: 21993876 DOI: 10.1007/s12185-011-0950-4] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
136 Jakubowiak AJ, Siegel DS, Martin T, Wang M, Vij R, Lonial S, Trudel S, Kukreti V, Bahlis N, Alsina M, Chanan-Khan A, Buadi F, Reu FJ, Somlo G, Zonder J, Song K, Stewart AK, Stadtmauer E, Harrison BL, Wong AF, Orlowski RZ, Jagannath S. Treatment outcomes in patients with relapsed and refractory multiple myeloma and high-risk cytogenetics receiving single-agent carfilzomib in the PX-171-003-A1 study. Leukemia 2013;27:2351-6. [PMID: 23670297 DOI: 10.1038/leu.2013.152] [Cited by in Crossref: 55] [Cited by in F6Publishing: 55] [Article Influence: 6.9] [Reference Citation Analysis]
137 Liu J, Yang H, Liang X, Wang Y, Hou J, Liu Y, Wang J, Zhou F. Meta-analysis of the efficacy of treatments for newly diagnosed and relapsed/refractory multiple myeloma with del(17p). Oncotarget 2017;8:62435-44. [PMID: 28977957 DOI: 10.18632/oncotarget.18722] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 2.5] [Reference Citation Analysis]
138 Woo YR, Kim JS, Lim JH, Hwang S, Kim M, Bae JM, Park YM, Min C, Kim D, Park HJ. Prevalence and clinicopathologic characteristics of multiple myeloma with cutaneous involvement: A case series from Korea. Journal of the American Academy of Dermatology 2018;78:471-478.e4. [DOI: 10.1016/j.jaad.2017.08.054] [Cited by in Crossref: 11] [Cited by in F6Publishing: 6] [Article Influence: 3.7] [Reference Citation Analysis]
139 Raje N, Faiman B, Harvey RD, Kurtin SE, Lonial S, Kumar SK, Cohen AD, Conde MA, Giralt SA, Recine MS, Tombler ER, Stadtmauer E, Jagannath S, Anderson KC. Identifying Professional Education Gaps and Barriers in Multiple Myeloma Patient Care: Findings of the Managing Myeloma Continuing Educational Initiative Advisory Committee. Clinical Lymphoma Myeloma and Leukemia 2014;14:356-69. [DOI: 10.1016/j.clml.2014.04.011] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.9] [Reference Citation Analysis]
140 Morrison T, Booth RA, Hauff K, Berardi P, Visram A. Laboratory assessment of multiple myeloma. Adv Clin Chem 2019;89:1-58. [PMID: 30797467 DOI: 10.1016/bs.acc.2018.12.001] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 3.5] [Reference Citation Analysis]
141 Al-Farsi K. Multiple myeloma: an update. Oman Med J 2013;28:3-11. [PMID: 23386937 DOI: 10.5001/omj.2013.02] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 2.1] [Reference Citation Analysis]
142 Palumbo A, Bringhen S, Ludwig H, Dimopoulos MA, Bladé J, Mateos MV, Rosiñol L, Boccadoro M, Cavo M, Lokhorst H, Zweegman S, Terpos E, Davies F, Driessen C, Gimsing P, Gramatzki M, Hàjek R, Johnsen HE, Leal Da Costa F, Sezer O, Spencer A, Beksac M, Morgan G, Einsele H, San Miguel JF, Sonneveld P. Personalized therapy in multiple myeloma according to patient age and vulnerability: a report of the European Myeloma Network (EMN). Blood 2011;118:4519-29. [PMID: 21841166 DOI: 10.1182/blood-2011-06-358812] [Cited by in Crossref: 225] [Cited by in F6Publishing: 203] [Article Influence: 22.5] [Reference Citation Analysis]
143 Murase T, Inagaki A, Masaki A, Fujii K, Narita T, Ri M, Hanamura I, Iida S, Inagaki H. Plasma cell myeloma positive for t(14;20) with relapse in the central nervous system. J Clin Exp Hematop 2019;59:135-9. [PMID: 31391406 DOI: 10.3960/jslrt.19011] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
144 Wallington-Beddoe CT, Mynott RL. Prognostic and predictive biomarker developments in multiple myeloma. J Hematol Oncol 2021;14:151. [PMID: 34556161 DOI: 10.1186/s13045-021-01162-7] [Reference Citation Analysis]
145 Coudre C, Alani J, Ritchie W, Marsaud V, Sola B, Cahu J. HIF-1α and rapamycin act as gerosuppressant in multiple myeloma cells upon genotoxic stress. Cell Cycle 2016;15:2174-82. [PMID: 27340936 DOI: 10.1080/15384101.2016.1196302] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
146 Møller HE, Preiss BS, Pedersen P, Kristensen IB, Hansen CT, Frederiksen M, Abildgaard N, Møller MB. Clinicopathological features of plasmablastic multiple myeloma: a population-based cohort. APMIS 2015;123:652-8. [PMID: 26152595 DOI: 10.1111/apm.12411] [Cited by in Crossref: 14] [Cited by in F6Publishing: 10] [Article Influence: 2.3] [Reference Citation Analysis]
147 Aydin C, Ulas T, Hangul C, Yucel OK, Iltar U, Salim O, Ekinci D, Berker Karauzum S. Conventional Cytogenetics and Interphase Fluorescence In Situ Hybridization Results in Multiple Myeloma: A Turkey Laboratory Analysis of 381 Cases. Indian J Hematol Blood Transfus 2020;36:284-91. [PMID: 32425379 DOI: 10.1007/s12288-019-01215-5] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
148 Broderick P, Chubb D, Johnson DC, Weinhold N, Försti A, Lloyd A, Olver B, Ma Y, Dobbins SE, Walker BA, Davies FE, Gregory WA, Childs JA, Ross FM, Jackson GH, Neben K, Jauch A, Hoffmann P, Mühleisen TW, Nöthen MM, Moebus S, Tomlinson IP, Goldschmidt H, Hemminki K, Morgan GJ, Houlston RS. Common variation at 3p22.1 and 7p15.3 influences multiple myeloma risk. Nat Genet 2011;44:58-61. [PMID: 22120009 DOI: 10.1038/ng.993] [Cited by in Crossref: 114] [Cited by in F6Publishing: 101] [Article Influence: 11.4] [Reference Citation Analysis]
149 Mitra AK, Harding T, Mukherjee UK, Jang JS, Li Y, HongZheng R, Jen J, Sonneveld P, Kumar S, Kuehl WM, Rajkumar V, Van Ness B. A gene expression signature distinguishes innate response and resistance to proteasome inhibitors in multiple myeloma. Blood Cancer J 2017;7:e581. [PMID: 28665416 DOI: 10.1038/bcj.2017.56] [Cited by in Crossref: 23] [Cited by in F6Publishing: 20] [Article Influence: 5.8] [Reference Citation Analysis]
150 Kyrtsonis MC, Bartzis V, Papanikolaou X, Koulieris E, Georgiou G, Dimou M, Tzenou T, Panayiotidis P. Genetic and molecular mechanisms in multiple myeloma: a route to better understand disease pathogenesis and heterogeneity. Appl Clin Genet 2010;3:41-51. [PMID: 23776351 DOI: 10.2147/tacg.s7456] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
151 Bird JM, Owen RG, D'Sa S, Snowden JA, Pratt G, Ashcroft J, Yong K, Cook G, Feyler S, Davies F, Morgan G, Cavenagh J, Low E, Behrens J; Haemato-oncology Task Force of British Committee for Standards in Haematology (BCSH) and UK Myeloma Forum. Guidelines for the diagnosis and management of multiple myeloma 2011. Br J Haematol 2011;154:32-75. [PMID: 21569004 DOI: 10.1111/j.1365-2141.2011.08573.x] [Cited by in Crossref: 199] [Cited by in F6Publishing: 171] [Article Influence: 19.9] [Reference Citation Analysis]
152 Xu P, Liu X, Ouyang J, Chen B. TP53 mutation predicts the poor prognosis of non-Hodgkin lymphomas: Evidence from a meta-analysis. PLoS One 2017;12:e0174809. [PMID: 28369138 DOI: 10.1371/journal.pone.0174809] [Cited by in Crossref: 6] [Cited by in F6Publishing: 10] [Article Influence: 1.5] [Reference Citation Analysis]
153 Gentile M, Recchia AG, Mazzone C, Lucia E, Vigna E, Morabito F. Perspectives in the treatment of multiple myeloma. Expert Opin Biol Ther 2013;13 Suppl 1:S1-22. [PMID: 23692500 DOI: 10.1517/14712598.2013.799132] [Cited by in Crossref: 14] [Cited by in F6Publishing: 16] [Article Influence: 1.8] [Reference Citation Analysis]
154 Bodet L, Gomez-bougie P, Touzeau C, Dousset C, Descamps G, Maïga S, Avet-loiseau H, Bataille R, Moreau P, Le Gouill S, Pellat-deceunynck C, Amiot M. ABT-737 is highly effective against molecular subgroups of multiple myeloma. Blood 2011;118:3901-10. [DOI: 10.1182/blood-2010-11-317438] [Cited by in Crossref: 79] [Cited by in F6Publishing: 73] [Article Influence: 7.9] [Reference Citation Analysis]
155 Chng WJ, Dispenzieri A, Chim CS, Fonseca R, Goldschmidt H, Lentzsch S, Munshi N, Palumbo A, Miguel JS, Sonneveld P. IMWG consensus on risk stratification in multiple myeloma. Leukemia. 2014;28:269-277. [PMID: 23974982 DOI: 10.1038/leu.2013.247] [Cited by in Crossref: 337] [Cited by in F6Publishing: 314] [Article Influence: 42.1] [Reference Citation Analysis]
156 Dimopoulos MA, Palumbo A, Attal M, Beksaç M, Davies FE, Delforge M, Einsele H, Hajek R, Harousseau J, da Costa FL, Ludwig H, Mellqvist U, Morgan GJ, San-miguel JF, Zweegman S, Sonneveld P; on behalf of the European Myeloma Network. Optimizing the use of lenalidomide in relapsed or refractory multiple myeloma: consensus statement. Leukemia 2011;25:749-60. [DOI: 10.1038/leu.2011.3] [Cited by in Crossref: 84] [Cited by in F6Publishing: 75] [Article Influence: 8.4] [Reference Citation Analysis]
157 Knop S, Engelhardt M, Liebisch P, Meisner C, Holler E, Metzner B, Peest D, Kaufmann M, Bunjes D, Straka C, Fischer T, Sezer O, Hentrich M, Ostermann H, Bassermann F, Hess G, Hertenstein B, Freund M, Kropff M, Schmidt CA, Wolf H, Jung W, Frickhofen N, Mielke S, Bargou RC, Maschmeyer G, Svaldi M, Langer CH, Gramatzki M, Hebart H, Kanz L, Einsele H; on behalf of Deutsche Studiengruppe Multiples Myelom. Allogeneic transplantation in multiple myeloma: long-term follow-up and cytogenetic subgroup analysis. Leukemia 2019;33:2710-9. [DOI: 10.1038/s41375-019-0537-2] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 8.5] [Reference Citation Analysis]
158 Richardson PG, Schjesvold F, Weisel K, Moreau P, Anderson LD Jr, White D, Rodriguez-Otero P, Sonneveld P, Engelhardt M, Jenner M, Corso A, Dürig J, Pavic M, Salomo M, Beksac M, Oriol A, Lindsay J, Liberati AM, Galli M, Robak P, Larocca A, Yagci M, Vural F, Kanate AS, Jiang R, Grote L, Peluso T, Dimopoulos M. Pomalidomide, bortezomib, and dexamethasone at first relapse in lenalidomide-pretreated myeloma: A subanalysis of OPTIMISMM by clinical characteristics. Eur J Haematol 2021. [PMID: 34496096 DOI: 10.1111/ejh.13706] [Reference Citation Analysis]
159 Sawyer JR. The prognostic significance of cytogenetics and molecular profiling in multiple myeloma. Cancer Genet 2011;204:3-12. [PMID: 21356186 DOI: 10.1016/j.cancergencyto.2010.11.002] [Cited by in Crossref: 126] [Cited by in F6Publishing: 109] [Article Influence: 12.6] [Reference Citation Analysis]
160 Larsen JT, Kumar S. Evolving Paradigms in the Management of Multiple Myeloma: Novel Agents and Targeted Therapies. Rare Cancers Ther 2015;3:47-68. [PMID: 27182478 DOI: 10.1007/s40487-015-0009-4] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
161 Chen D, Zhou D, Xu J, Zhou R, Ouyang J, Chen B. Prognostic Value of 1q21 Gain in Multiple Myeloma. Clinical Lymphoma Myeloma and Leukemia 2019;19:e159-64. [DOI: 10.1016/j.clml.2018.12.002] [Cited by in Crossref: 6] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
162 Vargas-Rondón N, Villegas VE, Rondón-Lagos M. The Role of Chromosomal Instability in Cancer and Therapeutic Responses. Cancers (Basel) 2017;10:E4. [PMID: 29283387 DOI: 10.3390/cancers10010004] [Cited by in Crossref: 65] [Cited by in F6Publishing: 50] [Article Influence: 16.3] [Reference Citation Analysis]
163 João C, Figueiredo A, Martins HF. Advantageous use of lenalidomide in multiple myeloma: discussion of three case studies. Current Opinion in Oncology 2012;24:S13-20. [DOI: 10.1097/01.cco.0000410244.91697.5a] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
164 Buonaccorsi JN, Kroft SH, Harrington AM, VanTuinen P, Olteanu H. Clinicopathologic analysis of the impact of CD23 expression in plasma cell myeloma with t(11;14)(q13;q32). Ann Diagn Pathol 2011;15:385-8. [PMID: 21724429 DOI: 10.1016/j.anndiagpath.2011.04.004] [Reference Citation Analysis]
165 Cardona-Benavides IJ, de Ramón C, Gutiérrez NC. Genetic Abnormalities in Multiple Myeloma: Prognostic and Therapeutic Implications. Cells 2021;10:336. [PMID: 33562668 DOI: 10.3390/cells10020336] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
166 Rosiñol L, Oriol A, Teruel AI, Hernández D, López-Jiménez J, de la Rubia J, Granell M, Besalduch J, Palomera L, González Y, Etxebeste MA, Díaz-Mediavilla J, Hernández MT, de Arriba F, Gutiérrez NC, Martín-Ramos ML, Cibeira MT, Mateos MV, Martínez J, Alegre A, Lahuerta JJ, San Miguel J, Bladé J; Programa para el Estudio y la Terapéutica de las Hemopatías Malignas/Grupo Español de Mieloma (PETHEMA/GEM) group. Superiority of bortezomib, thalidomide, and dexamethasone (VTD) as induction pretransplantation therapy in multiple myeloma: a randomized phase 3 PETHEMA/GEM study. Blood 2012;120:1589-96. [PMID: 22791289 DOI: 10.1182/blood-2012-02-408922] [Cited by in Crossref: 325] [Cited by in F6Publishing: 303] [Article Influence: 36.1] [Reference Citation Analysis]
167 Herath NI, Rocques N, Garancher A, Eychène A, Pouponnot C. GSK3-mediated MAF phosphorylation in multiple myeloma as a potential therapeutic target. Blood Cancer J 2014;4:e175. [PMID: 24442204 DOI: 10.1038/bcj.2013.67] [Cited by in Crossref: 30] [Cited by in F6Publishing: 29] [Article Influence: 4.3] [Reference Citation Analysis]
168 Walker ZJ, VanWyngarden MJ, Stevens BM, Abbott D, Hammes A, Langouët-Astrie C, Smith CA, Palmer BE, Forsberg PA, Mark TM, Jordan CT, Sherbenou DW. Measurement of ex vivo resistance to proteasome inhibitors, IMiDs, and daratumumab during multiple myeloma progression. Blood Adv 2020;4:1628-39. [PMID: 32311014 DOI: 10.1182/bloodadvances.2019000122] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
169 Galtseva IV, Davydova YO, Kapranov NM, Julhakyan HL, Mendeleeva LP. Minimal residual disease in multiple myeloma: Benefits of flow cytometry. Int J Lab Hematol. 2018;40:12-20. [PMID: 29058372 DOI: 10.1111/ijlh.12757] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
170 Boyd KD, Pawlyn C, Morgan GJ, Davies FE. Understanding the molecular biology of myeloma and its therapeutic implications. Expert Rev Hematol 2012;5:603-17. [PMID: 23216592 DOI: 10.1586/ehm.12.51] [Cited by in Crossref: 13] [Cited by in F6Publishing: 8] [Article Influence: 1.6] [Reference Citation Analysis]
171 Jung S, Kim S, Gale M, Cherni I, Fonseca R, Carpten J, Salhia B. DNA methylation in multiple myeloma is weakly associated with gene transcription. PLoS One 2012;7:e52626. [PMID: 23285118 DOI: 10.1371/journal.pone.0052626] [Cited by in Crossref: 17] [Cited by in F6Publishing: 13] [Article Influence: 1.9] [Reference Citation Analysis]
172 Zatula A, Dikic A, Mulder C, Sharma A, Vågbø CB, Sousa MML, Waage A, Slupphaug G. Proteome alterations associated with transformation of multiple myeloma to secondary plasma cell leukemia. Oncotarget 2017;8:19427-42. [PMID: 28038447 DOI: 10.18632/oncotarget.14294] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
173 Rajkumar SV. Optimising bortezomib in newly diagnosed multiple myeloma. The Lancet Oncology 2010;11:909-10. [DOI: 10.1016/s1470-2045(10)70199-6] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
174 Shin HJ, Kim K, Lee JJ, Song MK, Lee EY, Park SH, Kim SH, Jang MA, Kim SJ, Chung JS. The t(11;14)(q13;q32) translocation as a poor prognostic parameter for autologous stem cell transplantation in myeloma patients with extramedullary plasmacytoma. Clin Lymphoma Myeloma Leuk 2015;15:227-35. [PMID: 25812994 DOI: 10.1016/j.clml.2014.12.007] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.6] [Reference Citation Analysis]
175 Murase T, Ri M, Narita T, Fujii K, Masaki A, Iida S, Inagaki H. Immunohistochemistry for identification of CCND1, NSD2, and MAF gene rearrangements in plasma cell myeloma. Cancer Sci 2019;110:2600-6. [PMID: 31218784 DOI: 10.1111/cas.14109] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
176 Korde N, Kristinsson SY, Landgren O. Monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma (SMM): novel biological insights and development of early treatment strategies. Blood 2011;117:5573-81. [PMID: 21441462 DOI: 10.1182/blood-2011-01-270140] [Cited by in Crossref: 117] [Cited by in F6Publishing: 104] [Article Influence: 11.7] [Reference Citation Analysis]
177 Paul B, Kang S, Zheng Z, Kang Y. The challenges of checkpoint inhibition in the treatment of multiple myeloma. Cell Immunol 2018;334:87-98. [PMID: 30342750 DOI: 10.1016/j.cellimm.2018.10.003] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
178 Sawyer JR, Tian E, Shaughnessy JD Jr, Epstein J, Swanson CM, Stangeby C, Hale CL, Parr L, Lynn M, Sammartino G, Lukacs JL, Stein C, Bailey C, Zangari M, Davies FE, Van Rhee F, Barlogie B, Morgan GJ. Hyperhaploidy is a novel high-risk cytogenetic subgroup in multiple myeloma. Leukemia 2017;31:637-44. [PMID: 27694925 DOI: 10.1038/leu.2016.253] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 3.6] [Reference Citation Analysis]
179 Hussain T, Liu B, Shrock MS, Williams T, Aldaz CM. WWOX, the FRA16D gene: A target of and a contributor to genomic instability. Genes Chromosomes Cancer 2019;58:324-38. [PMID: 30350478 DOI: 10.1002/gcc.22693] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 4.7] [Reference Citation Analysis]
180 Paiva B, Gutiérrez NC, Rosiñol L, Vídriales MB, Montalbán MÁ, Martínez-López J, Mateos MV, Cibeira MT, Cordón L, Oriol A, Terol MJ, Echeveste MA, de Paz R, de Arriba F, Palomera L, de la Rubia J, Díaz-Mediavilla J, Sureda A, Gorosquieta A, Alegre A, Martin A, Hernández MT, Lahuerta JJ, Bladé J, San Miguel JF; PETHEMA/GEM (Programa para el Estudio de la Terapéutica en Hemopatías Malignas/Grupo Español de Mieloma) Cooperative Study Groups. High-risk cytogenetics and persistent minimal residual disease by multiparameter flow cytometry predict unsustained complete response after autologous stem cell transplantation in multiple myeloma. Blood 2012;119:687-91. [PMID: 22128143 DOI: 10.1182/blood-2011-07-370460] [Cited by in Crossref: 214] [Cited by in F6Publishing: 195] [Article Influence: 21.4] [Reference Citation Analysis]
181 Bila J, Sretenovic A, Jelicic J, Tosic N, Glumac I, Fekete MD, Antic D, Balint MT, Markovic O, Milojevic Z, Radojkovic M, Trajkovic G, Puric M, Pavlovic S, Mihaljevic B. Prognostic Significance of Cereblon Expression in Patients With Multiple Myeloma. Clin Lymphoma Myeloma Leuk 2016;16:610-5. [PMID: 27618360 DOI: 10.1016/j.clml.2016.08.007] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
182 Kastritis E, Dimopoulos MA. Appraising myc involvement in high risk myeloma. Leuk Lymphoma 2015;56:551-2. [PMID: 25257347 DOI: 10.3109/10428194.2014.961015] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
183 Zhang Y, Bao L, Lu J, Liu KY, Li JL, Qin YZ, Chen H, Li LD, Kong Y, Shi HX, Lai YY, Liu YR, Jiang B, Chen SS, Huang XJ, Ruan GR. The clinical value of the quantitative detection of four cancer-testis antigen genes in multiple myeloma. Mol Cancer 2014;13:25. [PMID: 24499297 DOI: 10.1186/1476-4598-13-25] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
184 Roullet M, Bagg A. The Basis and Rational Use of Molecular Genetic Testing in Mature B-cell Lymphomas. Advances in Anatomic Pathology 2010;17:333-58. [DOI: 10.1097/pap.0b013e3181ec7466] [Cited by in Crossref: 6] [Article Influence: 0.5] [Reference Citation Analysis]
185 Roos-Weil D, Moreau P, Avet-Loiseau H, Golmard JL, Kuentz M, Vigouroux S, Socié G, Furst S, Soulier J, Le Gouill S, François S, Thiebaut A, Buzyn A, Maillard N, Yakoub-Agha I, Raus N, Fermand JP, Michallet M, Blaise D, Dhédin N; Société Française de Greffe de Moelle et de Thérapie Cellulaire (SFGM-TC). Impact of genetic abnormalities after allogeneic stem cell transplantation in multiple myeloma: a report of the Société Française de Greffe de Moelle et de Thérapie Cellulaire. Haematologica 2011;96:1504-11. [PMID: 21685472 DOI: 10.3324/haematol.2011.042713] [Cited by in Crossref: 39] [Cited by in F6Publishing: 39] [Article Influence: 3.9] [Reference Citation Analysis]
186 Jackson GH, Davies FE, Pawlyn C, Cairns DA, Striha A, Collett C, Waterhouse A, Jones JR, Kishore B, Garg M, Williams CD, Karunanithi K, Lindsay J, Allotey D, Shafeek S, Jenner MW, Cook G, Russell NH, Kaiser MF, Drayson MT, Owen RG, Gregory WM, Morgan GJ, Clinical Studies Group UNHO. Lenalidomide before and after autologous stem cell transplantation for transplant-eligible patients of all ages in the randomized, phase III, Myeloma XI trial. Haematologica 2021;106:1957-67. [PMID: 32499244 DOI: 10.3324/haematol.2020.247130] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
187 Soekojo CY, de Mel S, Ooi M, Yan B, Chng WJ. Potential Clinical Application of Genomics in Multiple Myeloma. Int J Mol Sci 2018;19:E1721. [PMID: 29890777 DOI: 10.3390/ijms19061721] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
188 Lu G, Muddasani R, Orlowski RZ, Abruzzo LV, Qazilbash MH, You MJ, Wang Y, Zhao M, Chen S, Glitza IC, Medeiros LJ. Plasma cell enrichment enhances detection of high-risk cytogenomic abnormalities by fluorescence in situ hybridization and improves risk stratification of patients with plasma cell neoplasms. Arch Pathol Lab Med 2013;137:625-31. [PMID: 23627452 DOI: 10.5858/arpa.2012-0209-OA] [Cited by in Crossref: 18] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
189 Lohr JG, Stojanov P, Carter SL, Cruz-Gordillo P, Lawrence MS, Auclair D, Sougnez C, Knoechel B, Gould J, Saksena G, Cibulskis K, McKenna A, Chapman MA, Straussman R, Levy J, Perkins LM, Keats JJ, Schumacher SE, Rosenberg M; Multiple Myeloma Research Consortium, Getz G, Golub TR. Widespread genetic heterogeneity in multiple myeloma: implications for targeted therapy. Cancer Cell. 2014;25:91-101. [PMID: 24434212 DOI: 10.1016/j.ccr.2013.12.015] [Cited by in Crossref: 591] [Cited by in F6Publishing: 562] [Article Influence: 84.4] [Reference Citation Analysis]
190 Gole L, Lin A, Chua C, Chng WJ. Modified cIg-FISH protocol for multiple myeloma in routine cytogenetic laboratory practice. Cancer Genet 2014;207:31-4. [PMID: 24485403 DOI: 10.1016/j.cancergen.2013.12.001] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
191 Gillardin PS, Descamps G, Maiga S, Tessoulin B, Djamai H, Lucani B, Chiron D, Moreau P, Le Gouill S, Amiot M, Pellat-Deceunynck C, Moreau-Aubry A. Decitabine and Melphalan Fail to Reactivate p73 in p53 Deficient Myeloma Cells. Int J Mol Sci 2017;19:E40. [PMID: 29295500 DOI: 10.3390/ijms19010040] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
192 Li C, Wendlandt EB, Darbro B, Xu H, Thomas GS, Tricot G, Chen F, Shaughnessy JD Jr, Zhan F. Genetic Analysis of Multiple Myeloma Identifies Cytogenetic Alterations Implicated in Disease Complexity and Progression. Cancers (Basel) 2021;13:517. [PMID: 33572851 DOI: 10.3390/cancers13030517] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
193 Segges P, Braggio E. Genetic markers used for risk stratification in multiple myeloma. Genet Res Int 2011;2011:798089. [PMID: 22567368 DOI: 10.4061/2011/798089] [Cited by in Crossref: 3] [Cited by in F6Publishing: 6] [Article Influence: 0.3] [Reference Citation Analysis]
194 Plunkett GA, West VC. Systemic joint laxity and mandibular range of movement. Cranio. 1988;6:320-326. [PMID: 3255516 DOI: 10.1038/s41408-020-0336-z] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 0.3] [Reference Citation Analysis]
195 Kumar AK, Dakhil C, Teeka Satyan M, Haideri N. Extramedullary progression of multiple myeloma despite concomitant medullary response to multiple combination therapies and autologous transplant: a case report. J Med Case Rep 2014;8:299. [PMID: 25200389 DOI: 10.1186/1752-1947-8-299] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 0.9] [Reference Citation Analysis]
196 Ko YH, Niedźwiecka K, Casal M, Pedersen PL, Ułaszewski S. 3-Bromopyruvate as a potent anticancer therapy in honor and memory of the late Professor André Goffeau. Yeast 2019;36:211-21. [PMID: 30462852 DOI: 10.1002/yea.3367] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
197 Kryukov F, Nemec P, Dementyeva E, Kubiczkova L, Ihnatova I, Budinska E, Jarkovsky J, Sevcikova S, Kuglik P, Hajek R. Molecular heterogeneity and centrosome-associated genes in multiple myeloma. Leukemia & Lymphoma 2013;54:1982-8. [DOI: 10.3109/10428194.2013.764416] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
198 Rizzieri D, Paul B, Kang Y. Metabolic alterations and the potential for targeting metabolic pathways in the treatment of multiple myeloma. J Cancer Metastasis Treat 2019;5:26. [PMID: 31020046 DOI: 10.20517/2394-4722.2019.05] [Cited by in Crossref: 7] [Cited by in F6Publishing: 14] [Article Influence: 3.5] [Reference Citation Analysis]
199 Bhutani M, Landgren O, Usmani SZ. Multiple myeloma: is it time for biomarker-driven therapy? Am Soc Clin Oncol Educ Book 2015;:e493-503. [PMID: 25993214 DOI: 10.14694/EdBook_AM.2015.35.e493] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 1.8] [Reference Citation Analysis]
200 Russell SJ, Rajkumar SV. Multiple myeloma and the road to personalised medicine. Lancet Oncol 2011;12:617-9. [PMID: 21664869 DOI: 10.1016/S1470-2045(11)70143-7] [Cited by in Crossref: 40] [Cited by in F6Publishing: 17] [Article Influence: 4.0] [Reference Citation Analysis]
201 Wong KY, Huang X, Chim CS. DNA methylation of microRNA genes in multiple myeloma. Carcinogenesis 2012;33:1629-38. [DOI: 10.1093/carcin/bgs212] [Cited by in Crossref: 53] [Cited by in F6Publishing: 54] [Article Influence: 5.9] [Reference Citation Analysis]
202 Paiva B, Gutiérrez N, Chen X, Vídriales M, Montalbán M, Rosiñol L, Oriol A, Martínez-lópez J, Mateos M, López-corral L, Díaz-rodríguez E, Pérez J, Fernández-redondo E, de Arriba F, Palomera L, Bengoechea E, Terol M, de Paz R, Martin A, Hernández J, Orfao A, Lahuerta J, Bladé J, Pandiella A, Miguel JS; on behalf of the GEM (Grupo Español de Mieloma)/PETHEMA (Programa para el Estudio de la Terapéutica en Hemopatías Malignas) cooperative study groups. Clinical significance of CD81 expression by clonal plasma cells in high-risk smoldering and symptomatic multiple myeloma patients. Leukemia 2012;26:1862-9. [DOI: 10.1038/leu.2012.42] [Cited by in Crossref: 51] [Cited by in F6Publishing: 44] [Article Influence: 5.7] [Reference Citation Analysis]
203 Gomez-Bougie P, Amiot M. Apoptotic machinery diversity in multiple myeloma molecular subtypes. Front Immunol 2013;4:467. [PMID: 24391642 DOI: 10.3389/fimmu.2013.00467] [Cited by in Crossref: 16] [Cited by in F6Publishing: 19] [Article Influence: 2.0] [Reference Citation Analysis]
204 Khalife J, Ghose J, Martella M, Viola D, Rocci A, Troadec E, Terrazas C, Satoskar AR, Gunes EG, Dona A, Sanchez JF, Bergsagel PL, Chesi M, Pozhitkov A, Rosen S, Marcucci G, Keats JJ, Hofmeister CC, Krishnan A, Caserta E, Pichiorri F. MiR-16 regulates crosstalk in NF-κB tolerogenic inflammatory signaling between myeloma cells and bone marrow macrophages. JCI Insight 2019;4:129348. [PMID: 31593552 DOI: 10.1172/jci.insight.129348] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 5.5] [Reference Citation Analysis]
205 Nassar S, Taher A, Spear R, Wang F, Madewell JE, Mujtaba B. Multiple Myeloma: Role of Imaging in Diagnosis, Staging, and Treatment Response Assessment. Semin Ultrasound CT MR 2021;42:184-93. [PMID: 33814104 DOI: 10.1053/j.sult.2020.08.019] [Reference Citation Analysis]
206 Saitoh T, Oda T. DNA Damage Response in Multiple Myeloma: The Role of the Tumor Microenvironment. Cancers (Basel) 2021;13:504. [PMID: 33525741 DOI: 10.3390/cancers13030504] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
207 Morel P, Merlini G. Risk stratification in Waldenström macroglobulinemia. Expert Rev Hematol 2012;5:187-99. [PMID: 22475287 DOI: 10.1586/ehm.11.82] [Cited by in Crossref: 12] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
208 Jiang A, Reece D, Chang H. Genomic stratification of multiple myeloma treated with novel agents. Leuk Lymphoma 2012;53:202-7. [PMID: 21823830 DOI: 10.3109/10428194.2011.608449] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 0.9] [Reference Citation Analysis]
209 Oh S, Koo DH, Kwon MJ, Kim K, Suh C, Min CK, Yoon SS, Shin HJ, Jo DY, Kwak JY, Kim JS, Sohn SK, Joo YD, Eom HS, Kim SH, Kim YS, Kim C, Mun YC, Kim H, Lee DS, Lee JH; Korean Multiple Myeloma Working Party (KMMWP). Chromosome 13 deletion and hypodiploidy on conventional cytogenetics are robust prognostic factors in Korean multiple myeloma patients: web-based multicenter registry study. Ann Hematol 2014;93:1353-61. [PMID: 24671365 DOI: 10.1007/s00277-014-2057-5] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 2.0] [Reference Citation Analysis]
210 Hultcrantz M, Yellapantula V, Rustad EH. Genomic profiling of multiple myeloma: New insights and modern technologies. Best Pract Res Clin Haematol 2020;33:101153. [PMID: 32139018 DOI: 10.1016/j.beha.2020.101153] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
211 Kalff A, Spencer A. The t(4;14) translocation and FGFR3 overexpression in multiple myeloma: prognostic implications and current clinical strategies. Blood Cancer J. 2012;2:e89. [PMID: 22961061 DOI: 10.1038/bcj.2012.37] [Cited by in Crossref: 56] [Cited by in F6Publishing: 56] [Article Influence: 6.2] [Reference Citation Analysis]
212 Bi C, Chng WJ. MicroRNA: important player in the pathobiology of multiple myeloma. Biomed Res Int 2014;2014:521586. [PMID: 24991558 DOI: 10.1155/2014/521586] [Cited by in Crossref: 29] [Cited by in F6Publishing: 37] [Article Influence: 4.1] [Reference Citation Analysis]
213 Duek A, Trakhtenbrot L, Amariglio N, Benyamini N, Zilbershats I, Ganzel C, Shevetz O, Leiba R, Rozic G, Nagler A, Leiba M. Newly diagnosed multiple myeloma patients carrying monoallelic deletion of the whole locus of immunoglobulin heavy chain gene have a better prognosis compared to those with t(4;14) and t(14;16). Genes Chromosomes Cancer 2019;58:516-20. [PMID: 30675954 DOI: 10.1002/gcc.22738] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
214 Chi J, Ballabio E, Chen XH, Kušec R, Taylor S, Hay D, Tramonti D, Saunders NJ, Littlewood T, Pezzella F, Boultwood J, Wainscoat JS, Hatton CS, Lawrie CH. MicroRNA expression in multiple myeloma is associated with genetic subtype, isotype and survival. Biol Direct 2011;6:23. [PMID: 21592325 DOI: 10.1186/1745-6150-6-23] [Cited by in Crossref: 66] [Cited by in F6Publishing: 69] [Article Influence: 6.6] [Reference Citation Analysis]
215 El-Ghammaz AM, Abdelwahed E. Bortezomib-based induction improves progression-free survival of myeloma patients harboring 17p deletion and/or t(4;14) and overcomes their adverse prognosis. Ann Hematol 2016;95:1315-21. [PMID: 27184486 DOI: 10.1007/s00277-016-2692-0] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
216 Tan D, Kim K, Kim JS, Eom HS, Teoh G, Ong KH, Goh YT, Durie BG, Chng WJ, Lee JH. The impact of upfront versus sequential use of bortezomib among patients with newly diagnosed multiple myeloma (MM): a joint analysis of the Singapore MM Study Group and the Korean MM Working Party for the Asian myeloma network. Leuk Res 2013;37:1070-6. [PMID: 23816344 DOI: 10.1016/j.leukres.2013.06.008] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 1.4] [Reference Citation Analysis]
217 Tarigopula A, Chandrashekar V, Govindasamy P. Cytogenetic Profiling of Myelomas, Association With Complete Blood Count: Study of 180 Patients. Lab Med 2017;49:68-74. [PMID: 29206983 DOI: 10.1093/labmed/lmx066] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
218 Bergstrom DJ, Kotb R, Louzada ML, Sutherland HJ, Tavoularis S, Venner CP; Myeloma Canada Research Network Consensus Guideline Consortium. Consensus Guidelines on the Diagnosis of Multiple Myeloma and Related Disorders: Recommendations of the Myeloma Canada Research Network Consensus Guideline Consortium. Clin Lymphoma Myeloma Leuk. 2020;20:e352-e367. [PMID: 32249195 DOI: 10.1016/j.clml.2020.01.017] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
219 Bochtler T, Hegenbart U, Kunz C, Benner A, Seckinger A, Dietrich S, Granzow M, Neben K, Goldschmidt H, Ho AD, Hose D, Jauch A, Schönland SO. Gain of chromosome 1q21 is an independent adverse prognostic factor in light chain amyloidosis patients treated with melphalan/dexamethasone. Amyloid 2013;21:9-17. [DOI: 10.3109/13506129.2013.854766] [Cited by in Crossref: 57] [Cited by in F6Publishing: 56] [Article Influence: 8.1] [Reference Citation Analysis]
220 An G, Acharya C, Deng S, Yi S, Xu Y, Qin X, Sui W, Li Z, Shi L, Zang M, Feng X, Hao M, Zou D, Zhao Y, Qi J, Cheng T, Ru K, Wang J, Tai YT, Qiu L. Cytogenetic and clinical marks for defining high-risk myeloma in the context of bortezomib treatment. Exp Hematol 2015;43:168-176.e2. [PMID: 25462022 DOI: 10.1016/j.exphem.2014.11.004] [Cited by in Crossref: 4] [Cited by in F6Publishing: 7] [Article Influence: 0.6] [Reference Citation Analysis]
221 Srour SA, Saliba RM, Bashir Q, Popat UR, Ahmed S, Mehta RS, Delgado R, Rondon G, Parmar S, Kebriaei P, Hosing C, Manasanch EE, Lee HC, Patel KK, Orlowski RZ, Shpall E, Champlin RE, Qazilbash MH, Nieto Y. Influence of Overlapping Genetic Abnormalities on Treatment Outcomes of Multiple Myeloma. Transplant Cell Ther 2021;27:243.e1-6. [PMID: 33781521 DOI: 10.1016/j.jtct.2020.10.021] [Reference Citation Analysis]
222 Hao S, Lin P, Medeiros LJ, Fang L, Carballo-Zarate AA, Konoplev SN, Sargent RL, Weber DM, Thomas SK, Manasanch EE, Orlowski RZ, Lu X. Clinical implications of cytogenetic heterogeneity in multiple myeloma patients with TP53 deletion. Mod Pathol 2017;30:1378-86. [PMID: 28664940 DOI: 10.1038/modpathol.2017.63] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
223 Reece DE, Masih-Khan E, Atenafu EG, Jimenez-Zepeda VH, McCurdy A, Song K, LeBlanc R, Sebag M, White D, Cherniawsky H, Reiman A, Stakiw J, Louzada ML, Kotb R, Aslam M, Gul E, Venner CP. Retrospective study of treatment patterns and outcomes post-lenalidomide for multiple myeloma in Canada. Eur J Haematol 2021. [PMID: 34129703 DOI: 10.1111/ejh.13678] [Reference Citation Analysis]
224 Borrello I. Can we change the disease biology of multiple myeloma? Leuk Res. 2012;36 Suppl 1:S3-12. [PMID: 23176722 DOI: 10.1016/s0145-2126(12)70003-6] [Cited by in Crossref: 38] [Cited by in F6Publishing: 23] [Article Influence: 4.8] [Reference Citation Analysis]
225 Groen RW, de Rooij MF, Kocemba KA, Reijmers RM, de Haan-Kramer A, Overdijk MB, Aalders L, Rozemuller H, Martens AC, Bergsagel PL, Kersten MJ, Pals ST, Spaargaren M. N-cadherin-mediated interaction with multiple myeloma cells inhibits osteoblast differentiation. Haematologica 2011;96:1653-61. [PMID: 21828122 DOI: 10.3324/haematol.2010.038133] [Cited by in Crossref: 23] [Cited by in F6Publishing: 22] [Article Influence: 2.3] [Reference Citation Analysis]
226 Cossu G, Terrier L, Benboubker L, Destrieux C, Velut S, François P, Zemmoura I, Amelot A. Spinal metastases in multiple myeloma: A high-risk subgroup for ISS III patients. Surgical Oncology 2018;27:321-6. [DOI: 10.1016/j.suronc.2018.05.005] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
227 Kumar S. Blind men and an elephant. Blood 2015;125:745-7. [PMID: 25634613 DOI: 10.1182/blood-2014-12-615328] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]
228 Okello CD, Mulumba Y, Omoding A, Ddungu H, Welch K, Thompson CL, Cowan AJ, Cooney MM, Orem J. Characteristics and outcomes of patients with multiple myeloma at the Uganda Cancer Institute. Afr Health Sci 2021;21:67-74. [PMID: 34394283 DOI: 10.4314/ahs.v21i1.11] [Reference Citation Analysis]
229 Stella F, Pedrazzini E, Agazzoni M, Ballester O, Slavutsky I. Cytogenetic Alterations in Multiple Myeloma: Prognostic Significance and the Choice of Frontline Therapy. Cancer Investigation 2015;33:496-504. [DOI: 10.3109/07357907.2015.1080833] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
230 Harrison SJ, Perrot A, Alegre A, Simpson D, Wang MC, Spencer A, Delimpasi S, Hulin C, Sunami K, Facon T, Vlummens P, Yong K, Campana F, Inchauspé M, Macé S, Risse ML, van de Velde H, Richardson P. Subgroup analysis of ICARIA-MM study in relapsed/refractory multiple myeloma patients with high-risk cytogenetics. Br J Haematol 2021;194:120-31. [PMID: 34036560 DOI: 10.1111/bjh.17499] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
231 Genadieva-Stavric S, Cavallo F, Palumbo A. New approaches to management of multiple myeloma. Curr Treat Options Oncol 2014;15:157-70. [PMID: 24578203 DOI: 10.1007/s11864-014-0276-6] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 1.8] [Reference Citation Analysis]
232 Avet-Loiseau H, Bahlis NJ, Chng WJ, Masszi T, Viterbo L, Pour L, Ganly P, Palumbo A, Cavo M, Langer C, Pluta A, Nagler A, Kumar S, Ben-Yehuda D, Rajkumar SV, San-Miguel J, Berg D, Lin J, van de Velde H, Esseltine DL, di Bacco A, Moreau P, Richardson PG. Ixazomib significantly prolongs progression-free survival in high-risk relapsed/refractory myeloma patients. Blood 2017;130:2610-8. [PMID: 29054911 DOI: 10.1182/blood-2017-06-791228] [Cited by in Crossref: 64] [Cited by in F6Publishing: 53] [Article Influence: 16.0] [Reference Citation Analysis]
233 Smetana J, Oppelt J, Štork M, Pour L, Kuglík P. Chromothripsis 18 in multiple myeloma patient with rapid extramedullary relapse. Mol Cytogenet 2018;11:7. [PMID: 29375670 DOI: 10.1186/s13039-018-0357-5] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
234 Iwama K, Chihara D, Tsuda K, Ugai T, Sugihara H, Nishida Y, Yamakura M, Takeuchi M, Matsue K. Normalization of free light chain kappa/lambda ratio is a robust prognostic indicator of favorable outcome in patients with multiple myeloma. Eur J Haematol 2013;90:134-41. [DOI: 10.1111/ejh.12050] [Cited by in Crossref: 24] [Cited by in F6Publishing: 22] [Article Influence: 3.0] [Reference Citation Analysis]
235 Wang ZL, Liu Y, Zhou YL, Li JL, Sun QY, Wu LX, Wen L, Lai YY, Liu YR, Chang YJ, Shi HX, Liu KY, Huang XJ, Lu J, Ruan GR. Osteoclast stimulatory transmembrane protein (OC-STAMP) is a promising molecular prognostic indicator for multiple myeloma. Eur J Haematol 2020;105:185-95. [PMID: 32282962 DOI: 10.1111/ejh.13425] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
236 Chubb D, Weinhold N, Broderick P, Chen B, Johnson DC, Försti A, Vijayakrishnan J, Migliorini G, Dobbins SE, Holroyd A, Hose D, Walker BA, Davies FE, Gregory WA, Jackson GH, Irving JA, Pratt G, Fegan C, Fenton JA, Neben K, Hoffmann P, Nöthen MM, Mühleisen TW, Eisele L, Ross FM, Straka C, Einsele H, Langer C, Dörner E, Allan JM, Jauch A, Morgan GJ, Hemminki K, Houlston RS, Goldschmidt H. Common variation at 3q26.2, 6p21.33, 17p11.2 and 22q13.1 influences multiple myeloma risk. Nat Genet 2013;45:1221-5. [PMID: 23955597 DOI: 10.1038/ng.2733] [Cited by in Crossref: 113] [Cited by in F6Publishing: 97] [Article Influence: 14.1] [Reference Citation Analysis]
237 Harousseau J. Ten Years of Improvement in the Management of Multiple Myeloma: 2000-2010. Clinical Lymphoma Myeloma and Leukemia 2010;10:424-42. [DOI: 10.3816/clml.2010.n.076] [Cited by in Crossref: 24] [Cited by in F6Publishing: 9] [Article Influence: 2.2] [Reference Citation Analysis]
238 Roy P, Sarkar UA, Basak S. The NF-κB Activating Pathways in Multiple Myeloma. Biomedicines 2018;6:E59. [PMID: 29772694 DOI: 10.3390/biomedicines6020059] [Cited by in Crossref: 28] [Cited by in F6Publishing: 22] [Article Influence: 9.3] [Reference Citation Analysis]
239 Schmidt-Hieber M, Gutiérrez ML, Pérez-Andrés M, Paiva B, Rasillo A, Tabernero MD, Sayagués JM, Lopez A, Bárcena P, Sanchez ML, Gutiérrez NC, San Miguel JF, Orfao A. Cytogenetic profiles in multiple myeloma and monoclonal gammopathy of undetermined significance: a study in highly purified aberrant plasma cells. Haematologica 2013;98:279-87. [PMID: 22929983 DOI: 10.3324/haematol.2011.060632] [Cited by in Crossref: 25] [Cited by in F6Publishing: 26] [Article Influence: 2.8] [Reference Citation Analysis]
240 Dalland JC, Smadbeck JB, Sharma N, Meyer RG, Pearce KE, Greipp PT, Peterson JF, Kumar S, Ketterling RP, King RL, Baughn LB. Increased complexity of t(11;14) rearrangements in plasma cell neoplasms compared with mantle cell lymphoma. Genes Chromosomes Cancer 2021;60:678-86. [PMID: 34124820 DOI: 10.1002/gcc.22977] [Reference Citation Analysis]
241 González-Calle V, Keane N, Braggio E, Fonseca R. Precision Medicine in Myeloma: Challenges in Defining an Actionable Approach. Clin Lymphoma Myeloma Leuk 2017;17:621-30. [PMID: 28743429 DOI: 10.1016/j.clml.2017.06.021] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
242 Shetty S, Siady M, Mallempati KC, Wilson A, Poarch J, Chandler B, Gray J, Salama ME. Utility of a column-free cell sorting system for separation of plasma cells in multiple myeloma FISH testing in clinical laboratories. Int J Hematol 2012;95:274-81. [PMID: 22328174 DOI: 10.1007/s12185-012-1021-1] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
243 Rajkumar SV, Dispenzieri A. Multiple Myeloma and Related Disorders. Abeloff's Clinical Oncology. Elsevier; 2020. pp. 1884-1910.e7. [DOI: 10.1016/b978-0-323-47674-4.00101-8] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
244 Rio-Machin A, Ferreira BI, Henry T, Gómez-López G, Agirre X, Alvarez S, Rodriguez-Perales S, Prosper F, Calasanz MJ, Martínez J, Fonseca R, Cigudosa JC. Downregulation of specific miRNAs in hyperdiploid multiple myeloma mimics the oncogenic effect of IgH translocations occurring in the non-hyperdiploid subtype. Leukemia 2013;27:925-31. [PMID: 23174883 DOI: 10.1038/leu.2012.302] [Cited by in Crossref: 23] [Cited by in F6Publishing: 25] [Article Influence: 2.6] [Reference Citation Analysis]
245 Wong KY, Chim CS. DNA methylation of tumor suppressor protein-coding and non-coding genes in multiple myeloma. Epigenomics 2015;7:985-1001. [DOI: 10.2217/epi.15.57] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 3.5] [Reference Citation Analysis]
246 Cazaubiel T, Mulas O, Montes L, Schavgoulidze A, Avet-Loiseau H, Corre J, Perrot A. Risk and Response-Adapted Treatment in Multiple Myeloma. Cancers (Basel) 2020;12:E3497. [PMID: 33255368 DOI: 10.3390/cancers12123497] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
247 Yoshizawa S, Ohyashiki JH, Ohyashiki M, Umezu T, Suzuki K, Inagaki A, Iida S, Ohyashiki K. Downregulated plasma miR-92a levels have clinical impact on multiple myeloma and related disorders. Blood Cancer J 2012;2:e53. [PMID: 22829237 DOI: 10.1038/bcj.2011.51] [Cited by in Crossref: 50] [Cited by in F6Publishing: 53] [Article Influence: 5.6] [Reference Citation Analysis]
248 Gandolfi S, Prada CP, Richardson PG. How I treat the young patient with multiple myeloma. Blood 2018;132:1114-24. [PMID: 29967130 DOI: 10.1182/blood-2017-05-693606] [Cited by in Crossref: 24] [Cited by in F6Publishing: 23] [Article Influence: 8.0] [Reference Citation Analysis]
249 Shumilov E, Flach J, Pabst T, Fiedler M, Angelillo-scherrer A, Trümper L, Joncourt R, Kohlmann A, Bacher U. Genetic alterations crossing the borders of distinct hematopoetic lineages and solid tumors: Diagnostic challenges in the era of high-throughput sequencing in hemato-oncology. Critical Reviews in Oncology/Hematology 2018;126:64-79. [DOI: 10.1016/j.critrevonc.2018.03.020] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
250 Munshi NC, Avet-Loiseau H. Genomics in multiple myeloma. Clin Cancer Res. 2011;17:1234-1242. [PMID: 21411439 DOI: 10.1158/1078-0432.ccr-10-1843] [Cited by in Crossref: 68] [Cited by in F6Publishing: 30] [Article Influence: 6.8] [Reference Citation Analysis]
251 Vrábel D, Pour L, Ševčíková S. The impact of NF-κB signaling on pathogenesis and current treatment strategies in multiple myeloma. Blood Reviews 2019;34:56-66. [DOI: 10.1016/j.blre.2018.11.003] [Cited by in Crossref: 35] [Cited by in F6Publishing: 35] [Article Influence: 17.5] [Reference Citation Analysis]
252 Chen X, Luo X, Zu Y, Issa HA, Li L, Ye H, Yang T, Hu J, Wei L. Severe renal impairment as an adverse prognostic factor for survival in newly diagnosed multiple myeloma patients. J Clin Lab Anal 2020;34:e23416. [PMID: 32710448 DOI: 10.1002/jcla.23416] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
253 Kryukov F, Nemec P, Radova L, Kryukova E, Okubote S, Minarik J, Stefanikova Z, Pour L, Hajek R. Centrosome associated genes pattern for risk sub-stratification in multiple myeloma. J Transl Med 2016;14:150. [PMID: 27234807 DOI: 10.1186/s12967-016-0906-9] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.4] [Reference Citation Analysis]
254 Greenberg AJ, Philip S, Paner A, Velinova S, Badros A, Catchatourian R, Ketterling R, Kyle RA, Kumar S, Vachon CM, Rajkumar SV. Racial differences in primary cytogenetic abnormalities in multiple myeloma: a multi-center study. Blood Cancer J 2015;5:e271. [PMID: 25555162 DOI: 10.1038/bcj.2014.91] [Cited by in Crossref: 8] [Cited by in F6Publishing: 11] [Article Influence: 1.3] [Reference Citation Analysis]
255 Wennmann M, Hielscher T, Kintzelé L, Menze BH, Langs G, Merz M, Sauer S, Kauczor HU, Schlemmer HP, Delorme S, Goldschmidt H, Weinhold N, Hillengass J, Weber MA. Analyzing Longitudinal wb-MRI Data and Clinical Course in a Cohort of Former Smoldering Multiple Myeloma Patients: Connections between MRI Findings and Clinical Progression Patterns. Cancers (Basel) 2021;13:961. [PMID: 33668879 DOI: 10.3390/cancers13050961] [Reference Citation Analysis]
256 Fan L, Hong J, Huang H, Fu D, Wu S, Wang Q, Ye Y, Liu Y. High Expression of Phosphorylated Extracellular Signal-Regulated Kinase (ERK1/2) is Associated with Poor Prognosis in Newly Diagnosed Patients with Multiple Myeloma. Med Sci Monit 2017;23:2636-43. [PMID: 28557972 DOI: 10.12659/msm.901850] [Cited by in Crossref: 3] [Article Influence: 0.8] [Reference Citation Analysis]
257 Chesi M, Bergsagel PL. Many multiple myelomas: making more of the molecular mayhem. Hematology Am Soc Hematol Educ Program 2011;2011:344-53. [PMID: 22160056 DOI: 10.1182/asheducation-2011.1.344] [Cited by in Crossref: 39] [Cited by in F6Publishing: 38] [Article Influence: 4.3] [Reference Citation Analysis]
258 Ai X, Wang X, Wang B, Chen S, Wang J, Li Q, An G, Ru K. [Application of BIOMED- 2 standardized Ig gene rearrangement system in multiple myeloma]. Zhonghua Xue Ye Xue Za Zhi 2015;36:918-21. [PMID: 26632463 DOI: 10.3760/cma.j.issn.0253-2727.2015.11.006] [Reference Citation Analysis]
259 Walker I, Coady A, Neat M, Ladon D, Benjamin R, El-Najjar I, Kazmi M, Schey S, Streetly M. Is the revised International staging system for myeloma valid in a real world population? Br J Haematol 2018;180:451-4. [PMID: 27734463 DOI: 10.1111/bjh.14341] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.4] [Reference Citation Analysis]
260 Hartmann L, Biggerstaff JS, Chapman DB, Scott JM, Johnson KR, Ghirardelli KM, Fritschle WK, Martinez DL, Bennington RK, de Baca ME, Wells DA, Loken MR, Zehentner BK. Detection of Genomic Abnormalities in Multiple Myeloma. American Journal of Clinical Pathology 2011;136:712-20. [DOI: 10.1309/ajcpf7nflw8uajep] [Cited by in Crossref: 18] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
261 Chang ET, Boffetta P, Adami H, Mandel JS. A critical review of the epidemiology of Agent Orange or 2,3,7,8-tetrachlorodibenzo-p-dioxin and lymphoid malignancies. Annals of Epidemiology 2015;25:275-292.e30. [DOI: 10.1016/j.annepidem.2015.01.002] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
262 Kortüm KM, Engelhardt M, Rasche L, Knop S, Einsele H. [Multiple myeloma]. Internist (Berl) 2013;54:963-77. [PMID: 23860514 DOI: 10.1007/s00108-013-3336-2] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
263 Stella F, Pedrazzini E, Rodríguez A, Baialardo E, Kusminsky G, Arbelbide J, Fantl D, Slavutsky I. New Recurrent Chromosome Alterations in Patients with Multiple Myeloma and Plasma Cell Leukemia. Cytogenet Genome Res 2011;134:249-59. [DOI: 10.1159/000329479] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
264 Lee B, Shin SH, Min C, Yhim H, Kwak J, Kim J. Role of high-dose melphalan with autologous stem cell transplantation in multiple myeloma patients receiving botezomib-containing induction therapy. Int J Hematol 2013;97:634-9. [DOI: 10.1007/s12185-013-1311-2] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
265 Rajkumar SV, Gahrton G, Bergsagel PL. Approach to the treatment of multiple myeloma: a clash of philosophies. Blood 2011;118:3205-11. [PMID: 21791430 DOI: 10.1182/blood-2011-06-297853] [Cited by in Crossref: 105] [Cited by in F6Publishing: 90] [Article Influence: 10.5] [Reference Citation Analysis]
266 Xu L, Su Y. Genetic pathogenesis of immunoglobulin light chain amyloidosis: basic characteristics and clinical applications. Exp Hematol Oncol 2021;10:43. [PMID: 34284823 DOI: 10.1186/s40164-021-00236-z] [Reference Citation Analysis]
267 Grzasko N, Hus M, Chocholska S, Pluta A, Hajek R, Dmoszynska A. 1q21 amplification with additional genetic abnormalities but not isolated 1q21 gain is a negative prognostic factor in newly diagnosed patients with multiple myeloma treated with thalidomide-based regimens. Leuk Lymphoma 2012;53:2500-3. [PMID: 22497640 DOI: 10.3109/10428194.2012.684349] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
268 Cumova J, Potacova A, Zdrahal Z, Hajek R. Proteomic Analysis in Multiple Myeloma Research. Mol Biotechnol 2011;47:83-93. [DOI: 10.1007/s12033-010-9326-x] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 1.2] [Reference Citation Analysis]
269 Chung TH, Mulligan G, Fonseca R, Chng WJ. A novel measure of chromosome instability can account for prognostic difference in multiple myeloma. PLoS One 2013;8:e66361. [PMID: 23840451 DOI: 10.1371/journal.pone.0066361] [Cited by in Crossref: 32] [Cited by in F6Publishing: 27] [Article Influence: 4.0] [Reference Citation Analysis]
270 Yamamoto K, Yakushijin K, Ito M, Goto H, Higashime A, Kajimoto K, Hayashi Y, Matsuoka H, Minami H. MYC amplification on double minute chromosomes in plasma cell leukemia with double IGH/CCND1 fusion genes. Cancer Genet 2020;242:35-40. [PMID: 32035866 DOI: 10.1016/j.cancergen.2020.01.049] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
271 Weißbach S, Langer C, Puppe B, Nedeva T, Bach E, Kull M, Bargou R, Einsele H, Rosenwald A, Knop S, Leich E. The molecular spectrum and clinical impact of DIS3 mutations in multiple myeloma. Br J Haematol 2015;169:57-70. [PMID: 25521164 DOI: 10.1111/bjh.13256] [Cited by in Crossref: 36] [Cited by in F6Publishing: 33] [Article Influence: 5.1] [Reference Citation Analysis]
272 Roy M, Liang L, Xiao X, Peng Y, Luo Y, Zhou W, Zhang J, Qiu L, Zhang S, Liu F, Ye M, Zhou W, Liu J. Lycorine Downregulates HMGB1 to Inhibit Autophagy and Enhances Bortezomib Activity in Multiple Myeloma. Theranostics 2016;6:2209-24. [PMID: 27924158 DOI: 10.7150/thno.15584] [Cited by in Crossref: 37] [Cited by in F6Publishing: 39] [Article Influence: 7.4] [Reference Citation Analysis]
273 Braggio E, Kortüm KM, Stewart AK. SnapShot: Multiple Myeloma. Cancer Cell 2015;28:678-678.e1. [PMID: 26555176 DOI: 10.1016/j.ccell.2015.10.014] [Cited by in Crossref: 21] [Cited by in F6Publishing: 19] [Article Influence: 4.2] [Reference Citation Analysis]
274 Grieve S, Wajnberg G, Lees M, Chacko S, Weir J, Crapoulet N, Reiman T. TAZ functions as a tumor suppressor in multiple myeloma by downregulating MYC. Blood Adv 2019;3:3613-25. [PMID: 31743393 DOI: 10.1182/bloodadvances.2019000374] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
275 Weaver CJ, Tariman JD. Multiple Myeloma Genomics: A Systematic Review. Semin Oncol Nurs 2017;33:237-53. [PMID: 28729121 DOI: 10.1016/j.soncn.2017.05.001] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 2.5] [Reference Citation Analysis]
276 Debes Marun CS, Belch AR, Pilarski LM. In multiple myeloma, bone-marrow lymphocytes harboring the same chromosomal abnormalities as autologous plasma cells predict poor survival. Am J Hematol 2012;87:579-87. [PMID: 22495885 DOI: 10.1002/ajh.23194] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.8] [Reference Citation Analysis]
277 Scott EC, Hari P, Sharma M, Le-Rademacher J, Huang J, Vogl D, Abidi M, Beitinjaneh A, Fung H, Ganguly S, Hildebrandt G, Holmberg L, Kalaycio M, Kumar S, Kyle R, Lazarus H, Lee C, Maziarz RT, Meehan K, Mikhael J, Nishihori T, Ramanathan M, Usmani S, Tay J, Vesole D, Wirk B, Yared J, Savani BN, Gasparetto C, Krishnan A, Mark T, Nieto Y, D'Souza A. Post-Transplant Outcomes in High-Risk Compared with Non-High-Risk Multiple Myeloma: A CIBMTR Analysis. Biol Blood Marrow Transplant 2016;22:1893-9. [PMID: 27496215 DOI: 10.1016/j.bbmt.2016.07.007] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 3.8] [Reference Citation Analysis]
278 Mark TM, Forsberg PA, Rossi AC, Pearse RN, Pekle KA, Perry A, Boyer A, Tegnestam L, Jayabalan D, Coleman M, Niesvizky R. Phase 2 study of clarithromycin, pomalidomide, and dexamethasone in relapsed or refractory multiple myeloma. Blood Adv 2019;3:603-11. [PMID: 30792190 DOI: 10.1182/bloodadvances.2018028027] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
279 Klein U, Jauch A, Hielscher T, Hillengass J, Raab MS, Seckinger A, Hose D, Ho AD, Goldschmidt H, Neben K. Chromosomal aberrations +1q21 and del(17p13) predict survival in patients with recurrent multiple myeloma treated with lenalidomide and dexamethasone. Cancer 2011;117:2136-44. [PMID: 21523726 DOI: 10.1002/cncr.25775] [Cited by in Crossref: 43] [Cited by in F6Publishing: 45] [Article Influence: 3.9] [Reference Citation Analysis]
280 Lu G, Zhang XX, You MJ, Chen W. Correlation of assessment of plasma cells by flow cytometry and detection of cytogenomic abnormalities by fluorescence in situ hybridization in plasma cell neoplasms. Int J Lab Hematol 2011;33:545-50. [PMID: 21470373 DOI: 10.1111/j.1751-553X.2011.01323.x] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
281 Krstevska SB, Sotirova T, Balkanov T, Genadieva-Stavric S. Tretatment approach of nontransplant patients with multiple myeloma. Mater Sociomed 2014;26:348-51. [PMID: 25568637 DOI: 10.5455/msm.2014.26.348-351] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
282 Tan D, Chng WJ, Chou T, Nawarawong W, Hwang SY, Chim CS, Chen W, Durie BG, Lee JH. Management of multiple myeloma in Asia: resource-stratified guidelines. Lancet Oncol 2013;14:e571-81. [PMID: 24176575 DOI: 10.1016/S1470-2045(13)70404-2] [Cited by in Crossref: 27] [Cited by in F6Publishing: 15] [Article Influence: 3.4] [Reference Citation Analysis]
283 Richardson PG, Harrison SJ, Bringhen S, Schjesvold F, Yong K, Campana F, Le-Guennec S, Macé S, Dimopoulos MA. Isatuximab for relapsed/refractory multiple myeloma: review of key subgroup analyses from the Phase III ICARIA-MM study. Future Oncol 2021;17:4797-812. [PMID: 34521277 DOI: 10.2217/fon-2021-0568] [Reference Citation Analysis]
284 Kumar S, Fonseca R, Ketterling RP, Dispenzieri A, Lacy MQ, Gertz MA, Hayman SR, Buadi FK, Dingli D, Knudson RA, Greenberg A, Russell SJ, Zeldenrust SR, Lust JA, Kyle RA, Bergsagel L, Rajkumar SV. Trisomies in multiple myeloma: impact on survival in patients with high-risk cytogenetics. Blood 2012;119:2100-5. [PMID: 22234687 DOI: 10.1182/blood-2011-11-390658] [Cited by in Crossref: 158] [Cited by in F6Publishing: 145] [Article Influence: 17.6] [Reference Citation Analysis]
285 Potluri V, Noothi SK, Vallabhapurapu SD, Yoon SO, Driscoll JJ, Lawrie CH, Vallabhapurapu S. Transcriptional repression of Bim by a novel YY1-RelA complex is essential for the survival and growth of Multiple Myeloma. PLoS One 2013;8:e66121. [PMID: 23874387 DOI: 10.1371/journal.pone.0066121] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 2.0] [Reference Citation Analysis]
286 Zhang Y, Chen XL, Chen WM, Zhou HB. Prognostic Nomogram for the Overall Survival of Patients with Newly Diagnosed Multiple Myeloma. Biomed Res Int 2019;2019:5652935. [PMID: 31080823 DOI: 10.1155/2019/5652935] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
287 Xiao G, Li Y, Wang Y, Zhao B, Zou Z, Hou S, Jia X, Liu X, Yao Y, Wan J, Xiong H. LncRNA PRAL is closely related to clinical prognosis of multiple myeloma and the bortezomib sensitivity. Experimental Cell Research 2018;370:254-63. [DOI: 10.1016/j.yexcr.2018.06.026] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 2.7] [Reference Citation Analysis]
288 Kassambara A, Hose D, Moreaux J, Rème T, Torrent J, Rossi JF, Goldschmidt H, Klein B. Identification of pluripotent and adult stem cell genes unrelated to cell cycle and associated with poor prognosis in multiple myeloma. PLoS One 2012;7:e42161. [PMID: 22860071 DOI: 10.1371/journal.pone.0042161] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 1.8] [Reference Citation Analysis]
289 Chen BJ, Chuang SS. Lymphoid Neoplasms With Plasmablastic Differentiation: A Comprehensive Review and Diagnostic Approaches. Adv Anat Pathol 2020;27:61-74. [PMID: 31725418 DOI: 10.1097/PAP.0000000000000253] [Cited by in Crossref: 8] [Cited by in F6Publishing: 3] [Article Influence: 8.0] [Reference Citation Analysis]
290 Bolli N, Martinelli G, Cerchione C. The molecular pathogenesis of multiple myeloma. Hematol Rep 2020;12:9054. [PMID: 33408844 DOI: 10.4081/hr.2020.9054] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
291 Festuccia M, Martino M, Ferrando F, Messina G, Moscato T, Fedele R, Boccadoro M, Giaccone L, Bruno B. Allogeneic stem cell transplantation in multiple myeloma: immunotherapy and new drugs. Expert Opin Biol Ther 2015;15:857-72. [PMID: 25865214 DOI: 10.1517/14712598.2015.1036735] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 2.8] [Reference Citation Analysis]
292 Zingone A, Kuehl WM. Pathogenesis of monoclonal gammopathy of undetermined significance and progression to multiple myeloma. Semin Hematol 2011;48:4-12. [PMID: 21232653 DOI: 10.1053/j.seminhematol.2010.11.003] [Cited by in Crossref: 48] [Cited by in F6Publishing: 41] [Article Influence: 4.8] [Reference Citation Analysis]
293 Sarasquete ME, Martínez-López J, Chillón MC, Alcoceba M, Corchete LA, Paiva B, Puig N, Sebastián E, Jiménez C, Mateos MV, Oriol A, Rosiñol L, Palomera L, Teruel AI, González Y, Lahuerta JJ, Bladé J, Gutiérrez NC, Fernández-Redondo E, González M, San Miguel JF, García-Sanz R. Evaluating gene expression profiling by quantitative polymerase chain reaction to develop a clinically feasible test for outcome prediction in multiple myeloma. Br J Haematol 2013;163:223-34. [PMID: 23952215 DOI: 10.1111/bjh.12519] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
294 Weisel K, Spencer A, Lentzsch S, Avet-Loiseau H, Mark TM, Spicka I, Masszi T, Lauri B, Levin MD, Bosi A, Hungria V, Cavo M, Lee JJ, Nooka A, Quach H, Munder M, Lee C, Barreto W, Corradini P, Min CK, Chanan-Khan AA, Horvath N, Capra M, Beksac M, Ovilla R, Jo JC, Shin HJ, Sonneveld P, Casneuf T, DeAngelis N, Amin H, Ukropec J, Kobos R, Mateos MV. Daratumumab, bortezomib, and dexamethasone in relapsed or refractory multiple myeloma: subgroup analysis of CASTOR based on cytogenetic risk. J Hematol Oncol 2020;13:115. [PMID: 32819447 DOI: 10.1186/s13045-020-00948-5] [Cited by in Crossref: 10] [Cited by in F6Publishing: 13] [Article Influence: 10.0] [Reference Citation Analysis]
295 Bolli N, Li Y, Sathiaseelan V, Raine K, Jones D, Ganly P, Cocito F, Bignell G, Chapman MA, Sperling AS, Anderson KC, Avet-Loiseau H, Minvielle S, Campbell PJ, Munshi NC. A DNA target-enrichment approach to detect mutations, copy number changes and immunoglobulin translocations in multiple myeloma. Blood Cancer J 2016;6:e467. [PMID: 27588520 DOI: 10.1038/bcj.2016.72] [Cited by in Crossref: 38] [Cited by in F6Publishing: 36] [Article Influence: 7.6] [Reference Citation Analysis]
296 Hsieh RW, Go RS, Abeykoon JP, Kapoor P, Kumar SK, Gertz MA, Buadi FK, Leung N, Gonsalves WI, Kourelis TV, Warsame RM, Dispenzieri A, Lacy MQ, Kyle RA, Rajkumar SV, Paludo J. Characteristics of long‐term survivors with multiple myeloma: A National Cancer Data Base analysis. Cancer 2019;125:3574-81. [DOI: 10.1002/cncr.32357] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
297 Tembhare PR, Ghogale S, Tauro W, Badrinath Y, Deshpande N, Kedia S, Cherian K, Patkar NV, Chatterjee G, Gujral S, Subramanian PG. Evaluation of CD229 as a new alternative plasma cell gating marker in the flow cytometric immunophenotyping of monoclonal gammopathies: CD229, A NEW RELIABLE PLASMA CELL GATING MARKER. Cytometry 2018;94:509-19. [DOI: 10.1002/cyto.b.21619] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.7] [Reference Citation Analysis]
298 Palumbo A, Avet-Loiseau H, Oliva S, Lokhorst HM, Goldschmidt H, Rosinol L, Richardson P, Caltagirone S, Lahuerta JJ, Facon T, Bringhen S, Gay F, Attal M, Passera R, Spencer A, Offidani M, Kumar S, Musto P, Lonial S, Petrucci MT, Orlowski RZ, Zamagni E, Morgan G, Dimopoulos MA, Durie BG, Anderson KC, Sonneveld P, San Miguel J, Cavo M, Rajkumar SV, Moreau P. Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group. J Clin Oncol 2015;33:2863-9. [PMID: 26240224 DOI: 10.1200/JCO.2015.61.2267] [Cited by in Crossref: 786] [Cited by in F6Publishing: 391] [Article Influence: 131.0] [Reference Citation Analysis]
299 Zhang W, Lai R, He X, Liu X, Zhang Y, Yang Z, Yang P, Wang J, Hu K, Yuan X, Zhang X, Liu W, Jing H. Clinical prognostic implications of EPB41L4A expression in multiple myeloma. J Cancer 2020;11:619-29. [PMID: 31942185 DOI: 10.7150/jca.33805] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
300 Başcı S, Yiğenoğlu TN, Yaman S, Bozan E, Ulu BU, Bakırtaş M, Kılınç A, Özcan N, Bahsi T, Dal MS, Çakar MK, Altuntaş F. Does myeloma genetic have an effect on stem cell mobilization? Transfus Apher Sci 2021;:103249. [PMID: 34419357 DOI: 10.1016/j.transci.2021.103249] [Reference Citation Analysis]
301 Jung HA, Jang MA, Kim K, Kim SH. Clinical Utility of a Diagnostic Approach to Detect Genetic Abnormalities in Multiple Myeloma: A Single Institution Experience. Ann Lab Med 2018;38:196-203. [PMID: 29401553 DOI: 10.3343/alm.2018.38.3.196] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
302 Ji M, Jang S, Lee J, Seo E. Double-hit myeloma with IGH/MYC and IGH/CCND1 translocations. Ann Hematol 2013;92:1129-31. [DOI: 10.1007/s00277-012-1668-y] [Cited by in Crossref: 4] [Cited by in F6Publishing: 7] [Article Influence: 0.5] [Reference Citation Analysis]
303 Olteanu H. Role of Flow Cytometry in the Diagnosis and Prognosis of Plasma Cell Myeloma. Surg Pathol Clin 2016;9:101-16. [PMID: 26940271 DOI: 10.1016/j.path.2015.09.009] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
304 Lonial S, Boise LH, Kaufman J. How I treat high-risk myeloma. Blood 2015;126:1536-43. [DOI: 10.1182/blood-2015-06-653261] [Cited by in Crossref: 57] [Cited by in F6Publishing: 56] [Article Influence: 9.5] [Reference Citation Analysis]
305 Inagaki A, Tajima E, Uranishi M, Totani H, Asao Y, Ogura H, Masaki A, Yoshida T, Mori F, Ito A, Yano H, Ri M, Kayukawa S, Kataoka T, Kusumoto S, Ishida T, Hayami Y, Hanamura I, Komatsu H, Inagaki H, Matsuda Y, Ueda R, Iida S. Global real-time quantitative reverse transcription-polymerase chain reaction detecting proto-oncogenes associated with 14q32 chromosomal translocation as a valuable marker for predicting survival in multiple myeloma. Leuk Res 2013;37:1648-55. [PMID: 24210217 DOI: 10.1016/j.leukres.2013.09.026] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
306 Fonseca R, Monge J, Dimopoulos MA. Staging and prognostication of multiple myeloma. Expert Rev Hematol 2014;7:21-31. [PMID: 24483346 DOI: 10.1586/17474086.2014.882224] [Cited by in Crossref: 21] [Cited by in F6Publishing: 19] [Article Influence: 3.0] [Reference Citation Analysis]
307 Dingli D, Ailawadhi S, Bergsagel PL, Buadi FK, Dispenzieri A, Fonseca R, Gertz MA, Gonsalves WI, Hayman SR, Kapoor P, Kourelis T, Kumar SK, Kyle RA, Lacy MQ, Leung N, Lin Y, Lust JA, Mikhael JR, Reeder CB, Roy V, Russell SJ, Sher T, Stewart AK, Warsame R, Zeldenrust SR, Rajkumar SV, Chanan Khan AA. Therapy for Relapsed Multiple Myeloma: Guidelines From the Mayo Stratification for Myeloma and Risk-Adapted Therapy. Mayo Clin Proc 2017;92:578-98. [PMID: 28291589 DOI: 10.1016/j.mayocp.2017.01.003] [Cited by in Crossref: 74] [Cited by in F6Publishing: 63] [Article Influence: 18.5] [Reference Citation Analysis]
308 Bluhm J, Kieback E, Marino SF, Oden F, Westermann J, Chmielewski M, Abken H, Uckert W, Höpken UE, Rehm A. CAR T Cells with Enhanced Sensitivity to B Cell Maturation Antigen for the Targeting of B Cell Non-Hodgkin's Lymphoma and Multiple Myeloma. Mol Ther 2018;26:1906-20. [PMID: 30078440 DOI: 10.1016/j.ymthe.2018.06.012] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 5.3] [Reference Citation Analysis]
309 Leiba M, Duek A, Amariglio N, Avigdor A, Benyamini N, Hardan I, Zilbershats I, Ganzel C, Shevetz O, Novikov I, Cohen Y, Ishoev G, Rozic G, Nagler A, Trakhtenbrot L. Translocation t(11;14) in newly diagnosed patients with multiple myeloma: Is it always favorable?: Prognostic Importance of t(11;14) in MM. Genes Chromosomes Cancer 2016;55:710-8. [DOI: 10.1002/gcc.22372] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 2.6] [Reference Citation Analysis]
310 Ghose J, Viola D, Terrazas C, Caserta E, Troadec E, Khalife J, Gunes EG, Sanchez J, McDonald T, Marcucci G, Kaur B, Rosenzweig M, Keats J, Rosen S, Krishnan A, Satoskar AR, Hofmeister CC, Pichiorri F. Daratumumab induces CD38 internalization and impairs myeloma cell adhesion. Oncoimmunology 2018;7:e1486948. [PMID: 30288349 DOI: 10.1080/2162402X.2018.1486948] [Cited by in Crossref: 23] [Cited by in F6Publishing: 16] [Article Influence: 7.7] [Reference Citation Analysis]
311 Naddaf E, Mauermann ML. Neurologic Complications of Plasma Cell Dyscrasias. In: Schiff D, Arrillaga I, Wen PY, editors. Cancer Neurology in Clinical Practice. Cham: Springer International Publishing; 2018. pp. 583-95. [DOI: 10.1007/978-3-319-57901-6_32] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
312 Ivyna Bong PN, Ng CC, Lam KY, Megat Baharuddin PJ, Chang KM, Zakaria Z. Identification of novel pathogenic copy number aberrations in multiple myeloma: the Malaysian context. Mol Cytogenet 2014;7:24. [PMID: 24690091 DOI: 10.1186/1755-8166-7-24] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
313 Hose D, Beck S, Salwender H, Emde M, Bertsch U, Kunz C, Scheid C, Hänel M, Weisel K, Hielscher T, Raab MS, Goldschmidt H, Jauch A, Moreaux J, Seckinger A. Prospective target assessment and multimodal prediction of survival for personalized and risk-adapted treatment strategies in multiple myeloma in the GMMG-MM5 multicenter trial. J Hematol Oncol 2019;12:65. [PMID: 31242924 DOI: 10.1186/s13045-019-0750-5] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
314 Moreau P, Stewart KA, Dimopoulos M, Siegel D, Facon T, Berenson J, Raje N, Berdeja JG, Orlowski RZ, Yang H, Ma H, Klippel Z, Zahlten-Kumeli A, Mezzi K, Iskander K, Mateos MV. Once-weekly (70 mg/m2 ) vs twice-weekly (56 mg/m2 ) dosing of carfilzomib in patients with relapsed or refractory multiple myeloma: A post hoc analysis of the ENDEAVOR, A.R.R.O.W., and CHAMPION-1 trials. Cancer Med 2020;9:2989-96. [PMID: 32108443 DOI: 10.1002/cam4.2945] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
315 Wang D, Yu F, Fang B, Song Y. [Clinical analysis of four multiple myeloma patients with - 13/13q- and 17p]. Zhonghua Xue Ye Xue Za Zhi 2016;37:65-7. [PMID: 26876257 DOI: 10.3760/cma.j.issn.0253-2727.2016.01.013] [Reference Citation Analysis]
316 Li F, Xu Y, Deng P, Yang Y, Sui W, Jin F, Hao M, Li Z, Zang M, Zhou D, Gu Z, Ru K, Wang J, Cheng T, Qiu L. Heterogeneous chromosome 12p deletion is an independent adverse prognostic factor and resistant to bortezomib-based therapy in multiple myeloma. Oncotarget 2015;6:9434-44. [PMID: 25831238 DOI: 10.18632/oncotarget.3319] [Cited by in Crossref: 5] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
317 Gowin K, Skerget S, Keats JJ, Mikhael J, Cowan AJ. Plasma cell leukemia: A review of the molecular classification, diagnosis, and evidenced-based treatment. Leuk Res 2021;111:106687. [PMID: 34425325 DOI: 10.1016/j.leukres.2021.106687] [Reference Citation Analysis]
318 Mutlu P, Kiraz Y, Gündüz U, Baran Y. An update on molecular biology and drug resistance mechanisms of multiple myeloma. Critical Reviews in Oncology/Hematology 2015;96:413-24. [DOI: 10.1016/j.critrevonc.2015.07.003] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.7] [Reference Citation Analysis]
319 Sidana S, Jevremovic D, Ketterling RP, Tandon N, Greipp PT, Baughn LB, Dispenzieri A, Gertz MA, Rajkumar SV, Kumar SK. Tetraploidy is associated with poor prognosis at diagnosis in multiple myeloma. Am J Hematol 2019;94:E117-20. [PMID: 30680770 DOI: 10.1002/ajh.25420] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
320 Jacobus SJ, Kumar S, Uno H, Van Wier SA, Ahmann GJ, Henderson KJ, Callander NS, Williams ME, Siegel DS, Greipp PR, Rajkumar SV, Fonseca R. Impact of high-risk classification by FISH: an eastern cooperative oncology group (ECOG) study E4A03. Br J Haematol 2011;155:340-8. [PMID: 21902684 DOI: 10.1111/j.1365-2141.2011.08849.x] [Cited by in Crossref: 24] [Cited by in F6Publishing: 20] [Article Influence: 2.4] [Reference Citation Analysis]
321 Larocca A, Palumbo A. Optimizing Treatment for Elderly Patients With Newly Diagnosed Multiple Myeloma: A Personalized Approach. JCO 2016;34:3600-4. [DOI: 10.1200/jco.2016.68.6113] [Cited by in Crossref: 17] [Cited by in F6Publishing: 5] [Article Influence: 3.4] [Reference Citation Analysis]
322 Cagnetta A, Lovera D, Grasso R, Colombo N, Canepa L, Ballerini F, Calvio M, Miglino M, Gobbi M, Lemoli R, Cea M. Mechanisms and Clinical Applications of Genome Instability in Multiple Myeloma. Biomed Res Int 2015;2015:943096. [PMID: 26579543 DOI: 10.1155/2015/943096] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
323 Lin R, Thall PF, Yuan Y. A Phase I-II Basket Trial Design to Optimize Dose-Schedule Regimes Based on Delayed Outcomes. Bayesian Anal 2021;16:179-202. [PMID: 34267857 DOI: 10.1214/20-ba1205] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
324 Abdallah N, Greipp P, Kapoor P, Gertz MA, Dispenzieri A, Baughn LB, Lacy MQ, Hayman SR, Buadi FK, Dingli D, Go RS, Hwa YL, Fonder A, Hobbs M, Lin Y, Leung N, Kourelis T, Warsame R, Siddiqui M, Lust J, Kyle RA, Bergsagel L, Ketterling R, Rajkumar SV, Kumar SK. Clinical characteristics and treatment outcomes of newly diagnosed multiple myeloma with chromosome 1q abnormalities. Blood Adv 2020;4:3509-19. [PMID: 32750129 DOI: 10.1182/bloodadvances.2020002218] [Cited by in Crossref: 13] [Cited by in F6Publishing: 17] [Article Influence: 13.0] [Reference Citation Analysis]
325 Thanendrarajan S, Davies FE, Morgan GJ, Schinke C, Mathur P, Heuck CJ, Zangari M, Epstein J, Yaccoby S, Weinhold N, Barlogie B, van Rhee F. Monoclonal antibody therapy in multiple myeloma: where do we stand and where are we going? Immunotherapy 2016;8:367-84. [PMID: 26888183 DOI: 10.2217/imt.15.118] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
326 Lacativa CP, Lacativa PG, Garnica M, Portugal RD, Schaffel R, Dutra Hdos S, Nogueira CM, Nucci M, Maiolino A. Risk factors for unsuccessful peripheral blood stem cell harvesting using granulocyte-colony stimulating factor mobilization in patients with multiple myeloma. Transfus Apher Sci. 2012;47:331-335. [PMID: 22874435 DOI: 10.1016/j.transci.2012.06.013] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
327 Couto Oliveira A, Ribeiro IP, Pires LM, Gonçalves AC, Paiva A, Geraldes C, Roque A, Sarmento-Ribeiro AB, Barbosa de Melo J, Carreira IM. Genomic characterisation of multiple myeloma: study of a Portuguese cohort. J Clin Pathol 2021:jclinpath-2020-207204. [PMID: 33653728 DOI: 10.1136/jclinpath-2020-207204] [Reference Citation Analysis]
328 Dupuis MM, Tuchman SA. Non-secretory multiple myeloma: from biology to clinical management. Onco Targets Ther 2016;9:7583-90. [PMID: 28008276 DOI: 10.2147/OTT.S122241] [Cited by in Crossref: 22] [Cited by in F6Publishing: 7] [Article Influence: 4.4] [Reference Citation Analysis]
329 de Carvalho F, Vettore AL, Colleoni GW. Cancer/Testis Antigen MAGE-C1/CT7: new target for multiple myeloma therapy. Clin Dev Immunol 2012;2012:257695. [PMID: 22481966 DOI: 10.1155/2012/257695] [Cited by in Crossref: 13] [Cited by in F6Publishing: 17] [Article Influence: 1.4] [Reference Citation Analysis]
330 Chaidos A, Barnes CP, Cowan G, May PC, Melo V, Hatjiharissi E, Papaioannou M, Harrington H, Doolittle H, Terpos E. Clinical drug resistance linked to interconvertible phenotypic and functional states of tumor-propagating cells in multiple myeloma. Blood. 2013;121:318-328. [PMID: 23169779 DOI: 10.1182/blood-2012-06-436220] [Cited by in Crossref: 85] [Cited by in F6Publishing: 89] [Article Influence: 9.4] [Reference Citation Analysis]
331 Fend F, Quintanilla-Martínez L. [B-cell neoplasms with plasmacellular and plasmablastic differentiation]. Pathologe 2013;34:198-209. [PMID: 23462793 DOI: 10.1007/s00292-013-1743-8] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
332 Bøgsted M, Bilgrau AE, Wardell CP, Bertsch U, Schmitz A, Bødker JS, Kjeldsen MK, Goldschmidt H, Morgan GJ, Dybkaer K, Johnsen HE. Proof of the concept to use a malignant B cell line drug screen strategy for identification and weight of melphalan resistance genes in multiple myeloma. PLoS One 2013;8:e83252. [PMID: 24376673 DOI: 10.1371/journal.pone.0083252] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 1.1] [Reference Citation Analysis]
333 Rocci A, Hofmeister CC, Pichiorri F. The potential of miRNAs as biomarkers for multiple myeloma. Expert Review of Molecular Diagnostics 2014;14:947-59. [DOI: 10.1586/14737159.2014.946906] [Cited by in Crossref: 14] [Cited by in F6Publishing: 17] [Article Influence: 2.0] [Reference Citation Analysis]
334 Lee N, Lee H, Moon SY, Sohn JY, Hwang SM, Yoon OJ, Youn HS, Eom HS, Kong SY. Adverse prognostic impact of bone marrow microvessel density in multiple myeloma. Ann Lab Med 2015;35:563-9. [PMID: 26354343 DOI: 10.3343/alm.2015.35.6.563] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 2.0] [Reference Citation Analysis]
335 Jekarl DW, Min CK, Kwon A, Kim H, Chae H, Kim M, Lim J, Kim Y, Han K. Impact of genetic abnormalities on the prognoses and clinical parameters of patients with multiple myeloma. Ann Lab Med 2013;33:248-54. [PMID: 23826560 DOI: 10.3343/alm.2013.33.4.248] [Cited by in Crossref: 16] [Cited by in F6Publishing: 11] [Article Influence: 2.0] [Reference Citation Analysis]
336 Akuzawa N, Hatori T, Imai K, Kitahara Y, Sakurai S, Kurabayashi M. Transient Plasmacytosis With Trisomy of Chromosome 8 in a Patient With Multiple Myeloma: A Case Report. World J Oncol 2013;4:194-200. [PMID: 29147355 DOI: 10.4021/wjon688w] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
337 Kanamori T, Sanada M, Ri M, Ueno H, Nishijima D, Yasuda T, Tachita T, Narita T, Kusumoto S, Inagaki A, Ishihara R, Murakami Y, Kobayashi N, Shiozawa Y, Yoshida K, Nakagawa MM, Nannya Y, Shiraishi Y, Chiba K, Tanaka H, Miyano S, Horibe K, Handa H, Ogawa S, Iida S. Genomic analysis of multiple myeloma using targeted capture sequencing in the Japanese cohort. Br J Haematol 2020;191:755-63. [PMID: 32386081 DOI: 10.1111/bjh.16720] [Reference Citation Analysis]
338 Besse L, Sedlarikova L, Greslikova H, Kupska R, Almasi M, Penka M, Jelinek T, Pour L, Adam Z, Kuglik P, Krejci M, Hajek R, Sevcikova S. Cytogenetics in multiple myeloma patients progressing into extramedullary disease. Eur J Haematol 2016;97:93-100. [PMID: 26432667 DOI: 10.1111/ejh.12688] [Cited by in Crossref: 17] [Cited by in F6Publishing: 20] [Article Influence: 2.8] [Reference Citation Analysis]
339 Kaiser MF, Johnson DC, Wu P, Walker BA, Brioli A, Mirabella F, Wardell CP, Melchor L, Davies FE, Morgan GJ. Global methylation analysis identifies prognostically important epigenetically inactivated tumor suppressor genes in multiple myeloma. Blood 2013;122:219-26. [PMID: 23699600 DOI: 10.1182/blood-2013-03-487884] [Cited by in Crossref: 109] [Cited by in F6Publishing: 107] [Article Influence: 13.6] [Reference Citation Analysis]
340 Cavo M, Rajkumar SV, Palumbo A, Moreau P, Orlowski R, Bladé J, Sezer O, Ludwig H, Dimopoulos MA, Attal M, Sonneveld P, Boccadoro M, Anderson KC, Richardson PG, Bensinger W, Johnsen HE, Kroeger N, Gahrton G, Bergsagel PL, Vesole DH, Einsele H, Jagannath S, Niesvizky R, Durie BG, San Miguel J, Lonial S; International Myeloma Working Group. International Myeloma Working Group consensus approach to the treatment of multiple myeloma patients who are candidates for autologous stem cell transplantation. Blood 2011;117:6063-73. [PMID: 21447828 DOI: 10.1182/blood-2011-02-297325] [Cited by in Crossref: 212] [Cited by in F6Publishing: 190] [Article Influence: 21.2] [Reference Citation Analysis]
341 Costa LJ, Iacobelli S, Pasquini MC, Modi R, Giaccone L, Blade J, Schonland S, Evangelista A, Perez-Simon JA, Hari P, Brown EE, Giralt SA, Patriarca F, Stadtmauer EA, Rosinol L, Krishnan AY, Gahrton G, Bruno B. Long-term survival of 1338 MM patients treated with tandem autologous vs. autologous-allogeneic transplantation. Bone Marrow Transplant 2020;55:1810-6. [PMID: 32286506 DOI: 10.1038/s41409-020-0887-4] [Cited by in Crossref: 15] [Cited by in F6Publishing: 11] [Article Influence: 15.0] [Reference Citation Analysis]
342 Lim JH, Seo EJ, Park CJ, Jang S, Chi HS, Suh C, Kim H, Kim SR. Cytogenetic classification in Korean multiple myeloma patients: prognostic significance of hyperdiploidy with 47-50 chromosomes and the number of structural abnormalities. Eur J Haematol 2014;92:313-20. [PMID: 24372944 DOI: 10.1111/ejh.12257] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.6] [Reference Citation Analysis]
343 Berry NK, Dixon-McIver A, Scott RJ, Rowlings P, Enjeti AK. Detection of complex genomic signatures associated with risk in plasma cell disorders. Cancer Genet 2017;218-219:1-9. [PMID: 29153091 DOI: 10.1016/j.cancergen.2017.08.004] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
344 Visco C, Hoeller S, Malik JT, Xu-Monette ZY, Wiggins ML, Liu J, Sanger WG, Liu Z, Chang J, Ranheim EA, Gradowski JF, Serrano S, Wang HY, Liu Q, Dave S, Olsen B, Gascoyne RD, Campo E, Swerdlow SH, Chan WC, Tzankov A, Young KH. Molecular characteristics of mantle cell lymphoma presenting with clonal plasma cell component. Am J Surg Pathol 2011;35:177-89. [PMID: 21263238 DOI: 10.1097/PAS.0b013e3182049a9c] [Cited by in Crossref: 17] [Cited by in F6Publishing: 3] [Article Influence: 1.7] [Reference Citation Analysis]
345 Sola B, Poirot M, de Medina P, Bustany S, Marsaud V, Silvente-Poirot S, Renoir JM. Antiestrogen-binding site ligands induce autophagy in myeloma cells that proceeds through alteration of cholesterol metabolism. Oncotarget 2013;4:911-22. [PMID: 23978789 DOI: 10.18632/oncotarget.1066] [Cited by in Crossref: 24] [Cited by in F6Publishing: 24] [Article Influence: 3.4] [Reference Citation Analysis]
346 Lonial S. Presentation and risk stratification--improving prognosis for patients with multiple myeloma. Cancer Treat Rev 2010;36 Suppl 2:S12-7. [PMID: 20472183 DOI: 10.1016/S0305-7372(10)70007-4] [Cited by in Crossref: 13] [Cited by in F6Publishing: 5] [Article Influence: 1.2] [Reference Citation Analysis]
347 Vij R, Mazumder A, Klinger M, O'dea D, Paasch J, Martin T, Weng L, Park J, Fiala M, Faham M, Wolf J. Deep Sequencing Reveals Myeloma Cells in Peripheral Blood in Majority of Multiple Myeloma Patients. Clinical Lymphoma Myeloma and Leukemia 2014;14:131-139.e1. [DOI: 10.1016/j.clml.2013.09.013] [Cited by in Crossref: 34] [Cited by in F6Publishing: 33] [Article Influence: 4.9] [Reference Citation Analysis]
348 Qu X, Chen L, Qiu H, Lu H, Wu H, Qiu H, Liu P, Guo R, Li J. Extramedullary manifestation in multiple myeloma bears high incidence of poor cytogenetic aberration and novel agents resistance. Biomed Res Int 2015;2015:787809. [PMID: 25984534 DOI: 10.1155/2015/787809] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 2.3] [Reference Citation Analysis]
349 Bories C, Jagannath S. Asymptomatic monoclonal gammopathies. Clin Lymphoma Myeloma Leuk 2014;14 Suppl:S78-86. [PMID: 25486961 DOI: 10.1016/j.clml.2014.05.004] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
350 Pour L, Sevcikova S, Greslikova H, Kupska R, Majkova P, Zahradova L, Sandecka V, Adam Z, Krejci M, Kuglik P, Hajek R. Soft-tissue extramedullary multiple myeloma prognosis is significantly worse in comparison to bone-related extramedullary relapse. Haematologica 2014;99:360-4. [PMID: 24038024 DOI: 10.3324/haematol.2013.094409] [Cited by in Crossref: 72] [Cited by in F6Publishing: 69] [Article Influence: 9.0] [Reference Citation Analysis]
351 Gagelmann N, Eikema DJ, Koster L, Caillot D, Pioltelli P, Lleonart JB, Reményi P, Blaise D, Schaap N, Trneny M, Passweg J, Porras RP, Cahn JY, Musso M, Poiré X, Fenk R, Itälä-Remes M, Pavone V, Fouillard L, Maertens J, Bron D, Pouli A, Schroyens W, Schönland S, Garderet L, Yakoub-Agha I, Kröger N. Tandem Autologous Stem Cell Transplantation Improves Outcomes in Newly Diagnosed Multiple Myeloma with Extramedullary Disease and High-Risk Cytogenetics: A Study from the Chronic Malignancies Working Party of the European Society for Blood and Marrow Transplantation. Biol Blood Marrow Transplant 2019;25:2134-42. [PMID: 31288095 DOI: 10.1016/j.bbmt.2019.07.004] [Cited by in Crossref: 15] [Cited by in F6Publishing: 17] [Article Influence: 7.5] [Reference Citation Analysis]
352 Oliva S, De Paoli L, Ruggeri M, Caltagirone S, Troia R, Oddolo D, D'Agostino M, Gilestro M, Mina R, Saraci E, Margiotta Casaluci G, Genuardi E, Bringhen S, Boccadoro M, Omedé P. A longitudinal analysis of chromosomal abnormalities in disease progression from MGUS/SMM to newly diagnosed and relapsed multiple myeloma. Ann Hematol 2021;100:437-43. [PMID: 33392702 DOI: 10.1007/s00277-020-04384-w] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
353 Papadas A, Asimakopoulos F. Mechanisms of Resistance in Multiple Myeloma. In: Mandalà M, Romano E, editors. Mechanisms of Drug Resistance in Cancer Therapy. Cham: Springer International Publishing; 2018. pp. 251-88. [DOI: 10.1007/164_2017_10] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 2.5] [Reference Citation Analysis]
354 Fouquet G, Gay F, Boyle E, Bringhen S, Larocca A, Facon T, Leleu X, Palumbo A. Treatment of Newly Diagnosed Elderly Multiple Myeloma. Cancer Treat Res 2016;169:123-43. [PMID: 27696261 DOI: 10.1007/978-3-319-40320-5_8] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
355 Siegel DS. Relapsed/Refractory multiple myeloma: defining refractory disease and identifying strategies to overcome resistance. Semin Hematol 2012;49 Suppl 1:S3-15. [PMID: 22727390 DOI: 10.1053/j.seminhematol.2012.05.005] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
356 Nair RR, Gebhard AW, Emmons MF, Hazlehurst LA. Emerging strategies for targeting cell adhesion in multiple myeloma. Adv Pharmacol 2012;65:143-89. [PMID: 22959026 DOI: 10.1016/B978-0-12-397927-8.00006-3] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
357 Brioli A, Melchor L, Cavo M, Morgan GJ. The impact of intra-clonal heterogeneity on the treatment of multiple myeloma. Br J Haematol 2014;165:441-54. [DOI: 10.1111/bjh.12805] [Cited by in Crossref: 62] [Cited by in F6Publishing: 59] [Article Influence: 8.9] [Reference Citation Analysis]
358 Tapper W, Chiecchio L, Dagrada GP, Konn ZJ, Stockley DM, Szubert AJ, Gregory WM, Bell SE, Jackson GH, Child JA, Morgan GJ, Ross FM. Heterogeneity in the Prognostic Significance of 12p Deletion and Chromosome 5 Amplification in Multiple Myeloma. JCO 2011;29:e37-9. [DOI: 10.1200/jco.2010.31.0516] [Cited by in Crossref: 11] [Cited by in F6Publishing: 3] [Article Influence: 1.1] [Reference Citation Analysis]
359 Baritaki S, Huerta-Yepez S, Cabrava-Haimandez MD, Sensi M, Canevari S, Libra M, Penichet M, Chen H, Berenson JR, Bonavida B. Unique Pattern of Overexpression of Raf-1 Kinase Inhibitory Protein in Its Inactivated Phosphorylated Form in Human Multiple Myeloma. For Immunopathol Dis Therap 2011;2. [PMID: 24286018 DOI: 10.1615/ForumImmunDisTher.v2.i2.90] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 0.6] [Reference Citation Analysis]
360 Liubarets TF, Minchenko ZM, Dmytrenko OO, Khomenko VI, Reznikova LS, Shlyahtichenko TY, Tovstogan AO, Silayev YO. CLINICAL, HEMATOLOGICAL CHARACTERIZATION AND POLYMORPHISM OF ABO AND Rh BLOOD GROUP SYSTEMS IN PLASMA CELL MYELOMA PATIENTS. Probl Radiac Med Radiobiol 2018;23:410-22. [PMID: 30582859 DOI: 10.33145/2304-8336-2018-23-410-422] [Reference Citation Analysis]
361 Abdi J, Chen G, Chang H. Drug resistance in multiple myeloma: latest findings and new concepts on molecular mechanisms. Oncotarget. 2013;4:2186-2207. [PMID: 24327604 DOI: 10.18632/oncotarget.1497] [Cited by in Crossref: 97] [Cited by in F6Publishing: 94] [Article Influence: 13.9] [Reference Citation Analysis]
362 Hébraud B, Caillot D, Corre J, Marit G, Hulin C, Leleu X, Lodé L, Wetterwald M, Dib M, Rodon P, Voillat L, Royer B, Voog E, Fitoussi O, Stoppa AM, Garderet L, Kolb B, Maigre M, Boullanger N, Allangba O, Karlin L, Daguindau N, Legros L, Sohn C, Joubert MV, Lenain P, Facon T, Attal M, Moreau P, Avet-Loiseau H. The translocation t(4;14) can be present only in minor subclones in multiple myeloma. Clin Cancer Res 2013;19:4634-7. [PMID: 23857603 DOI: 10.1158/1078-0432.CCR-12-3866] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.1] [Reference Citation Analysis]
363 Bai H, Zhu Y, Xu P, Chen B. PLP2 Expression as a Prognostic and Therapeutic Indicator in High-Risk Multiple Myeloma. Biomed Res Int 2020;2020:4286101. [PMID: 32596309 DOI: 10.1155/2020/4286101] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
364 Paszekova H, Kryukov F, Kubiczkova L, Hajek R, Sevcikova S. High-risk multiple myeloma: different definitions, different outcomes? Clin Lymphoma Myeloma Leuk 2014;14:24-30. [PMID: 24225331 DOI: 10.1016/j.clml.2013.09.004] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
365 Prideaux SM, Conway O'Brien E, Chevassut TJ. The genetic architecture of multiple myeloma. Adv Hematol 2014;2014:864058. [PMID: 24803933 DOI: 10.1155/2014/864058] [Cited by in Crossref: 47] [Cited by in F6Publishing: 52] [Article Influence: 6.7] [Reference Citation Analysis]
366 Parisi MS, Leotta S, Romano A, Del Fabro V, Martino EA, Calafiore V, Giubbolini R, Markovic U, Leotta V, Di Giorgio MA, Tibullo D, Di Raimondo F, Conticello C. Clinical Benefit of Long-Term Disease Control with Pomalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma Patients. J Clin Med 2019;8:E1695. [PMID: 31623097 DOI: 10.3390/jcm8101695] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
367 Sommaluan S, Rerkamnuaychoke B, Pauwilai T, Chancharunee S, Onsod P, Pornsarayuth P, Chareonsirisuthigul T, Tammachote R, Siriboonpiputtana T. The Utilization of Karyotyping, iFISH, and MLPA for the Detection of Recurrence Genetic Aberrations in Multiple Myeloma. Asian Pac J Cancer Prev 2017;18:3135-42. [PMID: 29172291 DOI: 10.22034/APJCP.2017.18.11.3135] [Reference Citation Analysis]
368 Zang M, Zou D, Yu Z, Li F, Yi S, Ai X, Qin X, Feng X, Zhou W, Xu Y, Li Z, Hao M, Sui W, Deng S, Acharya C, Zhao Y, Ru K, Qiu L, An G. Detection of recurrent cytogenetic aberrations in multiple myeloma: a comparison between MLPA and iFISH. Oncotarget 2015;6:34276-87. [PMID: 26416457 DOI: 10.18632/oncotarget.5371] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
369 Mikhael JR, Dingli D, Roy V, Reeder CB, Buadi FK, Hayman SR, Dispenzieri A, Fonseca R, Sher T, Kyle RA, Lin Y, Russell SJ, Kumar S, Bergsagel PL, Zeldenrust SR, Leung N, Drake MT, Kapoor P, Ansell SM, Witzig TE, Lust JA, Dalton RJ, Gertz MA, Stewart AK, Rajkumar SV, Chanan-Khan A, Lacy MQ; Mayo Clinic. Management of newly diagnosed symptomatic multiple myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus guidelines 2013. Mayo Clin Proc 2013;88:360-76. [PMID: 23541011 DOI: 10.1016/j.mayocp.2013.01.019] [Cited by in Crossref: 302] [Cited by in F6Publishing: 283] [Article Influence: 37.8] [Reference Citation Analysis]
370 Andrade VC, Vettore AL, Panepucci RA, Almeida MS, Yamamoto M, De Carvalho F, Caballero OL, Zago MA, Colleoni GW. Number of expressed cancer/testis antigens identifies focal adhesion pathway genes as possible targets for multiple myeloma therapy. Leuk Lymphoma 2010;51:1543-9. [PMID: 20528248 DOI: 10.3109/10428194.2010.491136] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
371 Mitsiades CS, Davies FE, Laubach JP, Joshua D, San Miguel J, Anderson KC, Richardson PG. Future directions of next-generation novel therapies, combination approaches, and the development of personalized medicine in myeloma. J Clin Oncol 2011;29:1916-23. [PMID: 21482978 DOI: 10.1200/JCO.2010.34.0760] [Cited by in Crossref: 55] [Cited by in F6Publishing: 25] [Article Influence: 5.5] [Reference Citation Analysis]
372 Chesi M, Bergsagel PL. Advances in the pathogenesis and diagnosis of multiple myeloma. Int J Lab Hematol 2015;37 Suppl 1:108-14. [PMID: 25976968 DOI: 10.1111/ijlh.12360] [Cited by in Crossref: 27] [Cited by in F6Publishing: 26] [Article Influence: 5.4] [Reference Citation Analysis]
373 Slovak ML. Multiple myeloma: current perspectives. Clin Lab Med 2011;31:699-724, x. [PMID: 22118745 DOI: 10.1016/j.cll.2011.08.009] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
374 Guerard EJ, Tuchman SA. Monoclonal Gammopathy of Undetermined Significance and Multiple Myeloma in Older Adults. Clin Geriatr Med 2016;32:191-205. [PMID: 26614868 DOI: 10.1016/j.cger.2015.08.012] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
375 Cordone I, Marchesi F, Masi S, Summa V, Pisani F, Merola R, Cigliana G, Orlandi G, Gumenyuk S, Palombi F, Romano A, Spadea A, Renzi D, Papa E, Canfora M, Conti L, Petti MC, Mengarelli A. Flow cytometry remission by Ig light chains ratio is a powerful marker of outcome in multiple myeloma after tandem autologous transplant: a real-life study. J Exp Clin Cancer Res 2016;35:49. [PMID: 26992692 DOI: 10.1186/s13046-016-0324-0] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
376 Lee KJ, Lee KH, Yoon KA, Sohn JY, Lee E, Lee H, Eom HS, Kong SY. Chromothripsis in Treatment Resistance in Multiple Myeloma. Genomics Inform 2017;15:87-97. [PMID: 29020724 DOI: 10.5808/GI.2017.15.3.87] [Cited by in Crossref: 8] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
377 Waheed S, Shaughnessy JD, van Rhee F, Alsayed Y, Nair B, Anaissie E, Szymonifka J, Hoering A, Crowley J, Barlogie B. International staging system and metaphase cytogenetic abnormalities in the era of gene expression profiling data in multiple myeloma treated with total therapy 2 and 3 protocols. Cancer 2011;117:1001-9. [PMID: 20945320 DOI: 10.1002/cncr.25535] [Cited by in Crossref: 26] [Cited by in F6Publishing: 20] [Article Influence: 2.4] [Reference Citation Analysis]
378 Chesi M, Bergsagel PL. Epigenetics and microRNAs combine to modulate the MDM2/p53 axis in myeloma. Cancer Cell 2010;18:299-300. [PMID: 20951939 DOI: 10.1016/j.ccr.2010.10.004] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
379 Nguyen-Khac F, Lambert J, Chapiro E, Grelier A, Mould S, Barin C, Daudignon A, Gachard N, Struski S, Henry C, Penther D, Mossafa H, Andrieux J, Eclache V, Bilhou-Nabera C, Luquet I, Terre C, Baranger L, Mugneret F, Chiesa J, Mozziconacci MJ, Callet-Bauchu E, Veronese L, Blons H, Owen R, Lejeune J, Chevret S, Merle-Beral H, Leblondon V; Groupe Français d'Etude de la Leucémie Lymphoïde Chronique et Maladie de Waldenström (GFCLL/MW)., Groupe Ouest-Est d’étude des Leucémie Aiguës et Autres Maladies du Sang (GOELAMS)., Groupe d’Etude des Lymphomes de l’Adulte (GELA). Chromosomal aberrations and their prognostic value in a series of 174 untreated patients with Waldenström's macroglobulinemia. Haematologica 2013;98:649-54. [PMID: 23065509 DOI: 10.3324/haematol.2012.070458] [Cited by in Crossref: 76] [Cited by in F6Publishing: 60] [Article Influence: 8.4] [Reference Citation Analysis]
380 Chesi M, Bergsagel PL. Molecular pathogenesis of multiple myeloma: basic and clinical updates. Int J Hematol 2013;97:313-23. [PMID: 23456262 DOI: 10.1007/s12185-013-1291-2] [Cited by in Crossref: 91] [Cited by in F6Publishing: 81] [Article Influence: 11.4] [Reference Citation Analysis]
381 Demchenko Y, Roschke A, Chen WD, Asmann Y, Bergsagel PL, Kuehl WM. Frequent occurrence of large duplications at reciprocal genomic rearrangement breakpoints in multiple myeloma and other tumors. Nucleic Acids Res 2016;44:8189-98. [PMID: 27353332 DOI: 10.1093/nar/gkw527] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.6] [Reference Citation Analysis]
382 Smetana J, Frohlich J, Zaoralova R, Vallova V, Greslikova H, Kupska R, Nemec P, Mikulasova A, Almasi M, Pour L, Adam Z, Sandecka V, Zahradová L, Hajek R, Kuglik P. Genome-wide screening of cytogenetic abnormalities in multiple myeloma patients using array-CGH technique: a Czech multicenter experience. Biomed Res Int 2014;2014:209670. [PMID: 24987674 DOI: 10.1155/2014/209670] [Cited by in Crossref: 14] [Cited by in F6Publishing: 20] [Article Influence: 2.0] [Reference Citation Analysis]
383 Ziogas DC, Dimopoulos MA, Kastritis E. Prognostic factors for multiple myeloma in the era of novel therapies. Expert Review of Hematology 2018;11:863-79. [DOI: 10.1080/17474086.2018.1537776] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 3.7] [Reference Citation Analysis]
384 Chavan SS, He J, Tytarenko R, Deshpande S, Patel P, Bailey M, Stein CK, Stephens O, Weinhold N, Petty N, Steward D, Rasche L, Bauer M, Ashby C, Peterson E, Ali S, Ross J, Miller VA, Stephens P, Thanendrarajan S, Schinke C, Zangari M, van Rhee F, Barlogie B, Mughal TI, Davies FE, Morgan GJ, Walker BA. Bi-allelic inactivation is more prevalent at relapse in multiple myeloma, identifying RB1 as an independent prognostic marker. Blood Cancer J 2017;7:e535. [PMID: 28234347 DOI: 10.1038/bcj.2017.12] [Cited by in Crossref: 32] [Cited by in F6Publishing: 30] [Article Influence: 8.0] [Reference Citation Analysis]
385 Nagao Y, Mimura N, Takeda J, Yoshida K, Shiozawa Y, Oshima M, Aoyama K, Saraya A, Koide S, Rizq O, Hasegawa Y, Shiraishi Y, Chiba K, Tanaka H, Nishijima D, Isshiki Y, Kayamori K, Kawajiri-manako C, Oshima-hasegawa N, Tsukamoto S, Mitsukawa S, Takeda Y, Ohwada C, Takeuchi M, Iseki T, Misawa S, Miyano S, Ohara O, Yokote K, Sakaida E, Kuwabara S, Sanada M, Iwama A, Ogawa S, Nakaseko C. Genetic and transcriptional landscape of plasma cells in POEMS syndrome. Leukemia 2019;33:1723-35. [DOI: 10.1038/s41375-018-0348-x] [Cited by in Crossref: 16] [Cited by in F6Publishing: 12] [Article Influence: 8.0] [Reference Citation Analysis]
386 Morgan GJ, Gregory WM, Davies FE, Bell SE, Szubert AJ, Brown JM, Coy NN, Cook G, Russell NH, Rudin C, Roddie H, Drayson MT, Owen RG, Ross FM, Jackson GH, Child JA; National Cancer Research Institute Haematological Oncology Clinical Studies Group. The role of maintenance thalidomide therapy in multiple myeloma: MRC Myeloma IX results and meta-analysis. Blood 2012;119:7-15. [PMID: 22021371 DOI: 10.1182/blood-2011-06-357038] [Cited by in Crossref: 254] [Cited by in F6Publishing: 223] [Article Influence: 25.4] [Reference Citation Analysis]
387 Manier S, Salem K, Glavey SV, Roccaro AM, Ghobrial IM. Genomic Aberrations in Multiple Myeloma. In: Roccaro AM, Ghobrial IM, editors. Plasma Cell Dyscrasias. Cham: Springer International Publishing; 2016. pp. 23-34. [DOI: 10.1007/978-3-319-40320-5_3] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 1.6] [Reference Citation Analysis]
388 Zhang Z, Liu Y, Song T, Xue Z, Shen X, Liang F, Zhao Y, Li Z, Sheng H. An antiapoptotic Bcl-2 family protein index predicts the response of leukaemic cells to the pan-Bcl-2 inhibitor S1. Br J Cancer 2013;108:1870-8. [PMID: 23558901 DOI: 10.1038/bjc.2013.152] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.3] [Reference Citation Analysis]
389 Giralt S, Costa LJ, Maloney D, Krishnan A, Fei M, Antin JH, Brunstein C, Geller N, Goodman S, Hari P, Logan B, Lowsky R, Qazilbash MH, Sahebi F, Somlo G, Rowley S, Vogl DT, Vesole DH, Pasquini M, Stadtmauer E. Tandem Autologous-Autologous versus Autologous-Allogeneic Hematopoietic Stem Cell Transplant for Patients with Multiple Myeloma: Long-Term Follow-Up Results from the Blood and Marrow Transplant Clinical Trials Network 0102 Trial. Biol Blood Marrow Transplant 2020;26:798-804. [PMID: 31756536 DOI: 10.1016/j.bbmt.2019.11.018] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 8.5] [Reference Citation Analysis]
390 Luo TC, Wu LL, Wu H, Lu M, Fu WJ, Du J. [Clinical prognosis analysis of patients with "double hit" multiple myeloma]. Zhonghua Xue Ye Xue Za Zhi 2019;40:918-23. [PMID: 31856440 DOI: 10.3760/cma.j.issn.0253-2727.2019.11.006] [Reference Citation Analysis]
391 Chaidos A, Caputo V, Gouvedenou K, Liu B, Marigo I, Chaudhry MS, Rotolo A, Tough DF, Smithers NN, Bassil AK, Chapman TD, Harker NR, Barbash O, Tummino P, Al-Mahdi N, Haynes AC, Cutler L, Le B, Rahemtulla A, Roberts I, Kleijnen M, Witherington JJ, Parr NJ, Prinjha RK, Karadimitris A. Potent antimyeloma activity of the novel bromodomain inhibitors I-BET151 and I-BET762. Blood 2014;123:697-705. [PMID: 24335499 DOI: 10.1182/blood-2013-01-478420] [Cited by in Crossref: 140] [Cited by in F6Publishing: 128] [Article Influence: 17.5] [Reference Citation Analysis]
392 Casalino G, Coluccia M, Pati ML, Pannunzio A, Vacca A, Scilimati A, Perrone MG. Intelligent Microarray Data Analysis through Non-negative Matrix Factorization to Study Human Multiple Myeloma Cell Lines. Applied Sciences 2019;9:5552. [DOI: 10.3390/app9245552] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 2.5] [Reference Citation Analysis]
393 Rajkumar SV. Multiple myeloma: 2011 update on diagnosis, risk-stratification, and management. Am J Hematol 2011;86:57-65. [PMID: 21181954 DOI: 10.1002/ajh.21913] [Cited by in Crossref: 106] [Cited by in F6Publishing: 87] [Article Influence: 10.6] [Reference Citation Analysis]
394 Neri P, Ren L, Gratton K, Stebner E, Johnson J, Klimowicz A, Duggan P, Tassone P, Mansoor A, Stewart DA, Lonial S, Boise LH, Bahlis NJ. Bortezomib-induced "BRCAness" sensitizes multiple myeloma cells to PARP inhibitors. Blood 2011;118:6368-79. [PMID: 21917757 DOI: 10.1182/blood-2011-06-363911] [Cited by in Crossref: 83] [Cited by in F6Publishing: 84] [Article Influence: 8.3] [Reference Citation Analysis]
395 Bochtler T, Hegenbart U, Heiss C, Benner A, Moos M, Seckinger A, Pschowski-zuck S, Kirn D, Neben K, Bartram CR, Ho AD, Goldschmidt H, Hose D, Jauch A, Schonland SO. Hyperdiploidy is less frequent in AL amyloidosis compared with monoclonal gammopathy of undetermined significance and inversely associated with translocation t(11;14). Blood 2011;117:3809-15. [DOI: 10.1182/blood-2010-02-268987] [Cited by in Crossref: 46] [Cited by in F6Publishing: 42] [Article Influence: 4.6] [Reference Citation Analysis]
396 Tacchetti P, Cavo M, Rocchi S, Pezzi A, Pantani L, Brioli A, Testoni N, Terragna C, Zannetti BA, Mancuso K, Marzocchi G, Borsi E, Martello M, Rizzello I, Zamagni E. Prognostic impact of serial measurements of serum-free light chain assay throughout the course of newly diagnosed multiple myeloma treated with bortezomib-based regimens. Leuk Lymphoma 2016;57:2058-64. [PMID: 26763357 DOI: 10.3109/10428194.2015.1124994] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
397 Lin R, Thall PF, Yuan Y. An adaptive trial design to optimize dose-schedule regimes with delayed outcomes. Biometrics 2020;76:304-15. [PMID: 31273750 DOI: 10.1111/biom.13116] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
398 Maschio M, Zarabla A, Maialetti A, Marchesi F, Giannarelli D, Gumenyuk S, Pisani F, Renzi D, Galiè E, Mengarelli A. The Effect of Docosahexaenoic Acid and α-Lipoic Acid as Prevention of Bortezomib-Related Neurotoxicity in Patients With Multiple Myeloma. Integr Cancer Ther 2019;18:1534735419888584. [PMID: 31868025 DOI: 10.1177/1534735419888584] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
399 Zhang W, Wang YE, Zhang Y, Leleu X, Reagan M, Zhang Y, Mishima Y, Glavey S, Manier S, Sacco A, Jiang B, Roccaro AM, Ghobrial IM. Global epigenetic regulation of microRNAs in multiple myeloma. PLoS One 2014;9:e110973. [PMID: 25330074 DOI: 10.1371/journal.pone.0110973] [Cited by in Crossref: 26] [Cited by in F6Publishing: 25] [Article Influence: 3.7] [Reference Citation Analysis]
400 Musto P, Pagano L, Petrucci MT, Morabito F, Caravita T, Di Raimondo F, Baldini L, Tosi P, Bringhen S, Offidani M, Omede' P, Neri A, D'Auria F, Bochicchio GB, Cavo M, Boccadoro M, Palumbo A. Primary plasma cell leukemia in the era of new drugs: has something changed? Crit Rev Oncol Hematol 2012;82:141-9. [PMID: 21719304 DOI: 10.1016/j.critrevonc.2011.04.005] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 1.3] [Reference Citation Analysis]
401 Hucthagowder V, Meyer R, Mullins C, Nagarajan R, DiPersio JF, Vij R, Tomasson MH, Kulkarni S. Resequencing analysis of the candidate tyrosine kinase and RAS pathway gene families in multiple myeloma. Cancer Genet 2012;205:474-8. [PMID: 22939401 DOI: 10.1016/j.cancergen.2012.06.007] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 1.4] [Reference Citation Analysis]
402 Nagy Z, Kajtár B, Jáksó P, Dávid M, Kosztolányi S, Hermesz J, Kereskai L, Pajor L, Alpár D. Evolutionary sequence of cytogenetic aberrations during the oncogenesis of plasma cell disorders. Direct evidence at single cell level. Leuk Res 2011;35:1114-6. [PMID: 21377730 DOI: 10.1016/j.leukres.2011.02.010] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
403 Chatterjee G, Gujral S, Subramanian PG, Tembhare PR. Clinical Relevance of Multicolour Flow Cytometry in Plasma Cell Disorders. Indian J Hematol Blood Transfus 2017;33:303-15. [PMID: 28824230 DOI: 10.1007/s12288-017-0822-z] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
404 López de Frutos L, Álvarez Y, Armengol G, Caballín MR. New mitogens in cultures for multiple myeloma cytogenetic analysis. Leuk Lymphoma 2013;54:2548-50. [PMID: 23418873 DOI: 10.3109/10428194.2013.777066] [Reference Citation Analysis]
405 Hebraud B, Leleu X, Lauwers-Cances V, Roussel M, Caillot D, Marit G, Karlin L, Hulin C, Gentil C, Guilhot F, Garderet L, Lamy T, Brechignac S, Pegourie B, Jaubert J, Dib M, Stoppa AM, Sebban C, Fohrer C, Fontan J, Fruchart C, Macro M, Orsini-Piocelle F, Lepeu G, Sohn C, Corre J, Facon T, Moreau P, Attal M, Avet-Loiseau H. Deletion of the 1p32 region is a major independent prognostic factor in young patients with myeloma: the IFM experience on 1195 patients. Leukemia 2014;28:675-9. [PMID: 23892719 DOI: 10.1038/leu.2013.225] [Cited by in Crossref: 55] [Cited by in F6Publishing: 53] [Article Influence: 6.9] [Reference Citation Analysis]
406 Miller A, Asmann Y, Cattaneo L, Braggio E, Keats J, Auclair D, Lonial S, Russell SJ, Stewart AK; MMRF CoMMpass Network. High somatic mutation and neoantigen burden are correlated with decreased progression-free survival in multiple myeloma. Blood Cancer J 2017;7:e612. [PMID: 28937974 DOI: 10.1038/bcj.2017.94] [Cited by in Crossref: 79] [Cited by in F6Publishing: 75] [Article Influence: 19.8] [Reference Citation Analysis]
407 Avet-Loiseau H, Facon T. Front-line therapies for elderly patients with transplant-ineligible multiple myeloma and high-risk cytogenetics in the era of novel agents. Leukemia 2018;32:1267-76. [PMID: 29720731 DOI: 10.1038/s41375-018-0098-9] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 4.0] [Reference Citation Analysis]
408 Manier S, Salem KZ, Park J, Landau DA, Getz G, Ghobrial IM. Genomic complexity of multiple myeloma and its clinical implications. Nat Rev Clin Oncol 2017;14:100-13. [DOI: 10.1038/nrclinonc.2016.122] [Cited by in Crossref: 219] [Cited by in F6Publishing: 204] [Article Influence: 43.8] [Reference Citation Analysis]
409 Hart AJ, Jagasia MH, Kim AS, Mosse CA, Savani BN, Kassim A. Minimal residual disease in myeloma: are we there yet? Biol Blood Marrow Transplant 2012;18:1790-9. [PMID: 22626785 DOI: 10.1016/j.bbmt.2012.05.009] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 2.1] [Reference Citation Analysis]
410 Jiang N, Qi C, Yu L, Ning Y, An G, Qiu L, Chang H. Analysis of chromosome 12p deletion in plasma cell dyscrasias. Leukemia Research 2012;36:32-6. [DOI: 10.1016/j.leukres.2011.07.030] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
411 van Beers EH, van Vliet MH, Kuiper R, de Best L, Anderson KC, Chari A, Jagannath S, Jakubowiak A, Kumar SK, Levy JB, Auclair D, Lonial S, Reece D, Richardson P, Siegel DS, Stewart AK, Trudel S, Vij R, Zimmerman TM, Fonseca R. Prognostic Validation of SKY92 and Its Combination With ISS in an Independent Cohort of Patients With Multiple Myeloma. Clinical Lymphoma Myeloma and Leukemia 2017;17:555-62. [DOI: 10.1016/j.clml.2017.06.020] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 3.8] [Reference Citation Analysis]
412 Ross FM, Avet-Loiseau H, Ameye G, Gutiérrez NC, Liebisch P, O'Connor S, Dalva K, Fabris S, Testi AM, Jarosova M, Hodkinson C, Collin A, Kerndrup G, Kuglik P, Ladon D, Bernasconi P, Maes B, Zemanova Z, Michalova K, Michau L, Neben K, Hermansen NE, Rack K, Rocci A, Protheroe R, Chiecchio L, Poirel HA, Sonneveld P, Nyegaard M, Johnsen HE; European Myeloma Network. Report from the European Myeloma Network on interphase FISH in multiple myeloma and related disorders. Haematologica 2012;97:1272-7. [PMID: 22371180 DOI: 10.3324/haematol.2011.056176] [Cited by in Crossref: 146] [Cited by in F6Publishing: 149] [Article Influence: 16.2] [Reference Citation Analysis]
413 Cheong CM, Mrozik KM, Hewett DR, Bell E, Panagopoulos V, Noll JE, Licht JD, Gronthos S, Zannettino ACW, Vandyke K. Twist-1 is upregulated by NSD2 and contributes to tumour dissemination and an epithelial-mesenchymal transition-like gene expression signature in t(4;14)-positive multiple myeloma. Cancer Lett 2020;475:99-108. [PMID: 32014459 DOI: 10.1016/j.canlet.2020.01.040] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 9.0] [Reference Citation Analysis]
414 Hao M, Zang M, Wendlandt E, Xu Y, An G, Gong D, Li F, Qi F, Zhang Y, Yang Y, Zhan F, Qiu L. Low serum miR-19a expression as a novel poor prognostic indicator in multiple myeloma. Int J Cancer 2015;136:1835-44. [PMID: 25220540 DOI: 10.1002/ijc.29199] [Cited by in Crossref: 43] [Cited by in F6Publishing: 43] [Article Influence: 6.1] [Reference Citation Analysis]
415 Jiang N, Qi C, Trieu Y, Reece D, Chang H. Genomic aberrations and survival of patients with light-chain-only multiple myeloma undergoing autologous stem cell transplantation. Biol Blood Marrow Transplant 2011;17:1790-5. [PMID: 21658460 DOI: 10.1016/j.bbmt.2011.05.009] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
416 Fujino M. The histopathology of myeloma in the bone marrow. J Clin Exp Hematop 2018;58:61-7. [PMID: 29998977 DOI: 10.3960/jslrt.18014] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
417 Put N, Lemmens H, Wlodarska I, Konings P, Moreau Y, Hagemeijer A, Vandenberghe P, Michaux L. Interphase fluorescence in situ hybridization on selected plasma cells is superior in the detection of cytogenetic aberrations in plasma cell dyscrasia. Genes Chromosom Cancer 2010;49:991-7. [DOI: 10.1002/gcc.20809] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 0.9] [Reference Citation Analysis]
418 Chang H, Jiang A, Qi C, Trieu Y, Chen C, Reece D. Impact of genomic aberrations including chromosome 1 abnormalities on the outcome of patients with relapsed or refractory multiple myeloma treated with lenalidomide and dexamethasone. Leuk Lymphoma 2010;51:2084-91. [PMID: 20929319 DOI: 10.3109/10428194.2010.524325] [Cited by in Crossref: 29] [Cited by in F6Publishing: 29] [Article Influence: 2.6] [Reference Citation Analysis]
419 Gu Y, Xu K, Torre C, Samur M, Barwick BG, Rupji M, Arora J, Neri P, Kaufman J, Nooka A, Bernal-mizrachi L, Vertino P, Sun S, Chen J, Munshi N, Fu H, Kowalski J, Boise LH, Lonial S. 14-3-3ζ binds the proteasome, limits proteolytic function and enhances sensitivity to proteasome inhibitors. Leukemia 2018;32:744-51. [DOI: 10.1038/leu.2017.288] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
420 Kuehl WM, Bergsagel PL. Molecular pathogenesis of multiple myeloma and its premalignant precursor. J Clin Invest. 2012;122:3456-3463. [PMID: 23023717 DOI: 10.1172/jci61188] [Cited by in Crossref: 219] [Cited by in F6Publishing: 139] [Article Influence: 24.3] [Reference Citation Analysis]
421 Reichard KK, Hanson CA. Hematological diseases: prototypical conditions requiring the diagnostic and prognostic use of molecular data. Semin Diagn Pathol 2013;30:382-92. [PMID: 24342292 DOI: 10.1053/j.semdp.2013.11.006] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 0.6] [Reference Citation Analysis]
422 Greenberg AJ, Rajkumar SV, Therneau TM, Singh PP, Dispenzieri A, Kumar SK. Relationship between initial clinical presentation and the molecular cytogenetic classification of myeloma. Leukemia 2014;28:398-403. [PMID: 24005246 DOI: 10.1038/leu.2013.258] [Cited by in Crossref: 44] [Cited by in F6Publishing: 36] [Article Influence: 5.5] [Reference Citation Analysis]
423 . Antibodies. Immunology for Pharmacy. Elsevier; 2012. pp. 70-8. [DOI: 10.1016/b978-0-323-06947-2.10009-4] [Cited by in Crossref: 3] [Article Influence: 0.3] [Reference Citation Analysis]
424 Gentile M, Recchia AG, Mazzone C, Morabito F. Emerging biological insights and novel treatment strategies in multiple myeloma. Expert Opin Emerg Drugs 2012;17:407-38. [PMID: 22920042 DOI: 10.1517/14728214.2012.713345] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 1.0] [Reference Citation Analysis]
425 Rasmussen T, Haaber J, Dahl IM, Knudsen LM, Kerndrup GB, Lodahl M, Johnsen HE, Kuehl M. Identification of translocation products but not K-RAS mutations in memory B cells from patients with multiple myeloma. Haematologica 2010;95:1730-7. [PMID: 20511669 DOI: 10.3324/haematol.2010.024778] [Cited by in Crossref: 39] [Cited by in F6Publishing: 40] [Article Influence: 3.5] [Reference Citation Analysis]
426 Buedts L, Smits S, Ameye G, Lehnert S, Ding J, Delforge M, Vermeesch J, Boeckx N, Tousseyn T, Michaux L, Vandenberghe P, Dewaele B. Ultra-low depth sequencing of plasma cell DNA for the detection of copy number aberrations in multiple myeloma. Genes Chromosomes Cancer 2020;59:465-71. [PMID: 32259320 DOI: 10.1002/gcc.22848] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
427 Campagnaro EL, Goebel TE, Lazarus HM. Management of Elderly Patients with Plasma Cell Myeloma. Drugs Aging 2015;32:427-42. [PMID: 26025116 DOI: 10.1007/s40266-015-0265-x] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
428 Naumann-Winter F, Greb A, Borchmann P, Bohlius J, Engert A, Schnell R. First-line tandem high-dose chemotherapy and autologous stem cell transplantation versus single high-dose chemotherapy and autologous stem cell transplantation in multiple myeloma, a systematic review of controlled studies. Cochrane Database Syst Rev 2012;10:CD004626. [PMID: 23076906 DOI: 10.1002/14651858.CD004626.pub3] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 1.4] [Reference Citation Analysis]
429 Boyd KD, Ross FM, Tapper WJ, Chiecchio L, Dagrada G, Konn ZJ, Gonzalez D, Walker BA, Hockley SL, Wardell CP, Gregory WM, Child JA, Jackson GH, Davies FE, Morgan GJ; NCRI Haematology Oncology Studies Group. The clinical impact and molecular biology of del(17p) in multiple myeloma treated with conventional or thalidomide-based therapy. Genes Chromosomes Cancer 2011;50:765-74. [PMID: 21961181 DOI: 10.1002/gcc.20899] [Cited by in Crossref: 48] [Cited by in F6Publishing: 43] [Article Influence: 4.8] [Reference Citation Analysis]
430 Zhou P, Hoffman J, Landau H, Hassoun H, Iyer L, Comenzo RL. Clonal Plasma Cell Pathophysiology and Clinical Features of Disease Are Linked to Clonal Plasma Cell Expression of Cyclin D1 in Systemic Light-Chain Amyloidosis. Clinical Lymphoma Myeloma and Leukemia 2012;12:49-58. [DOI: 10.1016/j.clml.2011.09.217] [Cited by in Crossref: 24] [Cited by in F6Publishing: 21] [Article Influence: 2.7] [Reference Citation Analysis]
431 Kosztolányi S, Kiss R, Atanesyan L, Gángó A, de Groot K, Steenkamer M, Jáksó P, Matolcsy A, Kajtár B, Pajor L, Szuhai K, Savola S, Bödör C, Alpár D. High-Throughput Copy Number Profiling by Digital Multiplex Ligation-Dependent Probe Amplification in Multiple Myeloma. J Mol Diagn 2018;20:777-88. [PMID: 30096382 DOI: 10.1016/j.jmoldx.2018.06.004] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
432 Dong H, Yang H, Jagannath S, Stephenson CF, Brenholz P, Mazumder A, Chari A. Risk Stratification of Plasma Cell Neoplasm: Insights From Plasma Cell–Specific Cytoplasmic Immunoglobulin Fluorescence in Situ Hybridization (cIg FISH) vs. Conventional FISH. Clinical Lymphoma Myeloma and Leukemia 2012;12:366-74. [DOI: 10.1016/j.clml.2012.05.003] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
433 Kapoulas S, Raptis V, Papaioannou M. New aspects on the pathogenesis of renal disorders related to monoclonal gammopathies. Nephrol Ther. 2015;11:135-143. [PMID: 25861714 DOI: 10.1016/j.nephro.2014.12.005] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 2.3] [Reference Citation Analysis]
434 Scherer F, Kurtz DM, Diehn M, Alizadeh AA. High-throughput sequencing for noninvasive disease detection in hematologic malignancies. Blood 2017;130:440-52. [PMID: 28600337 DOI: 10.1182/blood-2017-03-735639] [Cited by in Crossref: 40] [Cited by in F6Publishing: 30] [Article Influence: 10.0] [Reference Citation Analysis]
435 Vallabhapurapu SD, Noothi SK, Pullum DA, Lawrie CH, Pallapati R, Potluri V, Kuntzen C, Khan S, Plas DR, Orlowski RZ, Chesi M, Kuehl WM, Bergsagel PL, Karin M, Vallabhapurapu S. Transcriptional repression by the HDAC4-RelB-p52 complex regulates multiple myeloma survival and growth. Nat Commun 2015;6:8428. [PMID: 26455434 DOI: 10.1038/ncomms9428] [Cited by in Crossref: 36] [Cited by in F6Publishing: 33] [Article Influence: 6.0] [Reference Citation Analysis]
436 Braggio E. Incidence and prognostic value of recurrent chromosomal abnormalities in elderly patients with multiple myeloma. Future Oncol 2013;9:1805-8. [PMID: 24295409 DOI: 10.2217/fon.13.221] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
437 Josefsberg Ben-Yehoshua L, Beider K, Shimoni A, Ostrovsky O, Samookh M, Peled A, Nagler A. Characterization of cyclin E expression in multiple myeloma and its functional role in seliciclib-induced apoptotic cell death. PLoS One 2012;7:e33856. [PMID: 22558078 DOI: 10.1371/journal.pone.0033856] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 1.2] [Reference Citation Analysis]
438 Morgan GJ, Davies FE, Gregory WM, Cocks K, Bell SE, Szubert AJ, Navarro-Coy N, Drayson MT, Owen RG, Feyler S, Ashcroft AJ, Ross F, Byrne J, Roddie H, Rudin C, Cook G, Jackson GH, Child JA; National Cancer Research Institute Haematological Oncology Clinical Study Group. First-line treatment with zoledronic acid as compared with clodronic acid in multiple myeloma (MRC Myeloma IX): a randomised controlled trial. Lancet 2010;376:1989-99. [PMID: 21131037 DOI: 10.1016/S0140-6736(10)62051-X] [Cited by in Crossref: 394] [Cited by in F6Publishing: 155] [Article Influence: 35.8] [Reference Citation Analysis]
439 Alonso R, Cedena MT, Gómez-Grande A, Ríos R, Moraleda JM, Cabañas V, Moreno MJ, López-Jiménez J, Martín F, Sanz A, Valeri A, Jiménez A, Sánchez R, Lahuerta JJ, Martínez-López J. Imaging and bone marrow assessments improve minimal residual disease prediction in multiple myeloma. Am J Hematol 2019;94:853-61. [PMID: 31074033 DOI: 10.1002/ajh.25507] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 5.0] [Reference Citation Analysis]
440 Juárez Salcedo LM, López Rubio M, Gil Fernández JJ, Garcia-Suarez J, Magro E, Arranz E, Gutiérrez Jomarrón I, Marcellini Antonio S, Blasco A, Burgaleta C. Atypical IgM multiple myeloma with deletion of c-MAF. Int J Lab Hematol 2015;37:686-9. [PMID: 25996654 DOI: 10.1111/ijlh.12385] [Reference Citation Analysis]
441 Joseph NS, Gentili S, Kaufman JL, Lonial S, Nooka AK. High-risk Multiple Myeloma: Definition and Management. Clinical Lymphoma Myeloma and Leukemia 2017;17:S80-7. [DOI: 10.1016/j.clml.2017.02.018] [Cited by in Crossref: 25] [Cited by in F6Publishing: 18] [Article Influence: 6.3] [Reference Citation Analysis]
442 Smetana J, Berankova K, Zaoralova R, Nemec P, Greslikova H, Kupska R, Mikulasova A, Frohlich J, Sevcikova S, Zahradova L, Krejci M, Sandecka V, Almasi M, Kaisarova P, Melicharova H, Adam Z, Penka M, Jarkovsky J, Jurczyszyn A, Hajek R, Kuglik P. Gain(1)(q21) is an unfavorable genetic prognostic factor for patients with relapsed multiple myeloma treated with thalidomide but not for those treated with bortezomib. Clin Lymphoma Myeloma Leuk 2013;13:123-30. [PMID: 23291040 DOI: 10.1016/j.clml.2012.11.012] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 1.8] [Reference Citation Analysis]
443 Martín-Garcia D, Navarro A, Valdés-Mas R, Clot G, Gutiérrez-Abril J, Prieto M, Ribera-Cortada I, Woroniecka R, Rymkiewicz G, Bens S, de Leval L, Rosenwald A, Ferry JA, Hsi ED, Fu K, Delabie J, Weisenburger D, de Jong D, Climent F, O'Connor SJ, Swerdlow SH, Torrents D, Beltran S, Espinet B, González-Farré B, Veloza L, Costa D, Matutes E, Siebert R, Ott G, Quintanilla-Martinez L, Jaffe ES, López-Otín C, Salaverria I, Puente XS, Campo E, Beà S. CCND2 and CCND3 hijack immunoglobulin light-chain enhancers in cyclin D1- mantle cell lymphoma. Blood 2019;133:940-51. [PMID: 30538135 DOI: 10.1182/blood-2018-07-862151] [Cited by in Crossref: 31] [Cited by in F6Publishing: 32] [Article Influence: 10.3] [Reference Citation Analysis]
444 Roh J, Shin S, Lee A, Yoon DH, Suh C, Park C, Huh J, Park C. RGS1 expression is associated with poor prognosis in multiple myeloma. J Clin Pathol 2017;70:202-7. [DOI: 10.1136/jclinpath-2016-203713] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 2.4] [Reference Citation Analysis]
445 González-calle V, Slack A, Keane N, Luft S, Pearce KE, Ketterling RP, Jain T, Chirackal S, Reeder C, Mikhael J, Noel P, Mayo A, Adams RH, Ahmann G, Braggio E, Stewart AK, Bergsagel PL, Van Wier SA, Fonseca R. Evaluation of Revised International Staging System (R-ISS) for transplant-eligible multiple myeloma patients. Ann Hematol 2018;97:1453-62. [DOI: 10.1007/s00277-018-3316-7] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 4.0] [Reference Citation Analysis]
446 Moore S, Suttle JM, Nicola M. Cytoplasmic Immunoglobulin Light Chain Revelation and Interphase Fluorescence In Situ Hybridization in Myeloma. Methods Mol Biol 2017;1541:127-42. [PMID: 27910020 DOI: 10.1007/978-1-4939-6703-2_12] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]
447 Landau HJ, Gertz MA, Comenzo RL. Autologous Hematopoietic Cell Transplantation for Systemic Light Chain (AL-) Amyloidosis. In: Forman SJ, Negrin RS, Antin JH, Appelbaum FR, editors. Thomas’ Hematopoietic Cell Transplantation. Chichester: John Wiley & Sons, Ltd; 2015. pp. 724-41. [DOI: 10.1002/9781118416426.ch60] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
448 Dimopoulos MA, Leleu X, Palumbo A, Moreau P, Delforge M, Cavo M, Ludwig H, Morgan GJ, Davies FE, Sonneveld P, Schey SA, Zweegman S, Hansson M, Weisel K, Mateos MV, Facon T, Miguel JF. Expert panel consensus statement on the optimal use of pomalidomide in relapsed and refractory multiple myeloma. Leukemia 2014;28:1573-85. [PMID: 24496300 DOI: 10.1038/leu.2014.60] [Cited by in Crossref: 72] [Cited by in F6Publishing: 61] [Article Influence: 10.3] [Reference Citation Analysis]
449 Dimopoulos K, Gimsing P, Grønbæk K. The role of epigenetics in the biology of multiple myeloma. Blood Cancer J 2014;4:e207. [PMID: 24786391 DOI: 10.1038/bcj.2014.29] [Cited by in Crossref: 65] [Cited by in F6Publishing: 70] [Article Influence: 9.3] [Reference Citation Analysis]
450 Lamottke B, Kaiser M, Mieth M, Heider U, Gao Z, Nikolova Z, Jensen MR, Sterz J, von Metzler I, Sezer O. The novel, orally bioavailable HSP90 inhibitor NVP-HSP990 induces cell cycle arrest and apoptosis in multiple myeloma cells and acts synergistically with melphalan by increased cleavage of caspases. Eur J Haematol 2012;88:406-15. [PMID: 22309072 DOI: 10.1111/j.1600-0609.2012.01764.x] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 2.0] [Reference Citation Analysis]
451 Kassambara A, Hose D, Moreaux J, Walker BA, Protopopov A, Reme T, Pellestor F, Pantesco V, Jauch A, Morgan G, Goldschmidt H, Klein B. Genes with a spike expression are clustered in chromosome (sub)bands and spike (sub)bands have a powerful prognostic value in patients with multiple myeloma. Haematologica 2012;97:622-30. [PMID: 22102711 DOI: 10.3324/haematol.2011.046821] [Cited by in Crossref: 31] [Cited by in F6Publishing: 30] [Article Influence: 3.1] [Reference Citation Analysis]
452 Atamaniuk J, Gleiss A, Porpaczy E, Kainz B, Grunt TW, Raderer M, Hilgarth B, Drach J, Ludwig H, Gisslinger H, Jaeger U, Gaiger A. Overexpression of G protein-coupled receptor 5D in the bone marrow is associated with poor prognosis in patients with multiple myeloma: GPRC5D MRNA, A NOVEL PROGNOSTIC MARKER IN MM. European Journal of Clinical Investigation 2012;42:953-60. [DOI: 10.1111/j.1365-2362.2012.02679.x] [Cited by in Crossref: 41] [Cited by in F6Publishing: 35] [Article Influence: 4.6] [Reference Citation Analysis]
453 Dimopoulos K, Gimsing P, Grønbæk K. Aberrant microRNA expression in multiple myeloma. Eur J Haematol 2013;91:95-105. [PMID: 23586898 DOI: 10.1111/ejh.12124] [Cited by in Crossref: 35] [Cited by in F6Publishing: 34] [Article Influence: 4.4] [Reference Citation Analysis]
454 Wei G, Wang L, Yang H, Han X, Zheng G, Zheng W, Sun J, Shi J, Wu W, Zhao Y, He D, Wang B, Cai Z, He J. Clinical implications of c-maf expression in plasma cells from patients with multiple myeloma. Exp Hematol Oncol 2017;6:16. [PMID: 28560070 DOI: 10.1186/s40164-017-0076-3] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
455 Pak C, Callander NS, Young EW, Titz B, Kim K, Saha S, Chng K, Asimakopoulos F, Beebe DJ, Miyamoto S. MicroC(3): an ex vivo microfluidic cis-coculture assay to test chemosensitivity and resistance of patient multiple myeloma cells. Integr Biol (Camb) 2015;7:643-54. [PMID: 25998180 DOI: 10.1039/c5ib00071h] [Cited by in Crossref: 32] [Cited by in F6Publishing: 13] [Article Influence: 5.3] [Reference Citation Analysis]
456 Suzuki K, Yano S, Nishiwaki K, Sano K, Shimada T, Yahagi Y, Ogasawara Y, Sugiyama K, Takahara S, Saito T, Kasama K, Minami J, Yokoyama H, Kamiyama Y, Katsube A, Masuoka H, Katori M, Machishima T, Ouchi A, Dobashi N, Kaito K, Usui N, Aiba K. Clinical significance of granule-containing myeloma cells in patients with newly diagnosed multiple myeloma. Cancer Med 2016;5:3051-8. [PMID: 27734595 DOI: 10.1002/cam4.875] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
457 Demchenko YN, Kuehl WM. A critical role for the NFkB pathway in multiple myeloma. Oncotarget 2010;1:59-68. [PMID: 20890394 DOI: 10.18632/oncotarget.109] [Cited by in Crossref: 97] [Cited by in F6Publishing: 104] [Article Influence: 9.7] [Reference Citation Analysis]
458 Okayama M, Kitabatake S, Sato M, Fujimori K, Ichikawa D, Matsushita M, Suto Y, Iwasaki G, Yamada T, Kiuchi F, Hirao M, Kunieda H, Osada M, Okamoto S, Hattori Y. A novel derivative (GTN024) from a natural product, komaroviquinone, induced the apoptosis of high-risk myeloma cells via reactive oxygen production and ER stress. Biochemical and Biophysical Research Communications 2018;505:787-93. [DOI: 10.1016/j.bbrc.2018.09.177] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
459 Engelhardt M, Terpos E, Kleber M, Gay F, Wäsch R, Morgan G, Cavo M, van de Donk N, Beilhack A, Bruno B, Johnsen HE, Hajek R, Driessen C, Ludwig H, Beksac M, Boccadoro M, Straka C, Brighen S, Gramatzki M, Larocca A, Lokhorst H, Magarotto V, Morabito F, Dimopoulos MA, Einsele H, Sonneveld P, Palumbo A; European Myeloma Network. European Myeloma Network recommendations on the evaluation and treatment of newly diagnosed patients with multiple myeloma. Haematologica 2014;99:232-42. [PMID: 24497560 DOI: 10.3324/haematol.2013.099358] [Cited by in Crossref: 129] [Cited by in F6Publishing: 121] [Article Influence: 18.4] [Reference Citation Analysis]
460 de Jong D, Janz S. Anaplastic plasmacytoma of mouse--establishing parallels between subtypes of mouse and human plasma cell neoplasia. J Pathol 2010;221:242-7. [PMID: 20527018 DOI: 10.1002/path.2714] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
461 Di Martino MT, Guzzi PH, Caracciolo D, Agnelli L, Neri A, Walker BA, Morgan GJ, Cannataro M, Tassone P, Tagliaferri P. Integrated analysis of microRNAs, transcription factors and target genes expression discloses a specific molecular architecture of hyperdiploid multiple myeloma. Oncotarget 2015;6:19132-47. [PMID: 26056083 DOI: 10.18632/oncotarget.4302] [Cited by in Crossref: 34] [Cited by in F6Publishing: 26] [Article Influence: 6.8] [Reference Citation Analysis]
462 Neben K, Lokhorst HM, Jauch A, Bertsch U, Hielscher T, van der Holt B, Salwender H, Blau IW, Weisel K, Pfreundschuh M, Scheid C, Dührsen U, Lindemann W, Schmidt-Wolf IG, Peter N, Teschendorf C, Martin H, Haenel M, Derigs HG, Raab MS, Ho AD, van de Velde H, Hose D, Sonneveld P, Goldschmidt H. Administration of bortezomib before and after autologous stem cell transplantation improves outcome in multiple myeloma patients with deletion 17p. Blood 2012;119:940-8. [PMID: 22160383 DOI: 10.1182/blood-2011-09-379164] [Cited by in Crossref: 231] [Cited by in F6Publishing: 224] [Article Influence: 23.1] [Reference Citation Analysis]
463 Smith D, Stephenson C, Percy L, Lach A, Chatters S, Kempski H, Yong K. Cohort analysis of FISH testing of CD138(+) cells in relapsed multiple myeloma: implications for prognosis and choice of therapy. Br J Haematol 2015;171:881-3. [PMID: 25899469 DOI: 10.1111/bjh.13446] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
464 Kapoor P, Rajkumar SV. Update on risk stratification and treatment of newly diagnosed multiple myeloma. Int J Hematol 2011;94:310-20. [PMID: 22005834 DOI: 10.1007/s12185-011-0947-z] [Cited by in Crossref: 26] [Cited by in F6Publishing: 25] [Article Influence: 2.6] [Reference Citation Analysis]
465 Gao X, Li C, Zhang R, Yang R, Qu X, Qiu H, Xu J, Lu H, Li J, Chen L. Fluorescence in situ hybridization analysis of chromosome aberrations in 60 Chinese patients with multiple myeloma. Med Oncol 2012;29:2200-6. [DOI: 10.1007/s12032-011-9988-7] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
466 Pichiorri F, Suh SS, Rocci A, De Luca L, Taccioli C, Santhanam R, Zhou W, Benson DM, Hofmainster C, Alder H. Downregulation of p53-inducible microRNAs 192, 194, and 215 impairs the p53/MDM2 autoregulatory loop in multiple myeloma development. Cancer Cell. 2010;18:367-381. [PMID: 20951946 DOI: 10.1016/j.ccr.2010.09.005] [Cited by in Crossref: 318] [Cited by in F6Publishing: 313] [Article Influence: 28.9] [Reference Citation Analysis]
467 Ríos R, González-Silva M, Molina E, García-Fernández JR, Clavero ME, Durán JM, López-Berenguel F, Romero MM, Jiménez-Moleón JJ, Sánchez MJ, Sáinz J, Jurado M. The impact of the type of hospital on survival of multiple myeloma patients: the MICORE study. Rev Clin Esp (Barc) 2013;213:330-5. [PMID: 23562426 DOI: 10.1016/j.rce.2013.02.014] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
468 Willenbacher W, Seeber A, Steiner N, Willenbacher E, Gatalica Z, Swensen J, Kimbrough J, Vranic S. Towards Molecular Profiling in Multiple Myeloma: A Literature Review and Early Indications of Its Efficacy for Informing Treatment Strategies. Int J Mol Sci 2018;19:E2087. [PMID: 30021955 DOI: 10.3390/ijms19072087] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 3.7] [Reference Citation Analysis]
469 Avilés A, Neri N, Huerta-Guzmán J, Nambo MJ. Randomized clinical trial of zoledronic acid in multiple myeloma patients undergoing high-dose chemotherapy and stem-cell transplantation. Curr Oncol 2013;20:e13-20. [PMID: 23443988 DOI: 10.3747/co.20.1055] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 1.5] [Reference Citation Analysis]
470 Tan D, Teoh G, Lau L, Lim A, Lim T, Yap K, Premalatha P, Lao Z, Wee N, Choo C, Wee H, Su S, Lee Y, Lee L, Hwang W, Goh Y. An abnormal nonhyperdiploid karyotype is a significant adverse prognostic factor for multiple myeloma in the bortezomib era. Am J Hematol 2010;85:752-6. [DOI: 10.1002/ajh.21812] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 1.5] [Reference Citation Analysis]
471 Rashid NU, Sperling AS, Bolli N, Wedge DC, Van Loo P, Tai YT, Shammas MA, Fulciniti M, Samur MK, Richardson PG, Magrangeas F, Minvielle S, Futreal PA, Anderson KC, Avet-Loiseau H, Campbell PJ, Parmigiani G, Munshi NC. Differential and limited expression of mutant alleles in multiple myeloma. Blood 2014;124:3110-7. [PMID: 25237203 DOI: 10.1182/blood-2014-04-569327] [Cited by in Crossref: 48] [Cited by in F6Publishing: 42] [Article Influence: 6.9] [Reference Citation Analysis]
472 Landgren O, Morgan GJ. Biologic frontiers in multiple myeloma: from biomarker identification to clinical practice. Clin Cancer Res 2014;20:804-13. [PMID: 24270684 DOI: 10.1158/1078-0432.CCR-13-2159] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 2.1] [Reference Citation Analysis]
473 Jimenez-Zepeda VH, Venner C, McCurdy A, Masih-Khan E, Atenafu EG, Sebag M, Stakiw J, Song K, LeBlanc R, Reiman T, Louzada M, Kotb R, Gul E, Reece D. Real-world outcomes with bortezomib-containing regimens and lenalidomide plus dexamethasone for the treatment of transplant-ineligible multiple myeloma: a multi-institutional report from the Canadian Myeloma Research Group database. Br J Haematol 2021;193:532-41. [PMID: 33559897 DOI: 10.1111/bjh.17350] [Reference Citation Analysis]
474 An G, Xu Y, Shi L, Zou D, Deng S, Sui W, Xie Z, Hao M, Chang H, Qiu L. t(11;14) multiple myeloma: A subtype associated with distinct immunological features, immunophenotypic characteristics but divergent outcome. Leukemia Research 2013;37:1251-7. [DOI: 10.1016/j.leukres.2013.06.020] [Cited by in Crossref: 36] [Cited by in F6Publishing: 34] [Article Influence: 4.5] [Reference Citation Analysis]
475 Boneva T, Brazma D, Gancheva K, Howard-Reeves J, Raynov J, Grace C, Nacheva EP. Can genome array screening replace FISH as a front-line test in multiple myeloma? Genes Chromosomes Cancer 2014;53:676-92. [PMID: 24757046 DOI: 10.1002/gcc.22178] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 1.3] [Reference Citation Analysis]
476 Kadam Amare PS, Jain H, Nikalje S, Sengar M, Menon H, Inamdar N, Subramanian PG, Gujral S, Shet T, Epari S, Nair R. Observation on frequency & clinico-pathological significance of various cytogenetic risk groups in multiple myeloma: an experience from India. Indian J Med Res 2016;144:536-43. [PMID: 28256461 DOI: 10.4103/0971-5916.200890] [Cited by in F6Publishing: 4] [Reference Citation Analysis]
477 McBride KM, Kil H, Mu Y, Plummer JB, Lee J, Zelazowski MJ, Sebastian M, Abba MC, Aldaz CM. Wwox Deletion in Mouse B Cells Leads to Genomic Instability, Neoplastic Transformation, and Monoclonal Gammopathies. Front Oncol 2019;9:517. [PMID: 31275852 DOI: 10.3389/fonc.2019.00517] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
478 Kaufman JL, Dimopoulos MA, White D, Benboubker L, Cook G, Leiba M, Morton J, Joy Ho P, Kim K, Takezako N, Moreau P, Sutherland HJ, Magen H, Iida S, Kim JS, Miles Prince H, Cochrane T, Oriol A, Bahlis NJ, Chari A, O'Rourke L, Trivedi S, Casneuf T, Krevvata M, Ukropec J, Kobos R, Avet-Loiseau H, Usmani SZ, San-Miguel J. Daratumumab, lenalidomide, and dexamethasone in relapsed/refractory myeloma: a cytogenetic subgroup analysis of POLLUX. Blood Cancer J 2020;10:111. [PMID: 33149130 DOI: 10.1038/s41408-020-00375-2] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
479 Souza LL, Cáceres CVBL, Vargas PA, Lopes MA, Santos-Silva AR, Silva WGD, Prado-Ribeiro AC, Brandão TB, Pereira J, Mesquita RA, Pontes FSC, González-Arriagada WA, Pedraza RM, Andrade BAB, Romañach MJ, Soares CD, Carvalho MGF, Pires FR, Carlos R, Fonseca FP, Pontes HAR, de Almeida OP. Plasmacytoma and plasma cell myeloma affecting the jaws: A multi-institutional collaborative study. J Oral Pathol Med 2021;50:613-21. [PMID: 34089204 DOI: 10.1111/jop.13213] [Reference Citation Analysis]
480 Stevens-Kroef M, Weghuis DO, Croockewit S, Derksen L, Hooijer J, Elidrissi-Zaynoun N, Siepman A, Simons A, Kessel AG. High detection rate of clinically relevant genomic abnormalities in plasma cells enriched from patients with multiple myeloma. Genes Chromosomes Cancer 2012;51:997-1006. [PMID: 22833442 DOI: 10.1002/gcc.21982] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 1.6] [Reference Citation Analysis]
481 Alzrigat M, Párraga AA, Jernberg-Wiklund H. Epigenetics in multiple myeloma: From mechanisms to therapy. Semin Cancer Biol 2018;51:101-15. [PMID: 28962927 DOI: 10.1016/j.semcancer.2017.09.007] [Cited by in Crossref: 35] [Cited by in F6Publishing: 31] [Article Influence: 8.8] [Reference Citation Analysis]
482 Fouquet G, Guidez S, Richez V, Stoppa AM, Le Tourneau C, Macro M, Gruchet C, Bobin A, Moya N, Syshenko T, Sabirou F, Levy A, Franques P, Gardeney H, Karlin L, Benboubker L, Ouali M, Vedovato JC, Ferre P, Pavlyuk M, Attal M, Facon T, Leleu X. Phase I dose-escalation study of F50067, a humanized anti-CXCR4 monoclonal antibody alone and in combination with lenalidomide and low-dose dexamethasone, in relapsed or refractory multiple myeloma. Oncotarget 2018;9:23890-9. [PMID: 29844860 DOI: 10.18632/oncotarget.25156] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
483 Musto P, Montefusco V. Are maintenance and continuous therapies indicated for every patient with multiple myeloma? Expert Review of Hematology 2016;9:743-51. [DOI: 10.1080/17474086.2016.1196127] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 2.2] [Reference Citation Analysis]
484 Bolli N, Biancon G, Moarii M, Gimondi S, Li Y, de Philippis C, Maura F, Sathiaseelan V, Tai YT, Mudie L, O'Meara S, Raine K, Teague JW, Butler AP, Carniti C, Gerstung M, Bagratuni T, Kastritis E, Dimopoulos M, Corradini P, Anderson KC, Moreau P, Minvielle S, Campbell PJ, Papaemmanuil E, Avet-Loiseau H, Munshi NC. Analysis of the genomic landscape of multiple myeloma highlights novel prognostic markers and disease subgroups. Leukemia 2018;32:2604-16. [PMID: 29789651 DOI: 10.1038/s41375-018-0037-9] [Cited by in Crossref: 75] [Cited by in F6Publishing: 72] [Article Influence: 25.0] [Reference Citation Analysis]
485 Gkotzamanidou M, Sfikakis PP, Kyrtopoulos SA, Bamia C, Dimopoulos MA, Souliotis VL. Chromatin structure, transcriptional activity and DNA repair efficiency affect the outcome of chemotherapy in multiple myeloma. Br J Cancer 2014;111:1293-304. [PMID: 25051404 DOI: 10.1038/bjc.2014.410] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 2.0] [Reference Citation Analysis]
486 Todinova S, Krumova S, Danailova A, Petkova V, Guenova M, Mihaylov G, Gartcheva L, Taneva SG. Calorimetric markers for monitoring of multiple myeloma and Waldenström's macroglobulinemia patients. Eur Biophys J 2018;47:549-59. [PMID: 29362827 DOI: 10.1007/s00249-018-1277-3] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
487 An G, Qin X, Acharya C, Xu Y, Deng S, Shi L, Zang M, Sui W, Yi S, Li Z, Hao M, Feng X, Jin F, Zou D, Qi J, Zhao Y, Tai Y, Wang J, Qiu L. Multiple myeloma patients with low proportion of circulating plasma cells had similar survival with primary plasma cell leukemia patients. Ann Hematol 2015;94:257-64. [DOI: 10.1007/s00277-014-2211-0] [Cited by in Crossref: 30] [Cited by in F6Publishing: 33] [Article Influence: 4.3] [Reference Citation Analysis]
488 Solimando AG, Da Vià MC, Cicco S, Leone P, Di Lernia G, Giannico D, Desantis V, Frassanito MA, Morizio A, Delgado Tascon J, Melaccio A, Saltarella I, Ranieri G, Ria R, Rasche L, Kortüm KM, Beilhack A, Racanelli V, Vacca A, Einsele H. High-Risk Multiple Myeloma: Integrated Clinical and Omics Approach Dissects the Neoplastic Clone and the Tumor Microenvironment. J Clin Med 2019;8:E997. [PMID: 31323969 DOI: 10.3390/jcm8070997] [Cited by in Crossref: 23] [Cited by in F6Publishing: 24] [Article Influence: 11.5] [Reference Citation Analysis]
489 Pittari G, Vago L, Festuccia M, Bonini C, Mudawi D, Giaccone L, Bruno B. Restoring Natural Killer Cell Immunity against Multiple Myeloma in the Era of New Drugs. Front Immunol 2017;8:1444. [PMID: 29163516 DOI: 10.3389/fimmu.2017.01444] [Cited by in Crossref: 36] [Cited by in F6Publishing: 37] [Article Influence: 9.0] [Reference Citation Analysis]
490 Mitra AK, Mukherjee UK, Harding T, Jang JS, Stessman H, Li Y, Abyzov A, Jen J, Kumar S, Rajkumar V, Van Ness B. Single-cell analysis of targeted transcriptome predicts drug sensitivity of single cells within human myeloma tumors. Leukemia 2016;30:1094-102. [DOI: 10.1038/leu.2015.361] [Cited by in Crossref: 39] [Cited by in F6Publishing: 37] [Article Influence: 6.5] [Reference Citation Analysis]
491 Mei J, Zhai Y, Li H, Li F, Zhou X, Song P, Zhao Q, Yu Y, An Z, Wang L. Prognostic impact of hyperdiploidy in multiple myeloma patients with high-risk cytogenetics: a pilot study in China. J Cancer Res Clin Oncol 2018;144:2263-73. [PMID: 30167888 DOI: 10.1007/s00432-018-2732-3] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
492 Herrero AB, Rojas EA, Misiewicz-Krzeminska I, Krzeminski P, Gutiérrez NC. Molecular Mechanisms of p53 Deregulation in Cancer: An Overview in Multiple Myeloma. Int J Mol Sci 2016;17:E2003. [PMID: 27916892 DOI: 10.3390/ijms17122003] [Cited by in Crossref: 35] [Cited by in F6Publishing: 36] [Article Influence: 7.0] [Reference Citation Analysis]
493 Da Vià MC, Ziccheddu B, Maeda A, Bagnoli F, Perrone G, Bolli N. A Journey Through Myeloma Evolution: From the Normal Plasma Cell to Disease Complexity. Hemasphere 2020;4:e502. [PMID: 33283171 DOI: 10.1097/HS9.0000000000000502] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
494 Choudhury SR, Ashby C, Tytarenko R, Bauer M, Wang Y, Deshpande S, Den J, Schinke C, Zangari M, Thanendrarajan S, Davies FE, van Rhee F, Morgan GJ, Walker BA. The functional epigenetic landscape of aberrant gene expression in molecular subgroups of newly diagnosed multiple myeloma. J Hematol Oncol 2020;13:108. [PMID: 32762714 DOI: 10.1186/s13045-020-00933-y] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
495 Kumar SK, Rajkumar SV. The multiple myelomas — current concepts in cytogenetic classification and therapy. Nat Rev Clin Oncol 2018;15:409-21. [DOI: 10.1038/s41571-018-0018-y] [Cited by in Crossref: 98] [Cited by in F6Publishing: 100] [Article Influence: 32.7] [Reference Citation Analysis]
496 Shachar I, Barak A, Lewinsky H, Sever L, Radomir L. SLAMF receptors on normal and malignant B cells. Clin Immunol 2019;204:23-30. [PMID: 30448442 DOI: 10.1016/j.clim.2018.10.020] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
497 Conticello C, Parisi M, Romano A, Calafiore V, Ancora F, La Fauci A, Consoli ML, Di Raimondo F. Pomalidomide experience: an effective therapeutic approach with immunomodulatory drugs in a patient with relapsed-refractory multiple myeloma. Future Oncol 2017;13:3-6. [PMID: 28116941 DOI: 10.2217/fon-2016-0368] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
498 Papathomas TG, Venizelos I, Dunphy CH, Said JW, Wang ML, Campo E, Swerdlow SH, Chan JC, Bueso-Ramos CE, Weisenburger DD, Medeiros LJ, Young KH. Mantle cell lymphoma as a component of composite lymphoma: clinicopathologic parameters and biologic implications. Hum Pathol 2012;43:467-80. [PMID: 22221705 DOI: 10.1016/j.humpath.2011.08.024] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 1.6] [Reference Citation Analysis]
499 Neri A, Todoerti K, Lionetti M, Simeon V, Barbieri M, Nozza F, Vona G, Pompa A, Baldini L, Musto P. Primary plasma cell leukemia 2.0: advances in biology and clinical management. Expert Review of Hematology 2016;9:1063-73. [DOI: 10.1080/17474086.2016.1244002] [Cited by in Crossref: 9] [Cited by in F6Publishing: 12] [Article Influence: 1.8] [Reference Citation Analysis]
500 Paiva B, Vídriales MB, Montalbán MÁ, Pérez JJ, Gutiérrez NC, Rosiñol L, Martínez-López J, Mateos MV, Cordón L, Oriol A, Terol MJ, Echeveste MA, De Paz R, De Arriba F, Palomera L, de la Rubia J, Díaz-Mediavilla J, Sureda A, Gorosquieta A, Alegre A, Martin A, Lahuerta JJ, Bladé J, Orfao A, San Miguel JF. Multiparameter flow cytometry evaluation of plasma cell DNA content and proliferation in 595 transplant-eligible patients with myeloma included in the Spanish GEM2000 and GEM2005<65y trials. Am J Pathol 2012;181:1870-8. [PMID: 22974582 DOI: 10.1016/j.ajpath.2012.07.020] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 2.1] [Reference Citation Analysis]
501 Gay F, Larocca A, Wijermans P, Cavallo F, Rossi D, Schaafsma R, Genuardi M, Romano A, Liberati AM, Siniscalchi A. Complete response correlates with long-term progression-free and overall survival in elderly myeloma treated with novel agents: analysis of 1175 patients. Blood. 2011;117:3025-3031. [PMID: 21228328 DOI: 10.1182/blood-2010-09-307645] [Cited by in Crossref: 183] [Cited by in F6Publishing: 165] [Article Influence: 18.3] [Reference Citation Analysis]
502 Jasielec JK, Jakubowiak AJ. Current approaches to the initial treatment of symptomatic multiple myeloma. Int J Hematol Oncol 2013;2. [PMID: 24286003 DOI: 10.2217/ijh.13.3] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 0.6] [Reference Citation Analysis]
503 Matarraz S, Paiva B, Díez-Campelo M, Bárrena S, Jara-Acevedo M, Gutiérrez ML, Sayagués JM, Sánchez ML, Bárcena P, Garrastazul MP, Berruezo MJ, Duran JM, Cerveró C, García-Erce JA, Florensa L, Méndez GD, Gutierrez O, Del Cañizo MC, van Dongen JJ, San Miguel JF, Orfao A. Immunophenotypic alterations of bone marrow myeloid cell compartments in multiple myeloma patients predict for myelodysplasia-associated cytogenetic alterations. Leukemia 2014;28:1747-50. [PMID: 24625552 DOI: 10.1038/leu.2014.103] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.4] [Reference Citation Analysis]
504 Kumar SK, Lee JH, Lahuerta JJ, Morgan G, Richardson PG, Crowley J, Haessler J, Feather J, Hoering A, Moreau P. Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: a multicenter international myeloma working group study. Leukemia. 2012;26:149-157. [PMID: 21799510 DOI: 10.1038/leu.2011.196] [Cited by in Crossref: 490] [Cited by in F6Publishing: 492] [Article Influence: 49.0] [Reference Citation Analysis]
505 Kaiser MF, Walker BA, Hockley SL, Begum DB, Wardell CP, Gonzalez D, Ross FM, Davies FE, Morgan GJ. A TC classification-based predictor for multiple myeloma using multiplexed real-time quantitative PCR. Leukemia 2013;27:1754-7. [PMID: 23318961 DOI: 10.1038/leu.2013.12] [Cited by in Crossref: 30] [Cited by in F6Publishing: 27] [Article Influence: 3.8] [Reference Citation Analysis]
506 Ghosh K. Proptosis with hemiplegia: Unusual presentation of multiple myeloma. J Postgrad Med 2018;64:204-5. [PMID: 30306967 DOI: 10.4103/jpgm.JPGM_119_18] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
507 Tang B, Xu A, Xu J, Huang H, Chen L, Su Y, Zhang L, Li J, Fan F, Deng J, Tang L, Sun C, Hu Y. MicroRNA-324-5p regulates stemness, pathogenesis and sensitivity to bortezomib in multiple myeloma cells by targeting hedgehog signaling: Targeting Hh signaling by miR-324-5p as therapeutic strategy for MM patients. Int J Cancer 2018;142:109-20. [DOI: 10.1002/ijc.31041] [Cited by in Crossref: 37] [Cited by in F6Publishing: 37] [Article Influence: 9.3] [Reference Citation Analysis]
508 Boyd KD, Ross FM, Chiecchio L, Dagrada G, Konn ZJ, Tapper WJ, Walker BA, Wardell CP, Gregory WM, Szubert AJ, Davies FE, Morgan GJ. Gender disparities in the tumor genetics and clinical outcome of multiple myeloma. Cancer Epidemiol Biomarkers Prev 2011;20:1703-7. [PMID: 21680536 DOI: 10.1158/1055-9965.EPI-11-0157] [Cited by in Crossref: 22] [Cited by in F6Publishing: 11] [Article Influence: 2.2] [Reference Citation Analysis]
509 Bozkurt S, Okay M, Haznedaroğlu İ. Aggressive Clinicopathological Course of Myeloma with t(3;16) (q21;q22) Cytogenetic Abnormality. Turk J Haematol 2019;36:62-3. [PMID: 29726398 DOI: 10.4274/tjh.galenos.2018.2018.0049] [Reference Citation Analysis]
510 Sonneveld P, Avet-Loiseau H, Lonial S, Usmani S, Siegel D, Anderson KC, Chng WJ, Moreau P, Attal M, Kyle RA, Caers J, Hillengass J, San Miguel J, van de Donk NW, Einsele H, Bladé J, Durie BG, Goldschmidt H, Mateos MV, Palumbo A, Orlowski R. Treatment of multiple myeloma with high-risk cytogenetics: a consensus of the International Myeloma Working Group. Blood 2016;127:2955-62. [PMID: 27002115 DOI: 10.1182/blood-2016-01-631200] [Cited by in Crossref: 387] [Cited by in F6Publishing: 368] [Article Influence: 77.4] [Reference Citation Analysis]
511 Awada H, Thapa B, Awada H, Dong J, Gurnari C, Hari P, Dhakal B. A Comprehensive Review of the Genomics of Multiple Myeloma: Evolutionary Trajectories, Gene Expression Profiling, and Emerging Therapeutics. Cells 2021;10:1961. [PMID: 34440730 DOI: 10.3390/cells10081961] [Reference Citation Analysis]
512 Rajan AM, Rajkumar SV. Interpretation of cytogenetic results in multiple myeloma for clinical practice. Blood Cancer J 2015;5:e365. [PMID: 26517360 DOI: 10.1038/bcj.2015.92] [Cited by in Crossref: 103] [Cited by in F6Publishing: 95] [Article Influence: 17.2] [Reference Citation Analysis]
513 Szalat R, Munshi NC. Genomic heterogeneity in multiple myeloma. Curr Opin Genet Dev 2015;30:56-65. [PMID: 25982873 DOI: 10.1016/j.gde.2015.03.008] [Cited by in Crossref: 26] [Cited by in F6Publishing: 20] [Article Influence: 4.3] [Reference Citation Analysis]
514 Suzuki K, Nishiwaki K, Gunji T, Katori M, Masuoka H, Yano S. Elevated eosinophil level predicted long time to next treatment in relapsed or refractory myeloma patients treated with lenalidomide. Cancer Med 2020;9:1694-702. [PMID: 31950647 DOI: 10.1002/cam4.2828] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
515 Zeng Y, Gao L, Luo X, Chen Y, Kabeer MH, Chen X, Stucky A, Loudon WG, Li SC, Zhang X, Zhong JF. Microfluidic enrichment of plasma cells improves treatment of multiple myeloma. Mol Oncol. 2018;12:1004-1011. [PMID: 29638042 DOI: 10.1002/1878-0261.12201] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
516 Barwick BG, Gupta VA, Vertino PM, Boise LH. Cell of Origin and Genetic Alterations in the Pathogenesis of Multiple Myeloma. Front Immunol 2019;10:1121. [PMID: 31231360 DOI: 10.3389/fimmu.2019.01121] [Cited by in Crossref: 37] [Cited by in F6Publishing: 34] [Article Influence: 18.5] [Reference Citation Analysis]
517 Billecke L, Murga Penas EM, May AM, Engelhardt M, Nagler A, Leiba M, Schiby G, Kröger N, Zustin J, Marx A, Matschke J, Tiemann M, Goekkurt E, Heidtmann HH, Vettorazzi E, Dierlamm J, Bokemeyer C, Schilling G. Cytogenetics of extramedullary manifestations in multiple myeloma. Br J Haematol 2013;161:87-94. [PMID: 23368088 DOI: 10.1111/bjh.12223] [Cited by in Crossref: 45] [Cited by in F6Publishing: 41] [Article Influence: 5.6] [Reference Citation Analysis]
518 Dhodapkar MV, Sexton R, Waheed S, Usmani S, Papanikolaou X, Nair B, Petty N, Shaughnessy JD Jr, Hoering A, Crowley J, Orlowski RZ, Barlogie B. Clinical, genomic, and imaging predictors of myeloma progression from asymptomatic monoclonal gammopathies (SWOG S0120). Blood 2014;123:78-85. [PMID: 24144643 DOI: 10.1182/blood-2013-07-515239] [Cited by in Crossref: 123] [Cited by in F6Publishing: 112] [Article Influence: 15.4] [Reference Citation Analysis]
519 Di Martino MT, Arbitrio M, Guzzi PH, Cannataro M, Tagliaferri P, Tassone P. Experimental treatment of multiple myeloma in the era of precision medicine. Expert Review of Precision Medicine and Drug Development 2016;1:37-51. [DOI: 10.1080/23808993.2016.1142356] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 0.8] [Reference Citation Analysis]
520 Zehentner BK, Hartmann L, Johnson KR, Stephenson CF, Chapman DB, de Baca ME, Wells DA, Loken MR, Tirtorahardjo B, Gunn SR, Lim L. Array-based karyotyping in plasma cell neoplasia after plasma cell enrichment increases detection of genomic aberrations. Am J Clin Pathol 2012;138:579-89. [PMID: 23010713 DOI: 10.1309/AJCPKW31BAIMVGST] [Cited by in Crossref: 10] [Cited by in F6Publishing: 2] [Article Influence: 1.1] [Reference Citation Analysis]